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Summary 
MMR -deficiency increases the rate of mutations and often sensitizes cells to 
DSB-inducing agents (e. g. camptothecin and etoposide) as well as MMC (Jacob et 
a/., 2001 and Fiumicino et al., 2000). MMR -deficient tumour cell lines are also 
sensitive to the cytotoxic effects thymidine (Mohindra et al., 2002). This sensitivity 
is not a direct consequence of MMR -deficiency or alterations of DNA precursor 
metabolism. Instead, the results described in the present study suggest that MMR 
-deficient cells are sensitive to thymidine as a result of defects in HRR. 
The ScNeo recombination reporter substrate was used to determine the integrity of 
the HRR pathway in several MMR -proficient and -deficient tumour cell lines. Four 
MMR -deficient tumour cell lines were defective in the production of neo+ 
recombinants by homology based recombination following the transient expression 
of a site specific break. Furthermore, all MMR -deficient tumour cell lines tested 
were sensitive to the cross-linking agent MMC; an effect that is consistent with 
cells being deficient in HRR (including XRCC2, XRCC3 and BRCAI). 
To determine the alterations responsible for such HRR defects, genes known to be 
required for this pathway were screened for mutations in eight tumour cell lines. 
This revealed a heterozygous frameshift mutation within the RAD51 paralog, 
XRCC2, (342deIT) in SKUT-1 cells. 342delT was introduced into HRR proficient 
cells containing the ScNeo substrate. In SW480/SN. 3 transfectants, expression of 
342delT conferred sensitivity to thymidine and MMC and suppressed HRR induced 
at the recombination reporter by thymidine but not by DSBs. In the 
MRC5VA/SN. 13 transfectants, expression of 342delT was accompanied by a 
decreased level of the full-length XRCC2. These cells were defective in the 
induction of HRR by either thymidine or DSBs. Thus 342delT suppresses 
recombination induced by thymidine in a dominant negative manner while 
recombination induced by DSBs appears to depend upon the level of wild-type 
XRCC2 as well as the expression of the mutant XRCC2 allele. These results 
suggest that HRR pathways responding to stalled replication forks or DSBs are 
genetically distinguishable. They further suggest a critical role for XRCC2 in HRR 
at replication forks, possibly in the loading of RAD51 onto gapped DNA. 
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1.1 Genomic Instability and Cancer. 
The transformation of a somatic cell to a cancerous one is a multi-step 
process that is characterised by the accumulation of mutations in genes 
responsible for controlling cell growth and proliferation. The exact number 
of mutations required for neoplastic transformation is unknown. However, it 
is proposed that as many a six to eight mutations may be necessary for the 
development of an invasive tumour (Renan M. J., 1993). 
In addition to acquiring numerous mutations, cancerous cells also exhibit 
increased spontaneous mutation rates. A study used the hprt locus to 
measure mutation rates in untransformed cells and showed that 
spontaneous mutations occur between 1.4 x 10.10 to 1x 10"9/nucleotide/cell 
generation (Loeb, L., 1991). This frequency is increased by up to 100-fold 
in neoplastic cells, although the effect seems to be cell type specific 
(Seshadri et al., 1987; Eshleman et al., 1995 and Bhattacharyya et al., 
1994). Cells displaying this 'mutator phenotype' have a high probability of 
incurring mutations in proto-oncogenes and tumour suppressor genes. 
Subsequently through its evolution, a cancerous cell may accumulate 
multiple molecular alterations including gene amplifications, 
insertions/deletions, rearrangements and point mutations (Cooper et al., 
1998). 
The gross genetic abnormalities observed in cancerous cells have led to the 
concept that neoplastic cells are genetically unstable with genomic 
instability helping to drive tumour development. This observation is 
illustrated by the increased incidence of neoplasia associated with 
genetically unstable disorders (reviewed in van Gent et al., 2001 and Levitt 
and Hickson, 2002). Both abnormal DNA repair (mutational instability) and 
chromosomal abnormalities (chromosomal instability) can give rise to such 
3 
CHAPTER ONE-INTRODUCTION 
instability. Mutational instability is characterised by point mutations or small 
deletions and is usually associated with mismatch repair defects (Jacoby et 
al., 1995; Konishi et al., 1996; Aaltonen et al., 1993 and 1994 and Baba S., 
1997). Chromosomal instability, however, involves the loss or gain of whole 
chromosomes (or fragments of chromosomes), as well as the amplification 
of chromosomal sequences. This form of instability is often associated with 
the inactivation of tumour suppressor genes or the activation of proto- 
oncogenes (reviewed in van Gent et aL, 2001). Both of these forms of 
progressive instability are discussed in detail below. 
1.2 Mutational Instability 
Eukaryotic cells have a number of repair pathways involved in the repair of 
abnormal DNA structures. One such pathway is the DNA Mismatch Repair 
(MMR) pathway. Such a pathway is required to repair errors present in 
replicated DNA as well as regulating recombination intermediates (reviewed 
in Buermeyer et al., 1999 and Harfe and Jinks-Robertson, 2000). Effective 
MMR must not only be able to identify the mismatch present in 'normal' 
DNA, but it must also be able to identify and correct the 'wrong' base. The 
existence of several MMR pathways correlates with the repair of various 
mismatched abnormalities (Karran and Bignami, 1999). For example, the 
'long patch' MMR pathway repairs relatively long stretches of DNA, whereas 
the more specialised, 'short patch' MMR correction pathway is responsible 
for the specific repair of G: T and A: G mispairs (Karran and Bignami, 
1999). 
Substrates that initiate MMR processes include: mispaired bases (that can 
arise during DNA replication) as well as mismatches that are present in 
heteroduplex recombination intermediates. In addition, MMR proteins also 
have a direct role in the post-replicative repair of DNA polymerisation errors 
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that can subsequently cause insertions or deletions of bases within 
repetitive coding sequences. 
Elucidation of the protective role of the MMR system in preventing human 
cancer has led to a better understanding of the processes involved in the 
repair of mismatched bases. Cell lines derived from tumours that are 
deficient in MMR have been shown to exhibit at least three distinct mutator 
phenotypes. Firstly, the rate of mutations that arise due to the gain or loss 
of bases in repeated sequences is dramatically increased in a MMR - 
deficient background (this phenomenon is often termed microsatellite 
instability) (Gragg et al., 2002; Parsons et al., 1995; Shibata et al., 1994 and 
Bhattacharyya et al., 1994). Secondly, the rate of spontaneous mutations 
at specific loci e. g. hprt and aprt, is also dramatically increased in MMR 
-deficient cells (Battacharyya et al., 1994; Kat et al., 1993 and Eshleman et 
a/., 1995 and Phear et al., 1996). This effect, however, seems to strongly 
depend on the growth conditions and the cell type. For example, MMR 
-deficient cells grown at a high density exhibit a more pronounced 
phenotype than the same cells grown in culture conditions which allows for 
rapid growth (Richards et aL, 1997). Thirdly, biochemical and functional 
studies have shown that the MMR proteins are also involved in cell cycle 
checkpoints (in particular the S- and G2/M-checkpoints) and apoptosis 
events (Yan et aL, 2001 and Brown et al., 2003). In addition to the three 
stated phenotypes, studies have also indicated that MMR -deficient cells 
are resistant to DNA alkylating agents or base analogues such as 6- 
thioguanine and cisplatinum (Aebi et al., 1996 and Fink et al., 1996). 
1.2.1 The E-coli MutHLS system. 
The proteins and mechanisms involved in MMR have been conserved from 
bacteria through to humans. The E. coli MutHLS MMR system has been 
largely characterized through the analysis of purified proteins. This has 
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subsequently allowed the MMR reaction to be reconstituted in vitro 
(reviewed in Modrich and Lahue, 1996). Within the E. coli'long-patch' MMR 
system, the MutS protein (acting as a homodimer) initially recognizes and 
binds onto base/base mismatches and small (up to 4 nucleotides) 
insertion/deletion loops that have escaped DNA polymerase proofreading 
(Parker and Marinus, 1992 and Modrich, P. 1991,1996 and 1997). Studies 
with deletion derivatives of MutS have suggested that the N-terminus is 
responsible for binding onto the mismatched DNA, whilst the C-terminus is 
responsible for protein dimerisation as well as ATP binding and hydrolysis 
(Wu and Marinus, 1999). The binding of MutS to DNA subsequently 
recruits the MutL homodimer, which is responsible for coupling mismatch 
recognition to downstream processing events. MutL protein dimerisation is 
also achieved via interactions between the C-terminal regions, whilst the N- 
terminus contains the ATP binding and hydrolysis domains (Ban and Yang, 
1998a and 1998b). Association of MutL with MutS enhances the ATP 
hydrolysis-dependent translocation properties of MutS and also stimulates 
the activities of the MutH endonuclease (Au et aL, 1992; Ban and Yang, 
1998c and Hall and Matson, 1999). MutH is methylation-sensitive and is 
responsible for discriminating between template DNA strands and newly 
replicated unmethylated daughter strands (Welsh et aL, 1987). In addition, 
MutH is also responsible for cleaving DNA 5' to such hemimethylated GATC 
sequences on the nascent strand (Au et aL, 1992 and Hall and Matson, 
1999). The cleaved DNA is then targeted by the UvrD (MutU) helicase, 
which unwinds the duplex DNA, beginning at the nick introduced by MutH 
and proceeding past the mismatched containing DNA (Dao and Modrich, 
1998; Hall et al., 1998 and Yamaguchi et al., 1998). Single-strand specific 
exonucleases (e. g. RecJ, ExoVII, Exol or ExoX) are thought to 
subsequently degrade DNA until the mismatch is removed (reviewed in 
Modrich and Lahue, 1996 and Viswanathan and Lovett, 1998). The MMR 
process is completed by re-synthesis and re-ligation. Such processes are 
thought to be predominantly conducted by the Single-strand binding (SSB) 
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protein, DNA polymerase III holoenzyme and DNA ligase (Modrich, P., 1991 
and Modrich and Lahue, 1996). 
1.2.2 The Eukaryotic MMR system. 
MuutS Homologs 
All eukaryotic organisms studied to date contain multiple MutS homologs 
that are often referred to as MSH proteins (termed MSH1-6). However, only 
three of the six such MutS homologs are thought to participate in the MMR 
process. Chi and Kolodner (1994) demonstrated that yeast MSH1 encodes 
a mitochondrial targeting sequence and is specifically involved in the 
correction of mismatches present in the mitochondria. To date, no MSH1 
mammalian homologue has been reported. Furthermore, the MSH4 and 
MSH5 proteins form a heterodimer that is proposed to be specifically 
involved in meiotic recombination and not in mismatch recognition (Ross- 
MacDonald and Roeder, 1994; Hollingsworth et al., 1995 and Hunter and 
Borts, 1997). 
The MSH2 protein is essential for mediating the repair of all types of 
mismatches that occur in mammalian cells. The MSH3 and MSH6 proteins, 
however, both confer substrate specificity when complexed with MSH2 
(Jiricny, 1998; Kolodner and Marsischky, 1999; Genschel et a!., 1998; 
Macpherson et a!., 1998; Palombo et aL, 1996 and Acharya et aL, 1996). 
The importance of MSH2 was illustrated in mammalian cell lines deficient in 
the protein, which exhibited MSI, a six to twelve-fold increase in mutation 
rate at the hprt locus as well as resistance to 6-thioguanine (Reitmair et a!., 
1997). The mammalian MSH2 protein interacts (via the C-terminus) with 
either MSH3 or MSH6 to form two distinct heterodimers, termed MutSß and 
MutSa respectively (Gurrette et aL, 1998). The MutSa heterodimer 
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recognizes single base/base mismatches as well as small and large 
insertion/deletion loops (Figure 1.1, Page 9). The MutSß complex, 
however, recognizes predominantly large (two-eight base pair) 
insertion/deletion loops (Figure 1). In addition, MutSß seems to have 
overlapping substrate specificities with MutSa, with respect to being able to 
recognize one base pair insertion/deletion loops (Alani, 1996; Habraken et 
a/., 1996 and Marsischky et al., 1996). Interestingly, studies using human 
MSH2, MSH3 and MSH6 proteins have showed that the MutSa heterodimer 
is present in a six-fold molar excess over the MutSß heterodimer at any 
given time in cultured cells (Drummond et al., 1997 and Marra et aL, 1998). 
Furthermore, the same study also showed that the MSH2 protein was 
almost entirely (90%) expressed as part of the MutSa complex. These 
results were consistent with observations that MutSa recognizes all types of 
mismatches and that inactivation of MSH6 has a greater detrimental effect 
than the inactivation of MSH3 (Bhattacharyya et al., 1994; Risinger et al., 
1996 and Marra et al., 1998). 
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Figure 1.1 MMR processes in eukaryotic cells. Adapted from Buermeyer et al., 
1999 
Recent biochemical studies have indicated that the C-terminus of both 
MSH2 and MSH6, like the MutS bacterial homolog, contain highly 
conserved Walker A and B boxes (Hughes and Jiricny, 1992; laccarino et 
al., 1998 and Studamire et al., 1998). These Walker motifs are responsible 
for ATP binding and hydrolysis, a function that is essential for MMR activity 
both in vitro and in vivo (Alani et al., 1997; laccarino et al., 1998 and 
Studamire et al., 1998). Gradia and co-workers (2000) proposed a model in 
which the MutSa complex exists in a mismatch binding competent ADP- 
bound state. The recognition of mismatched DNA was subsequently 
proposed to stimulate an ADP-ATP exchange reaction. Furthermore the 
addition of ATP in mismatch binding assays has suggested that the MutSa 
complex undergoes a conformational change that results in the release of 
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mismatched DNA (Alani et al., 1997; Habraken et al., 1998 and Studamire 
et al., 1998). This was also confirmed when an ADP-bound form of the 
MutSa complex was found to be capable of binding to mismatched DNA 
(Lamers et at., 2000 and Junop et al., 2001). Furthermore, the subsequent 
ADP-ATP exchange reaction resulted in the release of MutS from a DNA 
site (Allen et al., 1997). Two models have been proposed to explain the 
relevance of ATP hydrolysis in MutS and the MSH2/MSH6 complex. Fishel, 
R. (1998) proposes that the MutS protein is constantly re-cycled, enabling 
MutS (and MutSa) to translocate away from the mismatch in an ATP 
hydrolysis-independent manner in order to possibly interact with 
downstream processing proteins. However Allen and co-workers (1997) 
have used electron microscopy to suggest that ATP-hydrolysis is required 
for the translocation of MutS, resulting in a loop-like structure being formed, 
where the mismatched site is located within the loop, and the MutS 
homodimer holds the base of the loop together. Thus as yet the precise 
effect of ATP hydrolysis remains unclear. 
MutL Homologs 
Eukaryotic cells also possess multiple MutL homologs (termed MLH1, 
MLH3, PMS2 (PMS1 in yeast) and PMS1 (MLH3 in yeast)) that are all 
thought to act in a MSH2-dependent pathway (Habraken et al., 1997 and 
1998 and Prolla et al., 1994). The MLH1 protein was found to form a pair 
wise interaction with each of the other three MutL homologs and is therefore 
central to the MMR `coupling' process (Wang et al., 1999; Li G. and 
Modrich, 1995 and Lipkin et al., 2000). All four MutL homologs participate 
as distinct heterodimers and are involved in the repair of various 
intermediates. Furthermore, functional and biochemical studies have 
proposed that the MutLa (MLH1/PMS2) heterodimer has a greater role in 
MMR than the MutLß (MLH1/PMS1) heterodimer (Kato et al., 1998 and 
Raschle et al., 1999). However, unlike the role of MutL in the bacterial 
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MutHLS system, the roles of the MLH1/PMS2 and MLH1/MLH3 
heterodimers have not been fully characterized in the mammalian system, 
although clear involvement in MMR is proposed (Flores-Rozas and 
Kolodner, 1998). 
The suggested role of MutL in a 'coupling' reaction was confirmed when the 
C-terminus of MutL was found to directly interact with the MutH 
endonuclease as well as the UvrD helicase (Hall et al., 1998; Yamaguchi et 
a/., 1998 and Dao and Modrich, 1998). Indeed recent biochemical studies 
have shown that the human MutLa complex is able to interact with MSH2, 
MutSa, MutSß and PCNA (Prolla et al., 1994; Habraken et al., 1998; 
Habraken et al., 1997 and Gu et al., 1998). Therefore, by analogy to the 
bacterial MutL protein, this complex is thought to couple mismatch 
recognition to strand discrimination, excision and re-synthesis steps. The 
effects of both MLH1 and PMS2 proteins, however, maybe stimulated by 
ATP binding and/or hydrolysis (which is limited to the NH3 terminus) (Ban 
and Yang, 1998). 
Strand Discrimination, DNA Excision and Re-synthesis processes 
The mechanism of action of additional proteins involved in mammalian 
MMR processes is currently unknown. Two mechanisms have been 
proposed by which strand discrimination is achieved in the eukaryotic MMR 
system. Hare and Taylor (1985) initially suggested, by analogy to the E. coli 
MutHLS system, that methylation of the 5-position of cytosine in CpG 
islands was a sufficient enough signal to discriminate between the two 
strands in human MMR. However, biochemical evidence suggests that 
single-stranded nicks, such as those transiently occurring in Okazaki 
fragments during semi-conservative DNA replication, provides a better 
strand discrimination mechanism between daughter and template strands 
(Karran and Bignami, 1999). 
11 
CHAPTER ONE-INTRODUCTION 
The proliferating cell nuclear antigen (PCNA) protein is also implicated in 
various MMR steps including strand discrimination, excision and re- 
synthesis (Johnson et al., 1996 and Umar et al., 1996). This protein can not 
only directly interact with human MutS and MutL homologs, but is also 
required in both the excision and re-synthesis steps of the MMR process 
(Kleczkowska et al., 2001; Gu et al., 1998; Johnson et al., 1996; Kokoska et 
a/., 1999 and Umar et al., 1996). In addition functional studies, in which the 
yeast PCNA protein was mutated, resulted in increased frameshift 
mutations (Johnson et al., 1996 and Umar et al., 1996). Aside from PCNA, 
another proposed MutH homolog is MED1, which is a human methylation- 
sensitive endonuclease that causes MSI when over expressed (Bellacosa 
et al., 1999); however the involvement of MED1 in MMR remains unclear. 
The excision and re-synthesis steps of the eukaryotic MMR pathway have 
been proposed to be completed by Exol, DNA polymerase ö and DNA 
polymerase c (Szankasi and Smith, 1995) (Figure 1.1, Page 9). Recent 
biochemical and functional studies have shown interactions between these 
proteins and those involved in the MMR process (Tishkoff et al., 1997). 
Furthermore, an increase in mutation rates was observed in cells 
expressing inactivated forms of these proteins (Tran et al., 1999 and Qiu et 
al., 1999). 
1.2.3 Mutational instability and predisposition to cancer. 
MMR deficiency is correlated with a highly penetrant cancer predisposition 
syndrome termed hereditary non-polyposis colorectal cancer (HNPCC). 
HNPCC, otherwise known as Lynch syndrome, is responsible for 
approximately 5% of all colorectal cases. Such patients usually develop 
early onset tumours that are predominantly located in the colon. Less 
common cases have also been noted to have cancer in the endometrium, 
stomach, small intestine and ovary (Lynch et a/., 1998 and Peltomaki and 
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de la Chapelle, 1997). Mutations in MSH2 and MLH1 are associated with 
80-90% of HNPCC cases, although some cases do also have mutations in 
PMS1, PMS2 and MSH6 (Wagner et aL, 2003; Lynch and de la Chapelle, 
2003 and Buermeyer et al., 1999). A similar pattern is observed in mice 
lacking either MSH2 or MLH1. Such mice are predisposed to develop an 
early onset of tumours ranging from gastro-intestinal tumours to 
lymphomas, skin tumours and sarcomas (Reitmair et al., 1997 and Prolla et 
al., 1998). Furthermore, consistent with that seen in humans, mice lacking 
MSH6, MSH3, PMS1 or PMS2 exhibit milder phenotypes (de Wind et al., 
1999; Baker et al., 1995 and Prolla et a/., 1998). 
A high proportion of HNPCC patients are heterozygous for recessive, 
germline mutations in MMR genes. A second mutation of the functional 
allele, predominantly promoted by loss of heterozygosity, inactivates the 
MMR system and leads to an increase in mutation rates and tumour 
development (Leach et al., 1993; Shibata et al., 1994; Parsons et al., 1993; 
Boyer, et al., 1995; Loeb L., 1991; Bhattacharyya et al., 1994; Eshleman et 
a!., 1995; Lazar et al., 1994; Markowitz et al., 1995; Rampino et al., 1997 
and Huang, J., et al., 1996). In sporadic cases, however, mutations in MMR 
genes are rarely observed (approximately 15% of cases, Boland, C., 1997). 
This indicates that alternative mechanisms are responsible for MMR 
inactivation. Reports have suggested that the MMR system is inactivated in 
such cases as a result of gene silencing due to hyper-methylation of the 
promoter region (Wheeler et a!., 1999 and Esteller et al., 1996). 
Consistent with the phenotype observed in MMR -deficient cell lines, 
tumours derived from HNPCC patients frequently exhibit genomic instability 
which can be detected by changes in the length of repeated sequences 
(Aaltonen et al., 1993). Furthermore, microsatellite unstable tumours 
selectively contain frameshift mutations in tumour suppressor genes (e. g. 
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TGF-ßR11, BAX) and DNA repair genes (e. g. MSH3, MSH6 and BLM), thus 
promoting tumour development (McPherson et al., 1994). 
1.3 Chromosomal Instability 
Chromosomal instability is characterised by gross rearrangements of 
chromosomes. Such instability includes the loss or gain of whole 
chromosomes or fragments of chromosomes as well as the amplification of 
chromosome fragments. A majority of chromosomal instability disorders 
arise due to mutations in either tumour suppressor genes or proto- 
oncogenes. Tumour suppressor genes have been further categorized into 
two groups, namely 'caretakers' and 'gatekeepers' (reviewed in Levitt and 
Hickson, 2002). Alterations in expression, or mutations in 'gatekeeper' 
genes, directly give rise to uncontrolled cell proliferation. Mutations in 
'caretaker' genes (e. g. MMR genes), however, give rise to genetic instability 
by increasing the frequency of mutations occurring within 'gatekeeper' 
genes. 
Within normal living cells, chromosomal DNA is often subjected to 
mechanical stress as well as chemical modification. Such events have 
recently been documented to lead to chromosomal instability due to the 
presence of lethal breaks in one or both strands of the double helix 
(reviewed in van Gent et al., 2001). Erroneous rejoining of DNA DSBs 
gives rise to genetic alterations including gene deletion and translocations. 
Such events can subsequently result in inactivation of tumour suppressor 
genes or the activation of oncogenes (Weinberg, R., 1988 and Pierotti and 
Dragani, 1992). Cells are acutely sensitive to DSBs and as few as one or 
two such lesions are sufficient to trigger the activation of the ATM protein 
kinase, one of the prime regulators of the DNA damage response 
(Bakkenist and Kastan, 2003). Generally, DNA damaging agents are 
classified in two categories, namely endogenous and exogenous agents. 
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Both forms of agent can subsequently introduce mutations that will affect 
later generations or even lead to cell death. 
Endogenously induced damage can occur at any stage of the cell cycle, 
e. g. in non-dividing cells, during DNA replication and during mitosis (see 
Pfeiffer et al., 2000 for review). The major sources of endogenous DNA 
damaging agents include: water, oxygen, topoisomerases, and errors in 
base pairing occurring during replication at fragile sites (i. e. micro- or 
minisatellite sequences) (Sutherland et al., 1998 and Debrauwere et al., 
1999). In addition, normal aerobic metabolism gives rise to active oxygen 
species, such as hydroxyl and super oxide radicals, which particularly target 
guanine and thymine residues within duplexed DNA. Another source of 
endogenous DNA damage includes the non-enzymatic methylation of 
nucleotides which subsequently produce adducts such as O6- 
methylguanine and 3-methyladenine (reviewed in Pfeiffer et al., 2000). 
Ultraviolet irradiation (UV), ionizing irradiation (IR) and certain 
chemotherapeutic agents are some of the many examples of exogenous 
DNA damaging agents (see Pfeiffer et al., 2000 for review). Ionizing 
irradiation (such as 7-rays and X-rays) is capable of producing reactive 
oxygen species, as well as producing lethal double- and single-stranded 
breaks in DNA (Ward, J. 1985). In addition various endonucleases are also 
capable of inducing DSBs when acting on DNA (Bryant P., 1988 and 
Thacker J., 1994). 
In response to the threat of DNA DSBs, cells have a number of DNA repair 
mechanisms to ensure the fidelity of the genome and thereby prevent 
chromosomal instability. In mammalian cells, the Homologous 
recombination repair (HRR) (which predominates during the late S/early G2 
phases of the cell cycle) and Non-Homologous End Joining (NHEJ) (which 
predominates during the GO, G1 and early S-phases of the cell cycle) 
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pathways are involved in the repair of such breaks (Takata et al., 1998 and 
Essers et al., 2000). Biochemical and functional evidence suggests that 
proteins involved in these two repair pathways not only compete for binding 
onto the ends of DSBs, but also are capable of acting sequentially 
(Delacote et al., 2002). 
1.3.1. Mechanisms of Non-Homologous End Joining (NHEJ). 
The mechanisms involved in NHEJ mediated repair require no homology 
with a second DNA duplex and little or no homology between the two 
broken DNA ends. Subsequently NHEJ mediated repair products 
frequently contain DNA alterations. This fast acting pathway predominates 
in mammalian cells as indicated by studies using genomically integrated 
DNA substrates. Such studies showed that NHEJ mediated events 
occurred between 100-10,000 fold more frequently than HRR events in 
mammalian cells (Roth et al., 1985). The paradox as to why the 'erroneous' 
NHEJ pathway predominates over HRR is that, although it frequently results 
in alterations of DNA sequences around the break point, the chances of 
these alterations affecting coding regions remains minimal. 
The simplest form of the two NHEJ processes is the re-ligation of two blunt 
or complementary DNA ends. This process does not depend on base 
pairing interactions and subsequently restores the original sequence 
(Wilson et al., 1982 and Roth and Wilson, 1986) (Figure 1.2). This process 
is dependent upon the Ku70/80 heterodimeric complex and, depending on 
the structure of the ends, results in the production of either 'fill-in' or 
'overlap' junctions (Liang and Jasin, 1996; Critchlow and Jackson, 1998 and 
Feldmann et al., 2000). The production of two non-compatible DNA ends 
(such as those formed following exposure to irradiation) however, results in 
DNA re-sectioning to enable ligatable structures to be formed. This process 
occurs independently of the KU70/80 heterodimer and employs short 
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sequence homologies in order to direct re-joining (Roth and Wilson, 1986 
and Roth et al., 1991). Subsequently this results in an increase in deletion 
events. The factors involved in this second repair pathway are currently 











DNA LIGASE IV 
XRCC4 
Figure 1.2 NHEJ mediated DNA double-strand break repair. Following formation 
of a DSB, the DNA-PKcs/Ku70/80 complex initially recognizes and binds onto DNA ends. 
Such ends are thought to be processed (possibly by the RAD50/MRE11/NBS1 complex), 
thus resulting in the addition or subtraction of base pairs. This step is followed by end to 
end ligation by the DNA ligase IV/XRCC4 complex. Therefore, as NHEJ does not make 
use of a homologous template for repair, this DSB-repair pathway is error prone. (Adapted 
from van Gent et al., 2001). 
DNA damaging agents, such as irradiation, frequently cause DNA cross- 
links or produce DNA ends that are accompanied by additional base 
changes. These ends are thought to be exonucleolitically processed by the 
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MRE11/RAD50/NBS1 complex (described on Page 35) which seems not 
only to be involved in both NHEJ and cell signalling, but also in HRR 
processes (Goedecke et aL, 1999; Petrini, 2000 and Haber, 1998). The 
RAD50 component of this complex forms two long intra-molecular coiled 
coils that are thought to facilitate in finding the two ends of a DSB (de Jager 
et al., 2001 a and 2001 b and 2002 and Chen et al., 2001). 
In mammalian cells, the re-sected DNA ends are subsequently recognized 
and protected from further degradation by the Ku70/80 heterodimer. The 
Ku70/80 heterodimer, along with the XRCC4 protein, aligns and stabilizes 
end-joining intermediates (Liang and Jasin, 1996; Jeggo, P., 1998 and 
Kabotyanski et al., 1998). Following the alignment and stabilization of DNA 
ends; the Ku70/80 heterodimer subsequently recruits and binds with a DNA 
dependent protein-kinase catalytic subunit called DNA-PKcs (Smith and 
Jackson, 1999). The presence of DNA ends has been demonstrated to 
activate the kinase domain of DNA-PKcs, thus enabling it to phosphorylate 
a number of substrates required for repair, including XRCC4 (Critchlow et 
al., 1997 and Grawunder et al., 1997). However, the significance of such 
phosphorylation events remains unclear at present. It is possible that the 
DNA-PKcs protein could assist with trimming and tethering the two DNA 
ends together while they are re-joined. Alternatively, it could be responsible 
for regulating other repair molecules such as those involved in signal 
transduction. Finally the remaining gaps in the DNA sequence are filled, by 
an as yet unknown polymerase and the ends are ligated by DNA ligase IV. 
This ligase has been found to strongly interact with the XRCC4 protein 
which is a substrate for the DNA-PKcs kinase in vitro (Critchlow et al., 1997 
and Grawunder et al., 1997). 
Cells deficient in any gene involved in NHEJ display extremely similar 
phenotypes. For example, mutation analysis revealed that mutations in the 
Ku70/Ku80 heterodimer, DNA-PKcs or the XRCC4/DNA ligase IV 
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heterodimer conferred extreme hypersensitivity to ionizing irradiation 
(Karanjawala et al., 2002). 
1.3.2. Mechanisms of Homologous recombination repair (HRR). 
HRR is defined as any exchange of genetic material between homologous 
DNA sequences. This highly accurate repair mechanism is essential during 
meiosis (e. g. for the inherent separation of chromosomes) and mitosis 
(Roeder G., 1997). Several homology dependent pathways exist and can 
be sub-divided into conservative (e. g. gene conversion and break-induced 
replication) and non-conservative (e. g. single-strand annealing) processes. 
Conservative repair processes involve the DSB being accurately repaired 
through copying sequence information of a homologue or sister 
chromosome in order to restore the original sequence at the break. 
Pathways included within this type of repair process include double-strand 
break repair (DSBR), synthesis-dependent strand-annealing (SDSA) and 
break-induced replication (BIR) (Figure 1.3, Page 21). Non-conservative 
repair processes, such as single-strand annealing (SSA), occur when two 
direct repeats interact with each other such that one repeat copy and the 
subsequent intervening sequence are lost (Figure 1.4, Page 23). The 
preference of one pathway over another is dependent on a number of 
factors including the position of the homologous partner, the initiation event 
and the length of homology of recombinant molecules. 
The double-strand break repair (DSBR) pathway was originally proposed in 
yeast by Resnick and co-workers (1976) and later expanded by Szostak 
and colleagues (1983). Similar processes are also proposed to occur in 
mammalian cells. Within this pathway, recombination events are initiated 
by a DSB (Sun et aL, 1989 and Cao et al., 1990). The DNA ends are 
proposed to be processed by the MRE11/RAD50/NBS1 complex. However, 
this complex has 3'-5' exonuclease activity which is the opposite polarity to 
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what is needed (Usui et al., 1998; Furuse et al., 1998; Paull and Gellert, 
1998; Trujillo et al., 1998 and Trujillo and Sung, 2001). The subsequent re- 
sectioning of DNA produces long 3' single-stranded tails which are used to 
invade a homologous duplex and initiate synthesis (Sun et al., 1991). 
Pairing of the invading ssDNA with template dsDNA, results in a strand 
exchange reaction that subsequently generates heteroduplex DNA (Goyon 
and Lichten, 1993 and Nag and Petes, 1993). Thus in this DSBR model, 
both 3' ends are able to prime new DNA synthesis from the two strands of 
the donor template (McCulloch et al., 2003). The key steps of strand 
invasion and exchange are mediated by the proteins included within the 
RAD52 epistasis group. The double-strand exchange reactions lead to the 
formation of two, four-way junctions (called Holliday junctions) (Collins and 
Newlon, 1994 and Schwacha and Kleckner, 1994). Such junctions are 
capable of branch migrating and thus expanding the heteroduplex region. 
These gene conversion events may not only affect a single gene (short 
tract), but may cover several contiguous genes (long tract). Subsequent 
resolution of Holliday junctions, in either the same or opposite direction, 
results in non-crossover and crossover products being formed respectively. 
The SDSA model was initially proposed as an alternative to the DSBR 
model as a majority of mitotic gene conversion events were found not to be 
associated with crossover (Schiestl of al., 1988 and McGill of al., 1990). 
Within this model, following 3' ssDNA invasion, the newly synthesized DNA 
strands (short tracts) are displaced from the invaded DNA template and 
allowed to re-anneal to each other. Thus this differs from DSBR, in that all 
the newly synthesized sequences are on the same molecule. 
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Figure 1.3 Three proposed models for HRR in mammalian cells. Adapted from 
Pfeiffer et al., 2000 
21 
CHAPTER ONE-INTRODUCTION 
The BIR pathway was initially proposed for T4 phage (Mosig, 1987). Within 
this pathway, only one DSB end invades the homologue or sister chromatid. 
The invading 3' end subsequently primes DNA synthesis which can cover 
long DNA fragments. BIR is capable of proceeding to the end of a 
chromosome or alternatively can be converted into a gap repair (DSBR) if 
the other DNA end invades the homologous template. 
The non-conservative SSA pathway is the simplest of all the homology 
directed repair pathways. This pathway predominates if the DSB occurs 
between two flanking homologous DNA repeats and frequently results in a 
deletion event. The DSB is initially resected by exonucleases, as described 
above, until large sections of sequence flanking the break are exposed in 
the form of long 3'single-stranded tails (Figure 1.4, Page 23). The DNA 
repeats subsequently undergo strand annealing. 
The removal of non-homologous 3' ends during both GC and SSA is 
proposed to require some MMR proteins as well as the ERCC1/XPF 
heterodimer (Zhang, N. et al., 2002; Chipchase and Melton, 2002 and Adair 
of al., 2000). In vitro, this complex cuts at the junction of duplex DNA and a 
3' single stranded extension. SSA events occur independently of RAD51 
but requires RAD52 instead (van Dyck et al., 1999 and 2001). This is 
consistent with the DNA end binding and strand annealing activities of this 
protein (Mortensen et al., 1996). 
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Figure 1.4 Single-strand annealing mediated repair of a DNA DSB. Within this 
non-conservative form of HRR, two DSB ends interact directly at homologous repeated 
units. Subsequently, one repeat unit and the intervening sequence are lost due to 
nucleolytic trimming. 
1.3.2 1 Proteins involved in HRR - RAD52 epistasis group 
RAD51 
The eukaryotic RAD51 protein has important roles during both mitotic and 
meiotic recombination repair processes (Shinohara et al., 1992). This 
37kDa protein belongs to a general family of recombinases, which like the 
RecA bacterial homolog, forms helical filaments. The formation of such 
helical filaments enable RAD51 to catalyse homologous DNA pairing in the 
'pre-synaptic' phase of recombination and subsequently initiate strand 
exchange activities (Shinohara et al., 1992 and 1993 and Baumann et al., 
1996) (Figure 1.5, Page 25). RAD51 has been shown to interact with many 
proteins including RPA, RAD52, RAD54, XRCC3, BRCA2, BLM and p53 
(reviewed in Thompson and Schild 2001). Furthermore, knockout RAD51 
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mutations in both chicken and mammalian cells, is lethal (Tsuzuki et al., 
1996; Lim and Hasty, 1996 and Sonoda et al., 1998). Taken together, 
these results therefore underline the importance of this protein to normal 
cellular function. 
Biochemical studies have revealed that members of the recombinase 
family, from E-coli to eukaryotes, contain highly conserved Walker motifs 
which are responsible for ATP binding and hydrolysis (Yu et al., 2001; 
Benson et al., 1994; Ogawa et al., 1993). Mammalian cells expressing an 
ATP-hydrolysis defective RAD51 protein exhibit increased sensitivity to both 
MMC and IR, as well as a decreased rate of spontaneous sister chromatid 
exchange events (Stark et al,. 2002). Furthermore, spontaneous inter- 
chromosomal recombination events were diminished in Saccharomyces 
cerevisiae which expressed an ATP-hydrolysis deficient form of RAD51 
(Shinohara et al., 1992). Together these observations imply that ATP 
hydrolysis is a key step for RAD51 to mediate recombination processes. 
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NUCLEOLYTIC 4' BASC PROCESSING 
? MRE111RADSO/NBS1 
NUCLEOPROTEIN + RAD52/RAD511 RPA 
FILAMENT BRCAI/BRCA2 
FORMATION RAD51 PARALOGS 
HOMOLOGY 4, RAD52 SEARCH 
AND JOINT RAD54 
MOLECULE º 
FORMATION 
DNA SYNTHESIS 4' DNA POLYMERASES 
LIGATION AND 4' DNA LIGASE COMPLETION OF 
REPAIR RESOLVASES 
? RAD51C/XRCC3 
Figure 1.5 Homologous recombination mediated DNA DSB repair. The 
formation of a DSB activates the ATM kinase (and other proteins included within the BASC 
complex). Subsequently, the DNA ends are processed (possibly by the 
RAD50/MRE11/NBS1 complex), resulting in the generation of ss-3' overhangs. Such ends 
are recognized by RAD52 and/or RPA, which subsequently enable RAD51 to form 
nucleoprotein filaments. Other proteins involved at this step include the RAD51 paralogs 
(namely, RAD51 B, RAD51 C, RAD51D, XRCC2 and XRCC3) and BRCAIBRCA2. The 
RAD51 nucleoprotein filaments then search for homologous duplex DNA. Following such 
searching, DNA strand exchange generates a joint molecule between the homologous 
damaged and undamaged duplexed DNA. This step is thought to be stimulated by the 
RAD52 and/or RAD54 proteins. DNA polymerases and accessory factors fill in the break. 
Finally, ligation and resolution of the recombination intermediates complete this accurate 
repair process. Adapted from van Gent et al., 2001 
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Protein alignment studies between RecA and RAD51 have shown that 
outside of the homologous core (containing the ATP binding sites), these 
two proteins display poor homology. RecA has a C-terminal extension that 
is absent in RAD51 (Shinohara et al., 1992 and 1993). This region of the 
RecA protein is thought to be responsible for binding onto dsDNA regions 
(Kurumizaka et a/., 1996). Eukaryotic and Saccharomyces cerevisiae 
RAD51 proteins however, have an N-terminal extension that is absent in 
RecA. This extension has been shown to bind both single- and double- 
stranded DNA (Aihara et al., 1997 and Yu, X. et al., 2001). Furthermore, as 
both the N-terminus of RAD51 and the C-terminus lobe of RecA are mobile, 
this study also demonstrated that ATP mediated 'activation' of RAD51 
causes the extension of RAD51 polymers. The eukaryotic RAD51 protein 
has been shown to assemble into right-handed nucleoprotein helical 
filaments in the presence of DNA in an ATP binding-dependent manner 
(Symington, L., 2002; Krejci et al., 2003; Bianco et al., 1998; Yu et al., 2001; 
Sung, P., 1994 and Sung and Stratton, 1996). Filament formation 
subsequently catalyzes DNA pairing and strand exchange activities of 
RAD51, thus yielding heteroduplex DNA joints between homologous 
regions. The ATP hydrolysis reaction has been shown to cause the 
dissociation of RAD51 from complexes with DNA (Namsaraev and Berg, 
1998). This step seems to be important either for completing the 
recombination process or for converting the filaments into RAD51 
monomeric molecules thus enabling the re-cycling of the protein. 
The strand transfer and heteroduplex DNA extension-RAD51 mediated 
reactions also involve a number of additional proteins, including the 
heterotrimeric ssDNA binding factor, RPA. RPA sequesters free ssDNA 
regions, which if left uncovered strongly inhibits the homologous pairing 
reaction as well as being responsible for the removal of secondary 
structures that may be present on ssDNA (reviewed in Thompson and 
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Schild 2001). Following the disruption of DNA secondary structures by 
RPA, the protein is thought to be displaced by RAD52. 
Functional studies showing an involvement of RAD51 in HRR processes 
have been hampered as disruption of RAD51 in chicken DT40 cells, results 
in an increase in chromosomal breaks prior to cellular death (Tsuzuki et al., 
1996 and Sonoda et aL, 1998). A few approaches have, however, been 
developed to enable a clearer understanding of the expression and function 
of this protein in HRR. Expression studies have showed that, not only does 
the RAD51 protein form nuclear foci in the S and G2/M -phases of the cell 
cycle, but also that these foci rapidly become re-distributed to sites of DNA 
damage (Tashiro et al., 1996; Yuan et al., 2003 and Haaf at aL, 1995). In 
addition, Kim and co-workers (2001) showed that over-expression of wild 
type RAD51 and RAD52 in human and hamster cells causes an increase in 
frequency of spontaneous recombination events but a decrease in 
frequency of DSB induced HRR events. In addition, a similar approach was 
used to show that RAD51 prevents illegitimate HRR during DNA replication 
(Lundin at al., 2003). Therefore it seems that the presence of RAD51 in 
excess has an inhibitory effect on DSB-induced HRR. 
Finally it was shown, using a dominant negative form of RAD51, that this 
protein does not significantly control global DSBR events, but instead 
regulates the specific classes of recombination (i. e. strand invasion versus 
single-strand annealing) (Lambert and Lopez, 2000). 
RAD51 paralogs 
In addition to RAD51, five RAD51-like genes have also been discovered to 
be expressed in mammalian cells. These RAD51 paralogs were initially 
identified either due to their ability to functionally complement the X-ray 
sensitive hamster irs9 and irs1SF cell lines (in the case of XRCC2 and 
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XRCC3) (Jones et al., 1987; and Fuller and Painter, 1988), or due to data 
base searching for sequence similarities with XRCC2 and XRCC3 (in the 
case of RAD51 B, RAD51 C and RAD51 D) (Albala et al., 1997; Cartwright et 
a/., 1998; Dosanjh et al., 1998 and Pittman et al., 1998). All five paralogs 
share between 20 to 30% sequence homology with RAD51 and between 
one another. Such homology, however, is predominantly limited to the two 
nucleotide binding motifs (termed Walker Box A and B respectively) 
(Thacker, J., 1999 and Thompson and Schild, 1999). The importance of 
these motifs was illustrated in a study which showed that mutation of the 
conserved ATP binding domain in RAD51C severely impaired its function 
(French et aL, 2003). However experiments using Saccharomyces 
cerevisiae Rad55p and Rad57p (RAD51-related proteins) have shown that 
mutation of Walker box A in Rad55p but not in Rad57p disables the 
heterodimers function (Johnson and Symington, 1995). Taken together, 
these results suggest that ATP hydrolysis may be dispensable for function 
in some of the RAD51 paralogs. 
Initially Schild and co-workers (2000) showed (using yeast two-hybrid and 
three-hybrid screening) a variety of interactions between the RAD51 
paralogs. However, more recent biochemical studies have reported that the 
five paralogs co-precipitated as two distinct complexes both in vitro and in 
vivo (Masson et al., 2001; Weise et aL, 2002 and Miller et a/., 2002). The 
authors proposed that one complex comprised of RAD51 B, RAD51 C, 
RAD51 D and XRCC2, whereas the second complex comprised of RAD51 C 
and XRCC3. 
All five paralogs seem to play crucial roles in maintaining chromosomal 
stability as RAD51 B, RAD51D or XRCC2 gene disruption in mice often 
results in early embryonic lethality (Shu et al., 1999; Deans et al., 2000 and 
2003 and Pittman and Schimenti, 2000). However, viable knockout mutants 
of RAD51 B, RAD51C, RAD51D, XRCC2 and XRCC3 have been generated 
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in chicken B lymphocyte DT40 cells and mouse embryonic fibroblasts 
(Deans et al., 2003 and Takata et aL, 2001). Such studies have established 
similar phenotypic effects including elevated spontaneous chromosomal 
aberrations, extreme sensitivity to DNA cross-linking agents (such as MMC) 
and mild sensitivity to IR. 
Both biochemical and functional studies suggest that the RAD51 paralogs 
are involved in the homology directed repair of DNA DSBs. For example, 
purified XRCC2/RAD51 D and XRCC3/RAD51C heterodimers have been 
shown to bind to ssDNA and to catalyse homologous pairing between 
ssDNA and dsDNA regions (Masson et al., 2001 and Kurumizaka et al., 
2003). The same studies also showed that, in a similar fashion to RAD51 
and RAD52, both complexes form filamentous structures only in the 
presence of ssDNA. In addition, Yokoyama and co-workers (2003) purified 
RAD51 B to show that the protein specifically binds to Holliday Junctions in 
the presence of ATP. Furthermore, the RAD51C/XRCC3 complex is also 
involved in the processing of Holliday junctions (Liu et al., 2004) 
In addition to the biochemical evidence, many functional studies have also 
been conducted which suggest a possible involvement of the RAD51 
paralogs in HRR. Firstly, RAD51B"'" DT40 cells exhibit HRR deficiencies 
(with respect to intra-chromosomal gene conversion, gene targeting and 
sister chromatid exchange) in addition to being acutely sensitive to MMC 
and being unable to form RAD51 foci (Takata et aL, 2000). Secondly, 
French and co-workers (2002) showed that RAD51 C"'" hamster cells exhibit 
a decrease in sister chromatid exchange events, an increase in iso- 
chromosomal breaks and a decrease in damage dependent RAD51 foci 
formation. The same group also used site-directed mutagenesis to show 
that RAD51C mutant cells are deficient in the homology directed repair of 
DNA DSBs mediated by gene conversion events (French et al., 2003). 
Finally, both irs9 (XRCC2 deficient) and irs1SF (XRCC3 deficient) cell lines 
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have been shown to exhibit between a 25 to 100-fold decrease in HRR 
frequency when recombination events were induced by a site-specific break 
(Pierce et al., 1999 and Johnson et al., 1999). 
In addition, as the BCDX2 complex was shown to specifically bind to ssDNA 
as well as to single-stranded regions or nicks in duplexed DNA (Masson et 
a/., 2001) and the RAD51 C/XRCC3 complex was shown to bind ssDNA 
(and thus promote DNA-DNA interactions and annealing) (Masson et al., 
2001), it is proposed that the human RAD51 paralogs participate in repair 
as 'pre-RAD51' functional units. These proteins could therefore either 
promote the assembly of Rad5l nucleofilaments or alternatively stabilize 
the filaments once formed. 
XRCC2 and XRCC3 
The X-ray repair cross complementing (XRCC) genes are a diverse set of 
human genes that complement hamster cell mutants which have the 
common features of sensitivity to IR, DNA cross linking agents and 
increased missegregation of chromosomes (Liu et al., 1998; Tebbs et al., 
1995 and Griffin et al., 2000). Analysis of XRCC2 and XRCC3 cDNAs and 
genomic sequences showed that these proteins are RAD51-related 
(Thacker J., 1999). Furthermore, both gene products are involved in the 
repair of DSBs (Pierce et al., 1999 and Johnson et al., 1999). 
The human XRCC2 gene was identified by positional cloning and mapped 
to chromosome 7q36.1 (Liu et al., 1998; Tambini et al., 1997 and Thacker 
et al., 1995). The coding region contains three exons, with Exon III 
encoding 86% of the coding sequence. The 31.2kb gene encodes a 280 
amino acid protein. 
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Using XRCC2 mouse knockout cells it was possible to show that the 
XRCC2 protein plays a prominent role in ensuring normal embryonic 
development and in developing the nervous system (Deans et al., 2000). 
Furthermore, Johnson and co-workers (1999) used a recombination 
reporter substrate ScNeo, to show that XRCC2 is essential for the efficient 
repair of DNA DSBs mediated by HRR between sister chromatids. In 
addition O'Regan and co-workers (2001) investigated the localisation of 
XRCC2 in mammalian cells and showed that functional XRCC2 is required 
for damage-dependent RAD51 focus formation. Further evidence 
supporting a role for XRCC2 in assisting RAD51 foci formation came from 
studies which showed that XRCC2 interacted with RAD51D (the DNA- 
stimulated ATPase that binds to ssDNA) (Braybrooke et al., 2000). This 
complex may be required for RAD51 foci formation on ssDNA as it has 
been shown to form a filamentous structure, similar to RAD51, RAD52 and 
the XRCC3/RAD51 C heterodimer, in the presence of ssDNA (Kurumizaka 
et al., 2002). 
The human XRCC3 gene has been mapped to chromosome 14q32.3 
(Tebbs et aL, 1995). The gene consists of nine exons and spans a 16.8kb 
region. The encoded XRCC3 protein shares limited homology with Rad5l 
(Thacker, J., 1999). Furthermore, XRCC3 has been shown to directly 
interact with Rad5l (Liu et al., 1998). In further support of this observation, 
RAD51 foci failed to form in the irs9SF (XRCC3 deficient) cell line (Bishop 
et al., 1998). The XRCC3 protein therefore seems to have a pre-RAD51 
role as it is required for the assembly or stabilisation of a multimeric form of 
RAD51 during DNA repair. 
A recombination reporter system has been used to demonstrate that error- 
free homology-directed repair of DNA DSBs is decreased 25-fold in an 
XRCC3-deficient hamster cell line (Pierce et al., 1999). The authors further 
demonstrated that this effect was restored to wild type levels through 
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XRCC3 cDNA expression, thus indicating the direct role of XRCC3 in HRR. 
Interestingly, Brenneman and co-workers (2002) showed that XRCC3 
function was not limited to the initial stages of HRR, but rather also acted in 
the formation and resolution of HR intermediaries such as heteroduplex 
DNA. In addition to the role of XRCC3 in DSBR, Henry-Mowatt and co- 
workers (2003) suggested that the interaction between XRCC3 and RAD51 
can function to modulate the speed of replication fork progression in 
vertebrate cells following DNA damage. 
RAD52 
The yeast RAD52 gene was initially cloned and sequenced in 1984 
(Adzuma et a!., 1984) and found to encode a 504 amino acid protein. 
Electron microscopy studies indicated that both yeast and human RAD52 
proteins formed ring shaped structures on DNA in a similar fashion to 
RAD51 (Shinohara et a!., 1998 and van Dyck et a!., 1998). Furthermore, 
functional analysis showed that this protein is involved in HRR, as both 
spontaneous and DSB induced HRR activities are absent in yeast rad52 
mutants (Paques and Haber, 1999). 
Studies using purified Saccharomyces cerevisiae RAD52 indicated that the 
protein has at least two important functions during recombination. Firstly, 
RAD52 has been shown to directly interact with the RAD51 recombinase, 
where it serves as a mediator in the DNA strand exchange reaction (New 
and Kowalczykowski, 2002) (Figure 1.5, Page 25). Yeast-two-hybrid 
screening has suggested that the C-terminus of RAD52 directly interacts 
with RAD51 (Milne and Weaver, 1993). In addition to this, Krejci and co- 
workers (2002) showed that residues 409-420, of the Saccharomyces 
cerevisiae RAD52 protein, specifically are indispensable for function and 
were likely to be sufficient for the interaction with RAD51. The RAD52 
protein also facilitates the displacing of RPA in order to stabilize the RAD51 
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pre-synaptic filament and allows the RAD51 protein to gain access to 
ssDNA regions (New and Kowalczykowski, 2002). The RAD52 protein 
mediated stimulation of DNA strand exchange was, however, found to be 
protein specific. For example, RAD52 had no effect in reactions where RPA 
and/or RAD51 were replaced with bacterial Single-strand Binding (SSB) 
protein or RecA respectively (Sugiyama of al., 2002). Furthermore 
Sugiyama and co-workers (2002) showed that RAD52 forms a co-complex 
with RPA in the presence of ssDNA in order to recruit RAD51. This event is 
proposed to lead to the displacement of RPA. Thus in targeting RAD51 to 
ssDNA regions, RAD52 is also thought to prevent RAD51 from being 
sequestered by dsDNA segments. 
A second activity of RAD52 involves the annealing of ssDNA regions (i. e. 
single-strand annealing) (Figure 1.4, Page 23). The DNA binding activity of 
RAD52 is proposed to occur within the N-terminus and such interactions 
stimulate DNA strand annealing (Mortensen et al., 1996). In addition, 
biochemical studies have showed that human RAD52 is capable, not only of 
binding directly to DSBs, but also protecting these regions from further 
exonuclease resectioning (by the MRE11/RAD50/NBS1 complex) (van 
Dyck et al., 1999). The authors further suggest that following the 
occurrence of a DNA DSB, RAD52 competes with the Ku 70/80 complex for 
the binding of DNA ends, therefore regulating the mechanism of DNA 
repair. 
RAD54 
The RAD54 protein is also thought to play a key role in HRR of DNA DSBs. 
This protein belongs to the Snf2/Swi2 protein family of ATPase's which can 
utilize the energy produced from ATP hydrolysis to modulate protein to 
duplex DNA interactions (Eisen et al., 1995). Purified RAD54 protein has 
been shown to posses both DNA dependent-ATPase activity and DNA 
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supercoiling activity (Swagemakers et al., 1998; Tan et al., 1999; Ristic et 
a/., 2001). Furthermore a study, in which the ATPase domain of 
Saccharomyces cerevisiae RAD54 was mutated, revealed that ATP 
hydrolysis promotes conservative DSBR and suppresses spontaneous 
deletions (Kim P. et al., 2002). In addition, studies using human RAD54 
protein also revealed that inactivation of the ATPase activity severely 
impaired the ability to complete recombination in vivo (Tan et al., 1999). 
Taken together, such studies underline the importance of this domain of 
RAD54. In addition to RAD54, a distinct homologue, termed RAD54B, has 
also been cloned although the precise function of this protein remains 
unclear (Hiramoto et al., 1999). 
Mouse knockout RAD54 mutants are viable and display increased 
sensitivity to DNA damaging agents including ionizing radiation (Essers et 
a/., 2000). Various structure/function studies have indicated that RAD54 is 
involved in multiple stages of HRR including: pre-synaptic (i. e. 
nucleoprotein filament binding), 'synaptic' (i. e. homology search and strand 
invasion) and 'post-synaptic' (i. e. heteroduplex DNA extension) phases. 
The pre-synaptic function of this protein was illustrated when both RAD54 
and RAD54B foci were shown to co-localize with RAD51 foci following 
exposure to y-irradiation (Tanaka et al., 2000). Furthermore, the N- 
terminus of RAD54 has been shown to bind with RAD51 in a yeast two- 
hybrid screen (Golub et al., 1997). In addition, by using purified 
Saccharomyces cerevisiae RAD54 protein, the interaction with RAD51 was 
shown to stabilize the RAD51 nucleoprotein filament complex in a way that 
is independent of its ATPase activity (Mazin et al., 2003). 
The energy produced through ATP hydrolysis is thought to enable the 
RAD54 protein to produce negative and positive supercoils in duplexed 
DNA within the 'synaptic' phase of recombination (Petukhova et al., 2000; 
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Ristic et al., 2001 and van Komen et aL, 2000). Such studies have 
suggested that this activity subsequently leads to the transient opening of 
DNA strands therefore enhancing the rate at which the incoming duplex 
molecule can be sampled for homology by the pre-synaptic complex. Thus 
the RAD54 protein modifies the topology of the dsDNA, making it more 
accessible for DNA pairing in the `synaptic' phase. The catalytic ATP 
hydrolysis activity of RAD54 is essential for its function during this DNA 
strand exchange reaction in vitro (Solinger et al., 2001). Furthermore 
Sigurdsson and co-workers (2002) showed that the ability of human RAD54 
to promote the separation of DNA strands in duplex DNA (via its ATP 
hydrolysis-driven DNA supercoiling function) is greatly stimulated by its 
interaction with human RAD51. 
The dsDNA-dependent ATPase activity of RAD54 is also thought to 
facilitate in the 'post-synaptic' phase of heteroduplex DNA extension 
mediated by RAD51 in vitro (Solinger and Heyer, 2001). However, little is 
currently known about the mechanistic functions of RAD54 in this respect. 
The MREI I Complex 
Components of the mammalian MRE11 complex (namely MRE11, NBS1 
and RAD50) were initially identified in genetic screens using 
Saccharomyces cerevisiae mutants that were either hypersensitive to UV 
damage (RAD50) and X-ray induced damage (Xrs2, yeast homolog of 
NBS1) or deficient in meiotic recombination repair (MRE11) (Cox and Parry, 
1968; Suslova et aL, 1975 and Ajimura et al., 1993). Cloning studies 
revealed substantial homology between fungi and vertebrates for the 
MRE11 and RAD50 genes, indicating the importance of this complex 
(Tavassoli et al., 1995 and Petrini et al., 1995). 
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The 80kDa MRE11 protein is central to the function of the MRE1 1 complex 
and is capable of interacting independently with either NBS1 or RAD50 
(Johzuka and Ogawa, 1995; Carney et al., 1998; Usui et aL, 1998; 
Chamankhah and Xiao, 1999 and Desai-Mehta et al., 2001). Amino acid 
alignment studies revealed that the N-terminus of MRE11 contains a DNA 
nuclease domain (Tsubouchi et al., 1998). The authors further suggested 
that this domain enables the protein to show 3'-5' dsDNA exonuclease 
activity and ssDNA endonuclease activities. The DNA nuclease domain is 
not only regulated by RAD50 (which stimulates its endonuclease and 
exonuclease activities) (Paull and Gellert, 1998 and 1999), but also by 
NBS1 (which specifically stimulates its endonuclease activity) (Paull and 
Gellert, 1999) and ATP (in a RAD50 and NBS1 dependent manner) (Paull 
and Gellert, 1999). Biochemical and functional studies have also reported 
that the MRE11 protein has intrinsic DNA binding activity that can be 
stimulated by RAD50 and/or NBS1 (Usui et aL, 1998; Furse et al., 1998; 
Paull and Gellert, 1999; de Jager et al., 2001a and 2001b and 2002). 
Furthermore, the MRE11 complex has been shown to posses strand 
dissociation properties (Paull and Gellert, 1998), and can also mediate the 
annealing of complementary ssDNA (de Jager et aL, 2001 a and 2001 b and 
2002). In support of the latter finding, Mirzoeva and co-workers (2003) 
found that the MRE11 complex is deposited onto chromatin in an S-phase 
specific manner, where it could possibly play a key role in sister chromatid 
association and repair. 
The RAD50 protein belongs to a family of proteins that are involved in 
structural maintenance of chromosomes (SMC). Such proteins have 
predominant functions in sister chromatid cohesion and chromosome 
condensation (Hirano, T., 2002). In both cultured ES cells and in early 
developing embryos, a null rad50 mutation is lethal (Luo et al., 1999). This 
indicates that the MRE11/RAD50/NBS1 complex is essential for viability 
(Luo et al., 1999). The RAD50 protein, like RAD51 and its paralogs, also 
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posseses ATPase activity as it contains Walker A and B nucleotide binding 
motifs. These motifs are located at the N- and C-terminus respectively 
(Alani et aL, 1989). ATP binding and hydrolysis is essential for the function 
of RAD50, as defects in such domains result in the loss of nuclease activity 
in the human MRE11/RAD50/NBS1 complex in vitro (Alani et al., 1990). 
Addition of ATP results in a conformational change within the 
MRE11/RAD50 heterodimer, as it causes the two ATPase motifs of RAD50 
to move closer together (Hopfner et al., 2000). This event is subsequently 
thought to promote the nuclease activity of MRE11 (Hopfner et al., 2001). 
Both of the nucleotide binding boxes of RAD50 are separated by two 
heptad-repeat regions, which form an extended coiled-coil structure 
containing a putative globular domain (Alani et al., 1989 and Dolganov et 
a/., 1996). The MRE11 protein is speculated to bind to this coiled-coil 
region of RAD50, proximal to the catalytic domain (Anderson et al., 2001). 
This subsequently enables RAD50 to adopt a V-like structure thus allowing 
RAD50 to bind onto DNA ends and hold them close together (de Jager et 
aL, 2001a and 2001b and 2002 and Chen L. et al., 2001). However, both 
the function and significance of holding DNA ends close together remains 
speculative. It is possible that RAD50 could facilitate searches for 
homologous regions. Alternatively, it could stimulate the binding of DNA 
ligase, as proposed by Chen L. and co-workers (2001) using yeast ligase. 
RAD50 may also mediate cohesion between a broken sister chromatid, 
stabilize a damaged chromatid section or limit the extent of nucleolytic 
degradation activity exhibited by MRE11. 
The NBS1 protein interacts with MRE1 1 at the C-terminus and is not 
thought to be specifically essential for DNA repair (Desai-Mehta et a!., 
2001). However, disruptions of NBS1 in DT40 cells results in a decrease in 
gene conversion and sister chromatid exchanges (Tauchi et al., 2002). 
Such results therefore imply a role for this protein in HRR. The NBS1 
protein contains a BRCT domain next to an N-terminal fork head associated 
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(FHA) domain (Durocher et al., 1999; Tauchi et al., 2001 and Bork et al., 
1997). However the significance of such domains is not presently clear. 
Deletion of the FHA domain does not induce hypersensitivity to ionizing 
irradiation, but rather inhibits the MRE1 1 complex re-localization properties 
in vivo (Tauchi et al., 2001). 
NBS1 is phosphorylated on the Ser 278 and Ser 343 residues in an ATM- 
dependent manner as well as mediating the phophorylation of MRE11 in 
human cells (Dong et al., 1999; Gatei et al., 2000; Lim et al., 2000; Wu et 
aL, 2000 and Zhao et al., 2000). Paull and co-workers (1999) recently 
described that in vitro, NBS1 assists the human MRE11/RAD50 
heterodimer in unwinding short stretches of duplex DNA and cleaves fully 
paired hairpin structures. 
The MRE11 complex forms distinct nuclear foci upon DNA damage in an 
ATM/ATR dependent manner. This indicates that this complex is not only 
involved in DNA DSB processing, but also in checkpoint signalling during 
the S-phase (Maser et aL, 1997). The authors further showed that damage 
induced foci formed by both RAD50 and MRE1 1 are separate, in terms of 
both localization and time, from those formed by RAD51. 
1.3.3 The Sensing and Response to DNA DSB induced damage. 
The existence of DNA DSBs in mitotic cells is initially detected by so called 
'DNA damage sensors' which are capable of inducing cell cycle arrest at 
several points. This delay in cell cycle progression ultimately prevents 
chromosome instability by allowing time for damaged DNA to be repaired. 
Briefly, the mammalian cell cycle is divided into four well defined stages 
(Figure 1.6). Within the G1 (gap 1) phase, normal metabolism occurs and 
the components required for replication are assembled. The G1 phase is 
followed by the S (Synthesis) phase, where the cell's chromosomal DNA 
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replicates. This replication process is extremely accurate as the synthesis 
of a new strand is an exact replica of the template strand. Genes required 
for initiating and regulating DNA replication are abundant during this phase 
of the cell cycle. The G2 (gap2) phase of the cell cycle enables the cell to 
prepare for M (Mitosis) phase following the completion of chromosomal 
replication. 
DNA damage regulatory checkpoints are responsible for not only controlling 
cell cycle arrest, but also are thought to be involved in (i) controlling the 
activation of DNA repair pathways, (ii) the movement of DNA repair proteins 
to the site of DNA damage and (iii) the induction of apoptosis. Arrest in cell 
cycle progression at the G1/S or G2/M checkpoint provides the 
indispensable time required to prevent replication (with respect to the G1/S 
checkpoint) or to prevent entry into mitosis (with respect to the G2/M 
checkpoint). Failure to arrest or constitutive activation of these processes 
substantially results in genomic instability and cancer (reviewed in Hartwell 
and Kastan, 1994). 
Go 
Figure 1.6 The Cell Cycle. The cell cycle is divided into four phases: G1 (Gapl), S 
(DNA synthesis), G2 (Gap 2) and M (Mitosis). In addition, some cells remain for long 
periods in a non-dividing state (GO) after completing mitosis. 
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1.3.3.1 BRCA1 Associated Surveillance Complex (BASC). 
The ATM kinase (described below) was recently noted by Wang and co- 
workers (2000) to exist as part of a `super BASC complex' that consisted of 
at least fourteen DNA repair proteins (Figure 1.7). The study used co- 
immunoprecipitation to reveal that this complex included caretaker proteins, 
(such as BLM), the MRE11/RAD50/NBS1 complex, some MMR proteins 
(namely the MSH2/MSH6 heterodimer and the MLH1/PMS2 heterodimer) 
and replication factor C (RFC). The authors suggested that this complex 
acted "as a sensor of abnormal DNA structures and/or as a regulator of the 
post-replicative repair process". Components included within this complex 
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Figure 1.7 The BASC complex: a sensor of abnormal DNA structures and 
DNA damage. Proteins that have been demonstrated to physically interact are 




phosphorylation events are depicted. Furthermore, the significance of some 
phosphorylation events still remains unclear. The functions of gene products in boxes with 
red text are described in detail below. Adapted from Levitt and Hickson (2002) 
The ATM and ATR kinases 
DNA damage (induced by agents such as IR, UV irradiation and stalled 
replication forks) is thought to trigger signal transduction pathways that 
subsequently effects DNA repair, cell cycle arrest and even apoptosis 
(Lowndes and Murguia, 2000). Cellular failure to trigger such events 
frequently results in genomic instability, thus predisposing organisms to 
cancer. In eukaryotes, two members of the phosphatidylinositol 3-kinase 
related kinase (PIKK) family, namely ATM and ATR, play crucial roles in 
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DNA damage recognition and initiation of cellular responses (e. g. cell cycle 
arrest) (for reviews see: Tibbetts et al., 2000; Zhou and Elledge, 2000; 
Khanna et al., 2001a and 2001b and Rouse and Jackson, 2002). This 
super family of protein kinases (which also include Tell p and Mec1 p of 
Saccharomyces cerevisiae, Rad3p of Schizosaccharomyces pombe and 
mammalian DNA-PKcs) all contain a highly conserved phosphatidylinositol 
3-kinase domain at the C-terminus. This domain is essential for the signal 
transduction activities of ATM and ATR (reviewed in Rotman and Shiloh, 
1999). 
The ATM protein binds directly to DNA following exposure to IR in order to 
signal downstream effectors (Smith et al., 1999). This gene is 
approximately 150 kb in length and comprises of 66 exons which encode for 
a 370kDa protein (Savitsky et al., 1995). Bakkenist and co-workers (2003) 
showed that the ATM protein is held in an inactive state as a dimer or 
higher order multimer which becomes dissociated (by intermolecular auto- 
phosphorylation) following exposure to irradiation. The authors further 
suggested that this event subsequently initiates the intrinsic kinase activity 
of ATM through allowing accessibility to substrates of ATM. 
The 350 amino acid kinase domain of ATM is able, not only to control cell 
cycle checkpoints at the G1/S and G2/M boundaries, but also affects the 
repair of DNA DSBs mediated by HRR. For example, A-T cells were found 
to be unable to arrest at either the G1/S or G2/M boundaries following 
exposure to irradiation (Shiloh and Kastan, 2001). Furthermore, A-T cells 
exhibit radio resistant DNA synthesis (RDS) (i. e. they have a characteristic 
inability to arrest DNA synthesis after irradiation) (Houldsworth and Lavin, 
1980 and Painter and Young, 1980). 
ATM mediated phosphorylation of CHK2 has been shown to be crucial for 
G1, S and G2 arrest following exposure to IR. For example, Falck and co- 
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workers (2001) showed that the ATM protein is involved in S-phase arrest 
by noting that irradiation induced degradation of cdc25A required both ATM 
and CHK2 mediated phosphorylation on the serine 123 residue. In addition, 
ATM mediated phosphorylation of CHK2 negatively regulates cdc23c 
activity, which is involved in G2/M arrest (Matsuoka et al., 1998). Aside 
from the CHK2 substrate, ATM also phosphorylates p53 and Mdm2, both of 
which have been shown to be specifically involved in G1/S arrest following 
exposure to IR (Banin et al., 1998; Canman et al., 1998 and Maya et al., 
2001). ATM additionally influences S-phase arrest (through its ability to 
phosphorylate NBS1, BRCA1, FANCD2 and SMC1) and G2/M arrest 
(through its ability to phosphorylate BRCA1 and hRad17) (Taniguchi et al., 
2002; Lim et al., 2000; Kim S. et al., 2002; Xu B., et al., 2001 and 2002 and 
Bao et a/., 2001). 
Many lines of evidence have also implicated a function for ATM in HRR. 
For example, ATM has been shown to interact with and phosphorylate 
proteins such as RPA, NBS1, BRCA1 and c-Abl (for reviews see: Lavin and 
Khanna, 1999; Khanna et al., 2001 and Shiloh, 2001). In addition the 
kinetics of mammalian RAD51 complexes are greatly altered in A-T cells in 
response to DNA DSBs and in ATM-/- DT40 chicken cells (Chen et al., 
1999 and Morrison et aL, 2000). Furthermore, ATM -deficient cells not only 
showed altered kinetics of irradiation induced RAD51 and RAD54 foci 
formation, but also display defects in RAD54 mediated HRR (Morrison et 
a/., 2000). These findings, along with the observation of general aberrant 
recombination repair (such as increased intra-chromosomal recombination 
events) in A-T cells, indicate an important involvement of this kinase in HRR 
(Meyn S., 1993 and Luo et al., 1996). 
The ATR kinase was originally identified in 1996 as a member of the PIKK 
super family of proteins (Cimprich et al., 1996). At present Seckel 
syndrome is the only human disease that has been associated with ATR 
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deficiency (O'Driscoll et al., 2003). However, ATR deficiency in mice is 
embryonic lethal and cells lacking ATR become non-viable within a few cell 
divisions (Brown and Baltimore, 2000 and de Klein et al., 2000). Taken 
together such results demonstrate the importance of this protein for cell 
survival. 
The ATR protein is thought to function by regulating responses to bulky 
lesions as well as replication inhibitors. Such lesions range from pyrimidine 
dimmers to stalled replication forks to DNA DSBs (Brown and Baltimore, 
2003; Casper et a!., 2002 and Pichierri et al., 2003). Techniques 
predominantly used to study the function of ATR include: over-expression of 
a dominant negative construct or the use of a cre-/ox-mediated gene loss 
system. Recent reports indicate that ATR is required for checkpoint 
responses to DNA damage induced by agents such as UV light, replication 
inhibiting agents and hypoxia (Cilby et a!., 1998; Cortez et al., 2001; 
Nghiem et a!., 2001 and Hammond et a!., 2002). In support of this, 
substrates for ATR include CHK1, CHK2, p53 an BRCA1 (Tibbetts et a!., 
1999 and 2000; Xu X. et aL, 2002 and Zhao and Piwnica-Worms, 2001). 
Thus it seems likely that ATR has a key role in G1, S-phase and G2/M 
arrest. Furthermore, the ATR protein is thought to function in cooperation 
with an ATR-interacting protein (ATRIP) in order to bind to sites of DNA 
damage (Cortez et aL, 2001). 
Casper and co-workers (2002) demonstrated that ATR, and not ATM, is 
critical for the maintenance of fragile sites which are expressed when DNA 
replication is inhibited. The authors further suggested that ATR was 
responsible for not only stabilizing and later restarting stalled replication 
forks, but also inhibiting late origin firing in the presence of DNA stress, 
hence blocking M-phase entry before replication is complete. In line with 
this, deletion of Mecl p function in budding yeast, resulted in genome wide 
fork stalling followed by chromosome breakage (Cha and Kleckner, 2002). 
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Interestingly, ATR has recently been shown to also be involved in cell cycle 
arrest following exposure to irradiation and DNA replication inhibitors (such 
as aphidicolin) in conjunction with ATM (Tibbetts et al., 1999). Brown and 
Baltimore (2003) used the cre-lox-mediated gene loss system to 
demonstrate that, following exposure of cells to irradiation, ATR regulated 
late phase response to M-phase entry, in addition to cooperating with ATM 
in the early phase. The same study also showed that stalled DNA 
replication forks were found to instigate cell cycle arrest in an ATR and ATM 
mediated phosphorylation of the CHK1 and CHK2 (respectively) /cdc2 
pathway. 
CHKI/CHK2 
The ATM and ATR signal transduction control of DNA damage responses is 
well documented to be mediated in part by the CHK1 and CHK2 kinases 
(reviewed in Carr, 2002). The human CHK2 kinase is a structural and 
functional homolog of Saccharomyces cerevisiae RAD53 (26% identical 
and 37% similar) and Schizosaccharomyces pombe Cdsl (26% identical 
and 34% similar). CHK2 is predominantly involved in preventing entry into 
the synthesis phase and the mitotic phases of the cell cycle (Chebab et al., 
2000; Hirao et aL, 2000 and Shieh et al., 2000 and Matsuoka et al., 1998). 
CHK2 becomes phosphorylated and subsequently activated in an ATM and 
ATR dependent manner (Brown et al., 1999; Chaturvedi et al., 1999; 
Matsuoka et al., 1998 and 2000 and Xu X. et al., 2002). Phosphorylation 
specifically occurs within a phospho- amino acid binding motif (known as 
the FHA domain) and/or a SQ and TQ cluster domain located in the N- 
terminus (Matsuoka et al., 2000 and Xu X. et al., 2002). Dominant negative 
and CHK2 knockout mutants fail to arrest in the G1/S phase when 
responding to IR due to an inability to phosphorylate p53 (Hirao et al., 2000 
and Chehab et aL, 2000). Such results suggest an involvement of CHK2 in 
G1 phase cell cycle arrest. The involvement of CHK2 in intra-S phase cell 
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cycle arrest was initially illustrated when its yeast homolog, RAD53, was 
shown to be involved in protecting stalled replication forks from pathological 
rearrangements (Sogo et al., 2002). The authors proposed that active 
RAD53 prevented the accumulation of abnormal replication intermediates, 
hence allowing stalled replication forks to restart DNA synthesis. Following 
on from this study, Falck and co-workers (2001) reported that IR induced 
ATM dependent CHK2 phosphorylation inhibited the Cdc25A/cdk2 initiation 
of DNA replication, thus showing the involvement of CHK2 in an intra-S 
phase checkpoint in human cells. In addition it was noted that this specific 
checkpoint was also involved in an IR induced ATM dependent 
phosphorylation of NBS1, which subsequently inhibited DNA synthesis 
(Falck et aL, 2002). Irradiation induced ATM activation of CHK2 was also 
shown to require the phosphorylation of NBS1 within the MRE11 complex 
by Buscemi and co-workers (2001). Finally CHK2 mediates G2/M arrest 
through its ability to phosphorylate Cdc25c on an inhibitory site. This 
subsequently inhibits Cdc25c's ability to de-phosphorylate and activate 
Cdc/cyclinB complexes which are involved in the transition of mitotic cells 
(Matsuoka et aL, 1998). 
Like CHK2, the CHK1 kinase also becomes phosphorylated and activated 
in response to IR in mammals, as well as in yeast (Liu Q. et al., 2000; 
Sanchez et al., 1997 and 1999 and Walworth et al., 1996). This 58kDa 
protein is implicated in G1/S, intra-S and G2/M cell cycle arresting phases 
in an ATR predominant manner (Mailand et al., 2000; Zhou and Ellege, 
2000; Cliby et al., 2002 and Zhou et al., 2002). Furthermore, Feijoo and co- 
workers (2001) suggested that mammalian CHK1 was an essential 
component of the intra-S phase checkpoint. The authors suggested that 
CHK1 ensures that activation of late replication origins are blocked when 
early origin synthesis is inhibited. In addition, Xiao and co-workers (2003) 
demonstrated that CHK1 regulated not only the S-phase arrest, but also 
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G2/M phase arrest through its ability to target Cdc25A for degradation 
following camptothecin and doxorubicin treatment. 
BRCA I and BRCA2 
Both BRCA1 and BRCA2 gene products are thought to be involved in 
general genome maintenance as well as regulating HRR. Knockout 
mutations of either BRCA1 or BRCA2 in mice is lethal, even in early 
embryogenesis, although truncating mutations remain viable and have been 
used for functional studies (Ludwig et aL, 1997; Gowen et al., 1998 and 
Shen et aL, 1998). 
The BRCA1 gene was originally identified by positional cloning (Miki et aL, 
1994 and Futreal et al., 1994) and found to encode for an 1863 amino acid 
protein. Analysis of domain structures revealed that the N-terminus of 
BRCA1 contains a RING-finger domain. This domain regulates protein- 
protein or protein-DNA interactions via its interaction with zinc ions (Lorick 
et al, 1999 and Wu et al., 1996). In addition, this domain also has been 
shown to form a heterodimer with BARD1 (BRCA1-associated RING 
domain), which together mediates ubiquitin-conjugating enzyme-dependent 
ubiquitination in vitro (Hashizume et al., 2001). It therefore seems that 
BRCA1 regulates the proteosomal degradation of some proteins. Both 
FANCD2 and p53 co-localise with BRCA1 and undergo BRCA1-mediated 
monoubiquitination following the exposure of cells to IR (Garcia-Higuera et 
aL, 2001). The C-terminus of BRCA1 contains 2 BRCT repeats (Koonin et 
a/., 1996; Ekblad et aL, 2002 and Williams et al., 2001). Such repeats 
appear to be multifunctional in that they seem to be involved in, not only 
transcription control, but also in the repair of DNA DSBs (Gowen et al., 
1998 and Moynahan et al., 2001). Furthermore, missense mutations found 
in BRCA1 almost always occur within either the RING or BRCT domains, 
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thus underlining the importance of the two domains (Miki et al., 1994 and 
Futreal et al., 1994). 
Many lines of evidence suggest an involvement of BRCA1 in HRR and cell 
cycle regulation. Firstly, BRCA1 been shown to co-precipitate with RAD51 
and BRCA2 (Scully et al., 1997a). In addition, BRCA1, BRCA2 and RAD51 
foci co-localize following DNA damage or within the S-phase of the cell 
cycle (Scully et al., 1997b). Further studies have shown that BRCA1 
interacts with RAD51 (Chen et al., 1998). Interestingly, BRCA1 foci co- 
localize with the MRE11/RAD50/NBS1 complex although BRCA1/RAD51 
and BRCA1/RAD50 foci are not observed together (Zhong et al., 1999). 
Secondly, BRCA1 deficient cells have been shown to be hypersensitive to 
DNA cross linking agents and have impaired HRR (as measured by gene 
targeting and homology directed repair of a chromosomal break) 
(Moynahan et aL, 2001). Thirdly, BRCA1 appears to be involved in linking 
DNA repair and cell cycle arrest. For example, over-expression of BRCA1 
can activate the CDK inhibitor p21 which subsequently leads to G1 arrest 
(Deng and Brodie, 2000). In addition, Yarden and co-workers (2002) 
showed that BRCA1 also regulates the G2/M checkpoint through its 
interaction with CHK1 which subsequently acts as a negative feedback for 
the expression, phosphorylation and cellular localization of Cdc25c and the 
Cdc2/cyclinB kinase proteins. Thus in the absence of BRCA1, failure to 
activate the G1 and/or the G2/M checkpoint may result in irreversible 
chromosomal rearrangement and loss of genomic integrity. 
The BRCA2 gene was cloned in a similar fashion to BRCA1 (Wooster et al., 
1994 and Wooster et al., 1995) and shown to encode a 3418 amino acid 
protein. This protein interacts with BRCA1, RAD51 and RPA proteins, the 
foci of which re-localize in the S-phase or following DNA damage (Sharan et 
aL, 1997; Wong et al., 1997; Marmorstein et aL, 1998; Davies et al., 2001; 
Chen et al., 1998 and 1999). BRCA2 deficient tumour cells show increased 
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sensitivity to UV light, IR and to DNA cross linking agents (Morimatsu et al., 
1998 and Xia et al., 2001). Furthermore, such cells accumulated 
chromosomal abnormalities including breaks, aberrant chromatid 
exchanges and translocations (Patel et al., 1998; Tutt et al., 1999 and Yu 
V., et aL, 2000). 
Detailed amino acid alignment studies have showed that BRCA2 contains 
eight highly conserved `BRC' sequence repeats. These repeats are 
positioned between residues 990 and 2100 of the C-terminus of human 
BRCA2 (Wooster et a!., 1995; Bignell et a!., 1997 and Bork et a!., 1996). 
Each repeat is approximately 30 amino acids in length and appears to be 
the primary site by which BRCA2 interacts with RAD51 (Wong et a!., 1997 
and Chen et aL, 1999). Furthermore, Pellegrini and co-workers (2002) 
showed that the BRC4 repeat, within BRCA2, mimics a motif in RAD51 that 
serves as an interface for oligomerisation between individual RAD51 
monomers. Therefore BRCA2 may control the assembly of RAD51 
nucleoprotein filaments and therefore the initiation of HRR. Additional 
experimental data also suggest that BRCA2 is responsible for regulating 
HRR. For example, BRCA2 is required for the transportation of RAD51 to 
sites of DNA damage (Davies et aL, 2001). Furthermore, RAD51 foci failed 
to form in BRCA2 deficient cells following IR mediated DNA damage even 
though they co-localize in BRCA2 proficient cells (Chen et aL, 1999 and Yu 
V., et a!., 2000). Additional evidence for the involvement of BRCA2 in HRR 
was revealed when the C-terminus of BRCA2 was shown to have ssDNA 
binding activity (Yang H., et a!., 2002). Further more, Moynahan et a!., 
(2001) recently showed a severe defect in the repair of induced DNA DSBs 




Protein alignment studies have suggested that these three gene products 
share homology with the E. coli RecQ family of DNA and RNA helicases 
(Ellis et al., 1995 and Yu et al., 1996). The BLM gene encodes a 1417 
amino acid helicase that, like WRN, unwinds duplex DNA in a 3' to 5' 
manner in the presence of ATP (Karow et aL, 1997 and Neff et al., 1999). 
The involvement of BLM and WRN helicases in HRR has been 
demonstrated in many ways, most blatantly perhaps by the observation that 
both helicases can specifically bind to the crossover regions of Holliday 
junctions and subsequently assists in its resolution (Yang Q., et al., 2002). 
Furthermore, BLM has been shown to interact with several other proteins 
involved in DSB repair or DNA damage signalling, including BRCA1, 
MRE1 1 and ATM (Wang et al., 2000). Franchitto and co-workers (2002) 
demonstrated that the BLM protein is responsible for the re-localization of 
the MRE11/NBS1/RAD50 complex and BRCA1 to sites of replication arrest. 
This was supported by the observation that BLM is phosphorylated in an 
ATM dependent manner following replication arrest (Wang et al., 2000 and 
Ababou et aL, 2000). Thus it seems possible that BLM assists in the 
loading of these proteins onto abnormal DNA structures, similar to the yeast 
homolog, SGS1 (Frei and Gasser, 2000). Furthermore, hydroxyurea 
exposure to human fibroblasts resulted in the co-localization and 
association of BLM and RAD51 at sites of stalled replication forks 
(Sengupta et al., 2003). 
Amino acid alignment studies have revealed that the WRN helicase shares 
approximately 41% homology with the BLM helicase (Liu Z., et al., 1999). 
In addition to its helicase activity, this protein has a unique amino-terminal 
domain that has exonuclease activity (Kamath-Loeb et al., 1998 and Huang 
et al., 1998). Furthermore, all WS mutations have been reported to give 
rise to truncated proteins lacking C-terminal nuclear localization signals, 
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thus underlining the importance of this region (Matsumoto et al., 1997 and 
1998). The WRN helicase, like that reported for BLM, is involved in 
unwinding four-way structures as well as other abnormal duplex structures 
including hairpins (Brosh et al., 2001 and Bohr et al., 2000). 
The MUS81 protein was originally identified in a yeast-two hybrid screening 
assay where it was found to interact with RAD54 and Cdsl in budding and 
fission yeast, respectively (Boddy et al., 2000 and Interthal and Heyer, 
2000). MUS81 mutants are sensitive to agents that block replication fork 
progression (such as methyl methane suiphonate (MMS), hydroxyurea and 
UV irradiation) but resistant to y-radiation or DSBs when induced by the 
HO-endonuclease (Boddy of al., 2000 and Interthal and Heyer, 2000). 
These results, along with the observation that MUS81 mutants are defective 
in a late stage of meiotic recombination in Schizosaccharomyces pombe, 
have suggested that MUS81 has an important role in both mitotic and 
meiotic cells (Boddy et al., 2001). Protein alignment studies have revealed 
that the C-terminus of MUS81 shares high homology with a 200 amino acid 
domain in yeast RAD1 and human XPF endonucleases (Interthal and 
Heyer, 2000 and Mullen et al., 2001). In addition, biochemical studies have 
revealed that MUS81 acts as a heterodimer with MMS4 (in Saccharomyces 
cerevisiae) and Emel (in Schizosaccharomyces pombe). Such 
heterodimers exhibit endonuclease activity and have higher affinity for 3'flap 
regions or replication fork structures, than for Holliday junctions (Kaliraman 
of al., 2001 and Doe et al., 2002). The endonuclease activities of the 
MUS81/MMS4 heterodimer and the RAD1/RAD10 heterodimer are however 
distinct (Bastin-Shanower et al., 2003). Currently no human MUS81 partner 
has been reported, although this protein is speculated to share homology 
with MMS4 and Emel. In support of the observations in yeast, 
Constantinou and co-workers (2002) have suggested that human cells 
possess two distinct endonucleases that cleave Holliday junctions, with the 
MUS81 containing enonuclease involved in specifically resolving 3'flap 
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structures and replication fork intermediates. This study therefore supports 
a predominant role for human MUS81 in replication fork progression. 
Fanconi Anemia genes 
At least eight complementation groups have been associated with FA, 
although only six genes have been currently cloned (namely: FANC-A, 
FANC-C, FANC-D, FANC-E, FANC-F and FANC-G) (de Winter et al., 1998 
and 2000a and 2000b; Timmers et aL, 2001; Lo Ten Foe et al., 1996 and 
Strathdee et al., 1992). The FA proteins display little or no homology to 
other proteins and presently little is known about any functional domains. 
The highly conserved FANC-D gene encodes for two isoforms, namely 
FANCDI and FANCD2 respectively (Timmers et aL, 2001). The FANC-A, 
C, E, F and G gene products have been shown to interact in a nuclear 
complex (Garcia-Higuera et al., 1999; de Winter et aL, 2000 and Medhurst 
et al., 2001). Furthermore, Siddique and co-workers (2001) showed that 
FANC-F was specifically involved in stabilizing this complex, as well as 
being responsible for post-translational modification of FANCD2 in response 
to IR induced DNA damage. DNA DSBs, caused by IR, results in the ATM- 
dependent phosphorylation of serine 222 on FANCD2. Inter-strand DNA 
cross-links, however, caused by MMC, produce the mono-ubiquitination of 
FANCD2 on lysine 561 also via the FA nuclear complex (Grompe et al., 
2002). 
The FA gene products maybe involved in HRR as RAD51 foci fail to form in 
any of the FA deficient cells (Digweed et al., 2002). This effect was 
reversed when the deficiency was corrected in FA-A, C and G cells. 
Furthermore, using FA patient derived cells of several complementation 
groups, Donahue and co-workers (2003) showed that 'the FA-A, C and G 
proteins specifically functioned to suppress HRR and elevate end joining 
activities. Mono-ubiquitination of FANCD2 is therefore thought to generate 
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a separate signal that overcomes this suppression and activates HRR 
processes. This is supported by the observation that FANCD2 co-localizes 
and interacts with BRCA1, NBS1 and RAD51 following IR or MMC 
exposure in an ATM dependent manner (Taniguchi et al., 2002 and 
Nakanishi et aL, 2002). Fibroblasts derived from FA patients often display 
genomic instability that is exhibited by increased levels of spontaneous 
chromosomal breaks and deletions (Zakrzewski and Sperling, 1980; 
Papadopoulo et al., 1990 and Laquerbe et al., 1999). Furthermore, FA cells 
are hypersensitive to MMC and are deficient in DNA end joining (Auerbach 
and Wolman, 1976; Ishida and Buchwald, 1982; Carreau et al., 1999; 
Escarceller et al., 1997 and 1998; Lundberg et al., 2001 and Donahue and 
Campbell, 2002). 
1.3.4 Chromosomal instability and predisposition to Cancer. 
A majority of human cancers develop chromosomal abnormalities. Such 
abnormalities can range from alterations in chromosome numbers 
(aneuploidy) to structural aberrations (reviewed in van Gent et al., 2001). 
Most if not all human genetic disorders that exhibit chromosomal alterations 
are associated with an increased risk of developing cancer. Furthermore, 
defects in DNA repair pathways are thought to enhance tumourigenisis as a 
result of genetic instability. In support of this, mutations in tumour 
suppressor genes have been well documented to predispose individuals to 
cancer prone syndromes (reviewed in Levitt and Hickson, 2002). 
The human ATM gene is mutated in patients with the genetic pleotropic 
disorder Ataxia-Telangiectasia. This disorder is characterized by genetic 
instability, cerebellar degeneration, abnormalities in nervous, immune and 
reproductive systems, as well as a 30-40% lifetime risk of developing a 
malignancy (reviewed in Levitt and Hickson, 2002). Cells derived from such 
patients exhibit high levels of chromosomal aberrations, hypersensitivity to 
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IR, bleomycin, restriction endonucleases and inhibitors of topoisomerases 
(Johnson R., et al., 1999). In addition, mutations in the MRE11 or NBS1 
genes cause Ataxia-telangiectasia like disorder (ATLD) or Nijmegen 
breakage syndrome (NBS) respectively (Stewart et al., 1999 and Hall and 
Angele, 1999). Patients with ATLD exhibit similar symptoms to A-T patients 
but without telangiectasia. In addition, NBS has a similar phenotype to A-T, 
however, such patients are frequently mentally retarded as opposed 
possessing progressive cerebellar ataxia (Hall and Angele, 1999). Patients 
with A-T, ATLD or NBS frequently develop lymphomas (reviewed in Levitt 
and Hickson, 2002). 
Germline mutations in BRCA1 and BRCA2 account for 66% of breast and 
ovarian familial cancers and frequently encode a truncated protein (Castilla 
et al., 1994; Simard et al., 1994 and Friedman et al., 1994). Between 60 to 
80% of primary tumours associated with mutations in either BRCA1 or 
BRCA2 occur in the breast. Prostate and colon cancers make up for the 
majority of secondary tumours in such patients (reviewed in Levitt and 
Hickson, 2002). 
Mutations in BLM and WRN give rise to Bloom and Werner's syndrome 
respectively. Both of these syndromes are autosomal recessive disorders 
that are characterised by immunodeficiency, short stature, male infertility 
and an increased predisposition to malignancy (reviewed in Levitt and 
Hickson, 2002). Cells derived from Bloom and Werner's syndrome patient's 
exhibit chromosomal and DNA instability characterised by an increase in 
the frequency of sister chromatid exchanges, insertions and deletions and 
loss of heterozygosity (Thompson and Schild, 2002). 
Mutations in the Fanconi genes give rise to Fanconi Anemia (FA) which is a 
chromosome instability syndrome that is characterized by birth defects, 
bone marrow failure and cancer susceptibility. FA patients develop several 
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types of cancer including acute myeloid leukaemia's, squamous cell 
carcinoma of the head and neck and young onset pancreatic cancer (Alter, 
B. P., 1996 and van der Heijden et al., 2003). This syndrome affects 
between 1-5 million people worldwide (Joenje and Patel, 2001), with 
progressive bone marrow failure being the major cause of death. 
Although mutations in genes belonging to the RAD52 epistasis group have 
not been directly associated with cancer prone syndromes, chicken DT40 
cells in which HRR genes have been knocked out exhibit excessive 
chromosomal breaks and translocations (Thompson and Schild, 2002). 
1.4 Regulating roles of MMR proteins in Recombination 
repair. 
In addition to their role in removing replicative base mis-incorporations and 
polymerase slippage errors, the proteins involved in the eukaryotic MMR 
system also play a regulatory role in HRR. The importance of the 
interaction between the MMR system and recombination is illustrated in 
functional studies using mammalian cell lines deficient in MMR. Such 
studies have revealed that MMR deficient cells exhibit increased rates of 
spontaneous recombination as well as being sensitive to the recombination 
inducing agent, CPT, but resistant to MNNG (Ciotta et al., 1998; Pichierri et 
al., 2001 and Zhang et al., 2000). 
Several biochemical and genetic studies conducted in bacteria and yeast 
have suggested interactions between the MMR system and various 
recombination repair processes. Such studies have been based on the 
ability of MMR proteins to recognize various DNA structures. Firstly, the 
regulating activity of the MMR system in recombination was illustrated in 
studies using yeast, which showed that homeologous recombination 
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frequencies are increased in a MMR -deficient background (Chen W., et al., 
1999 and Nicholson et al., 2000). In particular, the disruption of the MSH2 
protein (in yeast) resulted in the highest increase in homeologous 
recombination events; this is consistent with the prominent role of MSH2 in 
MMR. A similar effect was also confirmed in mammalian cells derived from 
MSH2 knockout mice (Elliot and Jasin, 2001). Furthermore, Datta and co- 
workers (1997) also showed that a single mismatch was sufficient to inhibit 
recombination between otherwise identical sequences. This illustrates the 
close regulation for controlling recombination events between diverged 
sequences by the MMR system. Therefore it seems that the MMR system 
has a role in regulating recombination events between diverged sequences 
in order to prevent chromosome translocations, deletions and/or insertions. 
A second role for the MutS homologs in recombination processes was 
noted when the MSH2/MSH3 heterodimer was shown to be required to 
remove non-homologous DNA during both GC and SSA events (Evans et 
a/., 2000). During gene conversion, any non-homologous DNA that may be 
present at the 3' ends of the invading strand needs to be removed in order 
to initiate new DNA synthesis. The authors used chromatin 
immunoprecipitation to show that the MSH2/MSH3 heterodimer associated 
with these recombination intermediates early in DSBR in order to assist in 
the rejection of homeologous pairing and to stabilize non-homologous 3' 
end tails. This was consistent with initial work that showed that the 
MSH2/MSH3 heterodimer interacted with the RAD1/RAD10 heterodimer to 
remove any 3' ended ssDNA tails (Sugawara et al., 1997). In addition, it 
was shown that the MSH2/MSH3 heterodimer, along with RAD1/RAD10, 
was also involved in the deletion of intervening DNA sequences during 
SSA, and the resolution of SSA intermediates. However, the requirement 
for the MSH proteins was found to decrease as the length of the annealed 
homologous DNA flanking the DSB increases. Furthermore, Studamire and 
co-workers (1999) proposed that the MSH2/MSH3 heterodimer initially 
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binds to and stabilizes ssDNA tails before being displaced, in an ATP- 
dependent manner, to allow access for the RAD1/RAD10 endonuclease. 
However, the precise function of the MMR proteins in the removal of single- 
stranded 3' ends remains unclear. It is judged that the MMR proteins either 
stabilize annealed intermediates by binding to the unpaired ssDNA (thus 
enabling the RAD1/RAD10 heterodimer to trim off the non-homologous 
tails), or alternatively, the MMR proteins could recruit the NER proteins to 
the sites of recombination. Studies conducted in yeast indicated that these 
four proteins are only required to remove non-homologous ends that are 30 
nucleotides or longer, which also required the Srs2 helicase (Paques and 
Haber, 1997). 
Eukaryotic MutS homologs can also interact with mispaired bases occurring 
in recombination intermediates such as heteroduplex DNA, thereby 
preventing DNA extension. In Saccharomyces cerevisiae, proteins involved 
in MMR, have been shown to regulate not only heteroduplex tract length, 
but also the extension of the heteroduplex tract (Alani et al., 1994). 
Furthermore, in E. coli, both of the MutS and MutL proteins have been 
shown to inhibit RecA-mediated strand exchange activities in conditions 
where the newly formed heteroduplex DNA contained an excess of 
mispaired bases (Worth et al., 1994). The MutS homologs have also 
recently been shown to interact with Holliday junctions, thus triggering their 
resolution. For example, the Saccharomyces cerevisiae MSH2 protein was 
shown to have a high affinity for Holliday junctions in filter binding and 
electron microscopic analysis (Alani et al., 1997b). In addition, Marsischky 
and co-workers (1999) showed that the presence of the MSH6 protein 
changed the characteristics of the interaction between MSH2 and Holliday 
junctions in a way that greatly increased the affinity and specificity of MSH2 
for Holliday junctions. The importance for the binding of the MMR proteins 
to such a structure was proposed by the authors to enhance the activity of 
Holliday junction resolution enzymes. Thus the MMR proteins seem to be 
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involved in determining the extent of mispaired bases in heteroduplex DNA 
and in eliminating recombination intermediates. 
The final evidence for the involvement of MMR proteins in recombination 
processes is that the MSH4/MSH5 heterodimer has, to date, not been 
ascribed a role in MMR, but has rather been shown to be involved in meiotic 
recombination events (Ross-Macdonald and Roeder, 1994 and 
Hollingsworth et al., 1995). 
58 
CHAPTER ONE-INTRODUCTION 
1.5 Aim of present study. 
Cells that acquire MMR deficiency develop distinct mutator phenotypes that 
help drive the genetic changes needed for tumourigenisis. Such deficiency 
often results in cells acquiring an increased number of mutations as well as 
being hypersensitive to the cytotoxic effects of DSB-inducing agents (e. g. 
camptothecin and etoposide), MMC and S-phase cell cycle inhibitors (e. g. 
thymidine) (Mohindra et al., 2002; Jacob et aL, 2001 and Fiumicino of al., 
2000). Increasing evidence also suggests that components of the MMR 
system interact with other DNA repair pathways, including NER and HRR, 
in order to regulate DNA synthesis. 
A report published by Lundin and co-workers (2002a) has shown that HRR 
deficient cell lines also exhibit sensitivity to MMC and thymidine. Thus 
given the suggested involvement of the MMR proteins in HRR processes, 
and that such deficiency can confer thymidine sensitivity, the aim of this 
research project was three fold: 
To determine the integrity of the Homologous recombination repair 
pathway in MMR -deficient tumour cell lines. 
(ii) To determine the extent to which a deficiency in the Homologous 
recombination repair pathway is the result of mutations in genes. 
(iii) In the event of gene mutations contributing to Homologous 
recombination repair deficiency, to determine whether such 
mutations were responsible for the thymidine sensitivity observed in 
Mismatch repair tumour cells. 
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2.1 GENERAL MATERIALS. 
MATERIAL SUPPLIER 
6 well tissue culture plates Greiner Labortechnik 
12 well tissue culture plates Greiner Labortechnik 
100 mm tissue culture dishes Sarstedt Ltd. 
2m1,5m1,10ml Syringes Becton Dickinson & Company 
Syringe driven filter unit 0.22µm Millipore 
1.2ml Cryovials Nalgene Ltd. 
Genepulser electroporation cuvette 
0.4cm 
BioRad 
Centrifugal filter tube, 5000 NMWL Millipore 
Rehydration tray BioRad Laboratories Ltd. 
5ml plastic pipettes Corning Incoporated 
10 ml plastic pipettes Corning Incoporated 
10µ1,20µ1,200µI and Iml pipette tips Sarstedt Ltd. 
Filtered 10µ1,20µl, 200µ1 and 1ml pipette 
tips 
Starlab GMBH 
0.5ml, 1.5 ml and 2m1 eppendorf tubes Sarstedt Ltd. 
96 well PCR plates Advance Biotechnologies Ltd. 
Thin walled PCR tubes Intermountain Scientific 
Corporation 
PCR flat cap strips Advance Biotechnologies Ltd. 
Sterile disposable Scalpels Swann - Morton 
15m1 Falcon 2059 polypropylene tubes Becton Dickinson 
15 ml centrifuge tubes Iwakai Ltd. 
Table 2.1: Table showing plastics and disposables 
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EQUIPMENT SUPPLIER 
Ice Machine Scotsman Ice System Ltd. 
P2, P10, P200 and P1000 Pipettes Finpipette 
Coe Incubator Sanyo, Gallenkamp plc. 
Hereaus Centrifuge Sanyo 
UV spectrophotometer Eppendorf 
PCR machines MWG 
Water bath Grant Instruments Ltd. 
Vortex Scientific Industries Inc. 
Heating block Grant Instruments Ltd. 
Light Microscope Olympus 
Power Pac Bio-Rad Laboratories Ltd. 
Trans-Blot® Semi-dry Transfer cell Bio-Rad Laboratories Ltd. 
Water bath Grant Instruments Ltd. 
Vortex Scientific Industries Inc. 
Heating block Grant Instruments Ltd. 
Light Microscope Olympus 
Mini horizontal electrophoresis tank Bio-Rad Laboratories Ltd. 
UV Transilluminator UVP Inc. 
800W Microwave Panasonic 
Hotplate Magnetic Stirrer Chemlab 
PH meter Denever Instruments 
Electroporator Bio-Rad Laboratories Ltd. 
Orbital incubator Gallenkamp 
Orbital shaker Stuart Scientific 
ABI 7200 sequence detector Applied Biosystems 
ABI 377 sequencer Applied Biosystems 
Balance Toledo 
Table 2.2: Table showing Laboratory equipment and instruments 
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MATERIAL SUPPLIER 
Para film "M" laboratory film American National Can Ltd. 
Aluminium foil Terinex Ltd. 
Paper tissue Kimberly-Clark Corporation 
Autoclave tape Rexam Medical Packaging 
Latex examination gloves Ansell Medical 
Table 2.3: Table 
equipment 
showing miscellaneous disposable laboratory 
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2.2 METHODS. 
2.2.1 Western Blotting 
2.2.1.1 Buffers and Reagents. 
" RIPA buffer: 1% Nonidet P-40,0.5% Sodium deoxycholate, 0.1% SDS 
dissolved in PBS and stored at 4°C. 
" Phenyl Methyl Sulfonyl Fluoride (PMSF) (Calbiochem- Novabiochem 
Corporation) was dissolved in Isopropanol (57mM) at a concentration of 10 
mg/mI and stored at -20°C. 
" Protein electrolysis (sample) buffer: 1 ml glycerol, 0.5ml ß-mercaptoethanol, 
3ml 10% SDS, 1.25ml 1M Tris-base pH 6.7,1 mg Bromophenol Blue and 
stored at -20°C. 
"Ammonium Persulphate was prepared fresh at a concentration of 10% in 
ddH2O and stored at 4°C. 
"Acrylamide: 30% acrylogel solution (BDH Merck) was stored at 4°C until 
use. 
" Molecular weight marker: Dual Band Pre-stained protein marker (Bio-Rad) 
was stored at -20°C until use. 
"1 OX TGS (Running) buffer: 30g Tris-base, 144g Glycine, 1 Og SDS adjust up 
to 1000cc with ddH2O. 
" Sodium Dodecyl Sulphate (SDS) (Sigma). 10g of SDS was dissolved in 
100ml of ddH2O on a heating stirrer and kept at room temperature. 
" Towbin (transfer) buffer: 20mM Tris-base, 0.2M Glycine, 200ml Methanol 
adjust up to 1000cc with H20, autoclaved and stored at 4°C. 
" PBS-T: Phosphate Buffered Saline mixed with 0.1 % Tween- 20. 
" Blocking Solution. Dried low fat skimmed milk (Marvel) was dissolved in 
PBS-T. 
2.2.1.2 Experimental Procedure. 
Detailed analysis of protein expression was conducted using Sodium Dodecyl 
Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). This technique 
has been well documented to separate proteins in complex mixtures 
according to their size and molecular weight. The protein samples are 
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denatured and made monomeric by boiling in the presence of p- 
mercaptoethanol and negatively charged soap, namely SDS. p- 
mercaptoethanol is responsible for breaking disulphide bonds which occur 
between proteins. SDS, however, completely disrupts protein-protein 
interactions and denatures almost all proteins, thus resulting in the formation 
of linear molecules. This anionic detergent binds to protein polypeptide 
chains through its hydrophobic properties, thus imparting all proteins with a 
relatively equal negative charge. 
The acrylamide used in the gels is polymerised with the cross linker, 
bisacrylamide, which subsequently forms a matrix through which the protein 
monomers pass when in an electric field. The size of the protein being 
analysed correlated with the percentage of acrylamide used (Table 2.4). 
Large molecular weight proteins are separated using low percentage 
acrlyamide gels as opposed to small molecular weight proteins. The negative 
charge causes the proteins to migrate towards the cathode and become size 
fractionated. The smaller protein molecules are able to move faster through 
the polyacrylamide matrix than the larger molecules. A discontinuous gel 
system was used which enables the samples to be compressed into a thin 
starting band, from which finely resolved bands of individual proteins are 
separated. The discontinuous system has two parts, namely the upper gel 
(also called the stacking gel) and the lower resolving gel. Protein samples 
pass easily through the large poured matrix of the stacking gel before 
becoming concentrated and finely separated in the lower resolving gel. 
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PROTEIN %GEL 30% 1M TRIS- 10% 10% ddH2O TEMED 
SIZE RANG USED ACRLAMIDE BASE SDS APS (ml) (µl) 
kDa MIX (ml) pH8.8 (µl) (µl) 
(ml) 
40 - 200 8 2.6 3.75 100 100 3.45 10 
15 - 100 12 3.9 3.75 100 100 2.15 10 
5- 50 16 5.2 3.75 100 100 0.85 10 
TABLE 2.4 Table showing composition of 8-16% resolving gels. Stacking gels were 
composed of: 0.83ml (30% Acrylamide mix); 0.63ml (1M Tris pH 6.8); 3.45m! ddH2O; 50pl 
10%SDS; 50pl 10% APS and 1 OpI TEMED. 
Protein Extraction and Quantification 
All cells were grown in 100mm culture dishes to 80-90% confluence. 
Proteins of interest were extracted from the respective cell lines by re- 
suspending the cell pellet in 300µI of ice-cold RIPA buffer, containing the 
detergents NP-40 and sodium deoxycholate. The protease inhibitor, PMSF 
(3µI of 10mg/ml) was also added to the suspension. Cells were placed on ice 
for approximately 60 minutes, after which the protein was extracted by 
centrifuging at 15,000 xg using a bench-top micro-centrifuge at room 
temperature for 10 minutes to pellet out cell debris. The supernatant 
containing the extracted protein was aliquoted into 0.5m1 tubes and stored at 
-80°C until required. 
Protein samples were quantified based on the Bradford assay (1976), using 
the commercially available protein reagent CoomassieTM plus-200 (Pierce). 
Briefly, samples and standards were diluted in PBS to a final volume of 150µI. 
Bovine serum albumin (BSA) was used as the protein standard within the 
range of 0-25 µg/µl. Each sample was measured in triplicate. 150µI of Bio- 
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Rad protein dye was then added to all protein samples and standards. 
Protein concentrations were determined using an Anthos 2001 automated 
plate reader (Anthos Labtec Instruments) which measures the absorbance at 
595nm. All protein concentrations were calculated relative to the BSA 
standards. 
SDS-Polyacrylamide Gel Electrophoresis 
Components of resolving gels were selected in order to give optimal 
separation of the protein under investigation. Resolving gel mixes were 
prepared appropriately and poured into pre-assembled gel pouring 
apparatus. The gels were overlaid with butanol-saturated water and allowed 
to polymerise for 1 hour at room temperature. The butanol was drained off 
and the gel surface was briefly rinsed with water. The stacking gel was then 
poured, and a sample well comb (5.08mm by 0.75mm) inserted. The 
stacking gel was allowed to polymerise for approximately 20 minutes at room 
temperature. 50-100µg/ml of protein extracts was mixed with 10µI of 
reducing buffer and heated for 3 minutes at 100°C prior to loading. 12µI of 
pre-stained Rainbow molecular weight marker (Bio-Rad) was also loaded on 
each gel in order to aid the determination of molecular weight. Gels were 
then subjected to electrophoresis in 1x TGS running buffer at 125mV until 
the bromophenol blue tracking dye reached the bottom of the gel. 
Immuno-blotting 
Proteins resolved on SDS-PAGE gels were then transferred onto nitro- 
cellulose membrane (Hybond-ECL, Amersham) using a Trans-Blot® Semi- 
dry Transfer cell (Bio-Rad). Briefly, the gel and nitrocellulose membrane (of 
similar size) were allowed to soak in cold (4°C) transfer buffer for 10 minutes 
at room temperature. A blotting sandwich was then set up on the anode 
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plate of the transfer cell, such that the gel was in contact with a sheet of nitro- 
cellulose (Figure 2.1). Both were sandwiched between appropriately sized 
sheets of 3mm filter paper (Bio-Rad) (briefly soaked in cold transfer buffer). 
Any air bubbles were removed before the cathode plate was placed on top. 








Figure 2.1 Illustration of the Immuno-blotting procedure. A blotting sandwich was set 
up on the anode plate of the transfer cell. Proteins resolved on SDS-PAGE gels were 
transferred onto nitrocellulose membrane using a Trans-Blot® Semi-dry Transfer cell (Bio- 
Rad) 
Following the transfer of the proteins onto nitro-cellulose, the membrane was 
incubated on a rocking platform in 5% non-fat milk (w/v) for 1 hour at room 
temperature to block non-specific sites. The membrane was then incubated 
with the appropriate primary antibody mixed in 3% non-fat milk (w/v) 
overnight, shaking at 4°C. On the following day the membrane was washed 
(5 x 10 minutes, shaking at room temperature) in PBS-T to remove any 
excess unbound antibody. A species-specific IgG/horseradish peroxidase 
conjugate secondary antibody (diluted appropriately in 3% milk (w/v)) was 
then incubated with the membrane for 1 hour, shaking at room temperature. 
Membranes were finally washed (3 x5 minutes, shaking at room 
temperature) in PBS-T. 
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Protein detection 
All proteins were detected using the Amersham Enhanced 
Chemiluminescence (ECL) system according to manufacturer instructions. 
The two reagents were mixed in equal volumes (total volume of 3mls) and 
poured onto the membrane filter, which was agitated for 1 minute. The 
membrane was subsequently wrapped in cling film and then exposed to 
Kodak X-Ray film for between 5-15 minutes. Films were developed in the 
dark by initially immersing them in X-Ray developer (Kodak; diluted according 
to the enclosed instruction) for 2 minutes, followed by a brief wash in water. 
Films were then placed in X-Ray fixer (Kodak; diluted according to the 
enclosed instruction) for a further 2 minutes. Films were finally rinsed in tap 
water for 5 minutes and allowed to air dry. 
2.2.2 Southern Blotting. 
2.2.2.1 Buffers and Reagents. 
" DNA Lysis Buffer: 100mM Tris-HCI (pH8.5), 5mM EDTA, 0.2%SDS, 200mM 
NaCl. 
" Proteinase K (Sigma) was dissolved in water and used at a final 
concentration of 100µg/ml. 
" Restriction enzymes (Promega). Enzymes were used with supplied buffers 
and stored at -20°C. 
" Low melting agarose (BioWittaker) was dissolved in 1x TAE at a 
concentration of either 1 or 2% by heating in a microwave oven 
(Panasonic). 
" 1X TAE: 30mM Tris base, 20mM glacial acetic acid and 2 ml 0.5M EDTA 
dissolved in 1 litre of water; made to pH: 8.0. 
" Loading dye: 0.25% Bromophenol blue, 0.25% xylene cyanol and 30% 
glycerol in water. 
" Ethidium Bromide (Sigma). One tablet (100mg) was dissolved in 40ml of 
ddH2O. 
"100bp Molecular Weight Marker (Life Technologies Ltd). 
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" 20 x SSC stock solution: 3M NaCl, 300mM Na3 citrate salt (pH 7.0) 
dissolved in distilled water. Distilled water was also used in all subsequent 
dilutions. 
" 20% (w/v) SDS stock solution. 20g of SDS was dissolved in 90mis of 
distilled water. The SDS was dissolved by heating to 68°C, after which 
another 100mis of distilled water was added. Distilled water was also used in 
all subsequent dilutions. 
" Hybond-Nylon + transfer membrane (Amersham) was handled wearing 
gloves and stored at room temperature. 
" Sonicated DNA (Sigma). Was used at a concentration of 1 mg/ml and was 
dissolved in water and incubated overnight at 37°C. DNA was then sheered 
prior to use. 
" Denhardt's Solution: 2% (w/v) bovine serum albumin (Sigma), 2% (w/v) 
FicoIITM (Sigma) and 2% (w/v) polyvinylpyrrolidone (Sigma). The components 
were dissolved by incubating the solution overnight at 37°C. 
"Alpha dCTP 
" Pre-hybridisation solution: 5x SSC, 5x Denhardt's solution and 10% (w/v) 
SDS. The solution was made up to 25ml with sterile water. 0.5ml of a 
1 mg/ml solution of sonicated non-homologous DNA was denatured by 
heating to 100°C for 5 minutes prior to adding to the pre-hybridisation 
solution. 
" Hybridisation solution: 5x SSC, 5x Denhardt's solution and 10% (w/v) 
SDS. The solution was made up to 25ml with sterile water. 0.5ml of a 
1 mg/ml solution of sonicated non-homologous DNA was denatured by 
heating to 100°C for 5 minutes and added to the pre-hybridisation solution. 
0.1g/ml Dextran sulphate was also added to the hybridisation solution along 
with a labelled probe. 
2.2.2.2 Experimental Procedure. 
Southern Blotting is a technique initially developed by Edwin M. Southern in 
the late 1970s. This technique is often used to definitively ensure a particular 
fragment of DNA has been successfully integrated into the genome of a host 
organism. It enables the detection of a specific gene in a genome as well as 
being able to locate it with respect to restriction sites. Applications for 
Southern Blotting include the screening of DNA libraries, chromosome 
walking, in DNA-based disease diagnosis as well as in DNA fingerprinting. 
Both the integrity and copy number of the recombination reporter substrate, 
ScNeo was determined using this well established technique. 
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In brief, Southern Blotting involves the separation of digested DNA fragments 
on agarose gels followed by denaturation in situ (Figure 2.2, Page 75). The 
fragments are then transferred onto a solid support, e. g. nitrocellulose or 
nylon membrane, where the DNA fragments becomes fixed and immobilised. 
The DNA attached to the membrane is hybridised with a labelled nucleic acid 
probe of interest. The membrane is subsequently washed to remove 
unbound and weakly bound probe. Bands complementary to the probe are 
located by an appropriate detection system such as autoradiography. 
Estimating both the size and number of bands generated after the DNA is 
digested with different restriction enzymes, solely or in combination, makes it 
possible to place the target DNA within the context of restriction sites. 
Genomic DNA obtained from the MMR -proficient and -deficient cell lines, 
transfected with ScNeo, was extracted and purified using Proteinase K and 
phenol. Briefly, 500µI of DNA Lysis buffer was added to the monolayer of 
cells grown on 100mm culture dishes. Cells were then scrapped off the 
plates, using a rubber policeman, and placed into 15ml tubes. Proteinase K 
(final concentration 100µg/ml) was added to all samples and the DNA was 
incubated overnight at 37°C. The following day, DNA was precipitated using 
500µI of 100% Isopropanol and allowed to dry. All samples were then 
subjected to phenol-chloroform purification. Briefly, samples were re- 
suspended to a final volume of 5000 in distilled water. An equal volume of 
buffer saturated Phenol-Chloroform IsoAmyl alcohol mix (at a 25: 24: 1 ratio; 
BDH Labs) was added to the re-suspended DNA. Samples were briefly 
vortexed prior to centrifuging at room temperature at 13.2rpm for 3 minutes. 
The top aqueous layer was abstracted and placed in a clean Epindorff tube, 
after which the above step was repeated. DNA was then precipitated by 
adding 1.5mls of 100% Ethanol and 50µI of 3M Sodium Acetate (pH 5.2), 
samples briefly mixed and placed at -80°C for 30 minutes. Impurities were 
discarded by centrifuging all samples for 20 minutes at 13.2rpm at room 
temperature. The supernatant was then carefully removed and the pellet 
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obtained washed with ice-cold 70% ethanol. DNA was dried and re- 
suspended in an appropriate volume of distilled water. 
Careful attention was paid to ensure the purity of the DNA as contamination 
by salt, RNA, protein and DNases could render the DNA resistant to cleavage 
by restriction endonucleases. Restriction enzymes are protein enzymes that 
are capable of 'scanning' both single and double stranded DNA molecules 
and digesting the strands at a particular recognised sequence. Since the 
sites of cleavage of long DNA molecules are determined by their nucleotide 
sequence, the long DNAs are broken into discretely sized fragments; which is 
determined by the distance between restriction enzyme cleavage sites. Most 
enzymes are affected by high glycerol concentrations (as this can alter the 
dielectric constant of the mix and therefore affect the specificity of the 
enzyme). Subsequently the enzymes were used in conjunction with 
commercially supplied buffers which diluted the enzyme (thus keeping the 
glycerol concentration to <10%) to avoid this problem. The integrity of the 
recombination reporter substrate was determined by digesting approximately 
10pg of each DNA sample with 50U of Xho I and Hind III in a 60µI reaction 
supplemented with BSA. This double digest should produce a 4kb sized 
fragment (Johnson et al., 1999). All digests were performed overnight at 
37°C. The DNA samples were mixed with Bromophenol blue tracking dye 
and size fractionated by gel electrophoresis. 5µI of each sample was run on 
a 1% agarose gel at 90V in order to ensure that the DNA was completely 
digested. 
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Figure 2.2 Illustration of Southern blotting procedure. Digested genomic DNA, 
obtained from MMR -proficient and -deficient tumour strains transfected with the ScNeo 
recombination reporter substrate, was separated by electrophoresis on agarose gels. DNA 
was subsequently transferred onto a nitrocellulose membrane by capillary transfer. 
Membranes were then hybridised with a radioactively labelled probe in order to allow for 
ScNeo detection. 
A 1% agarose gel was made using 1x TAE buffer and poured into 
horizontally laid casting trays. The gel was allowed to cool to approximately 
55°C, after which it was mixed with ethidium bromide (0.5µg/ml). Combs 
were then inserted, any air bubbles were removed and the gels were allowed 
to set for 1 hour at room temperature. The combs were then removed and 
the gel tray loaded into a chamber containing 1x TAE electrophoresis buffer 
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such that the DNA concentration resembled equal amounts throughout. 20µI 
of marker was loaded on either side of the samples in order to determine the 
size of DNA fragments. An electric voltage of 32V was then applied and the 
DNA fragments were allowed to migrate through the agarose pores overnight. 
Photographs of the gels were then taken with a ruler placed alongside the 
gels, both with and without the marker lane. This was performed in order to 
avoid excess binding of labelled probe to the DNA contained within the 
marker and to enable the 4Kb fragment to be identified. 
Following gel electrophoresis, the DNA was de-purinated in order to render it 
single stranded. This was done by incubating the gel in 0.25M HCl, shaking 
at room temperature for 30 minutes, until the bromophenol blue dye front 
changed colour. The gel was twice washed briefly in distilled water and 
allowed to re-hydrate for 10 minutes at room temperature. Care was taken 
not to expose the gel to acid for too long, as this would have resulted in the 
DNA being cleaved into small fragments which are too short to bind efficiently 
to the membrane. 
An important step in Southern blot hybridisation is the transfer of fragmented 
DNA to a solid support. DNA is transferred to nylon membranes as the 
agarose gels used are often too fragile and the DNA within the gel too easily 
diffusible to withstand the blotting procedure. Supported nylon membranes, 
however, are far more durable and also have a high DNA binding capacity. 
During capillary transfer, DNA is carried from the gel in an upward flow of 
liquid where it attaches to the surface of the membrane. The liquid is 
attracted through the gel by capillary action which is secured and preserved 
by a stack of dry absorbent paper towels. The rate at which the DNA is 
transferred depends mainly on the concentration of the agarose gels used 
and the size of the DNA fragments. The efficiency of transfer of large DNA 
fragments is determined by the fraction of molecules that escape from the gel 
before it becomes de-hydrated. To alleviate this problem, the DNA in the 
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gels was exposed to HCI followed by denaturation using 0.4M NaOH, which 
subsequently hydrolysed the phosphodiester backbone at the sites of de- 
purination. The size fractionated DNA was transferred to a sheet of nylon H+ 
membrane by capillary action (Figure 2.2). Briefly, a wick was made on a 
raised platform by saturating three sheets of Whatman 3MM filter paper in 
0.4M NaOH. The agarose gel was then placed on top of the wick, with care 
taken to avoid trapping any air bubbles beneath the gel. A sheet of Hybond- 
N+ membrane (which was cut to the exact size of the gel) was carefully 
placed on top of the gel, again avoiding trapped air bubbles. Both the gel and 
the membrane were then surrounded with cling film in order to prevent the 
buffer being absorbed directly into the paper towels above. A further three 
sheets of 3MM filter paper (cut to an appropriate size) were saturated in 0.4M 
NaOH and placed on top of the membrane. A stack of absorbent paper 
towels (approximately 5cm high) were then placed on top of the filter paper. 
A tray and a1 Kg weight were placed on top of the paper towels. The DNA 
was allowed to transfer for approximately 12-16 hours at room temperature. 
Following the completion of transfer, the apparatus was dismantled and the 
membrane was marked with a pencil in order to identify which side the DNA 
was bound. The membrane was then briefly washed in 2x SSPE to remove 
any adhering agarose and was prepared for pre-hybridisation. 
Membranes were pre-hybridised in pre-hybridisation solution at 65°C for 24 
hours prior to the addition of the Neo probe (Figure 3.1). This pre- 
hybridisation step prepares the membrane for probe hybridisation by blocking 
off the non-specific nucleic acid binding sites on the membrane. This 
subsequently results in a lower signal to noise ratio. The pre-hybridisation 
solution also contains non-specific DNA, such as sonicated salmon sperm 
DNA, in order to lower the background. Following pre-hybridisation, the 
membrane was immersed in hybridisation solution which contained a 
radioactively labelled, denatured probe. The labelled probe molecules bind 
onto complementary molecules which are bound onto the membrane. The 
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subsequent formation of double-stranded DNA strands results in the binding 
of the probe to the sheet. The probe was labelled using a Prime-It® Random 
Primer Labelling Kit (Stratagene) following manufacturers instructions. This 
system makes use of the ability of random hexanucleotides annealing to 
multiple sites along the length of a DNA template. The primer-template 
complexes serve as a substrate for the Klenow fragment of DNA polymerase 
I, which subsequently synthesizes new DNA. The newly synthesised probe is 
made radioactive by addition of radio labelled 32P-adCTP to the mixture. 
Membranes were incubated in hybridisation solution for approximately 12-16 
hours, rotating at 65°C. Hybridisation is often carried out at a low stringency 
(which refers to the conditions of the hybridisation as compared to the 
temperature required to separate the DNA strands). This insures that the 
probe will bind to the target DNA. The membranes were washed repeatedly 
using low to high stringency conditions such that un-hybridised probe is 
removed but the hydrogen bonds between the probe and sample DNA are 
not disrupted. To begin with, all membranes were washed twice in 2x SSC, 
0.1% SDS (w/v) shaking, at room temperature for 10 minutes. The washing 
solution was then replaced with 1x SSC, 0.1% (w/v) SDS, and the 
membranes incubated shaking at 65°C for 15 minutes. In the final step, the 
membranes were washed with 0.1 x SSC, 0.1% (w/v) SDS at 65°C for 10 
minutes. The blots were then wrapped in plastic and of the areas where the 
labelled probe fragments bound was detected by phosphoimaging (Biorad 
Machine name, number software). Images were prepared for printing using 
Adobe Photoshop software. 
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2.2.3 DNA Amplification and Purification. 
2.2.3.1 Uterine Tissue Sample Preparation and microdissection. 
Appropriate formalin fixed, paraffin embedded tissue blocks were selected 
from eight cases of uterine leiomyosarcomas. Normal myometrium and 
tumour tissue were separately marked by the histopathologist (Dr. Jason 
Stone) after which 10µm sections were microdissected to give enriched 
(>80%) normal and tumour tissue. The paraffin wax was removed from the 
slides in two washes of xylene. Samples were subsequently re-hydrated 
using consecutive washes in 100% ethanol, 95% ethanol, 70% ethanol and 
distilled water. Following this, both the tumour tissue and surrounding 
tissue was micro-dissected out using a scalpel. Both tissue samples from 
each slide were transferred into respective 1.5ml microcentrifuge tubes. All 
samples were subsequently purified using a QlAamp DNA Mini Kit 
(QIAGEN). In this procedure, samples were lysed in 360µI of tissue lysis 
buffer and 400µg Proteinase K and incubated at 56°C until the tissue was 
completely lysed. The rest of the DNA extraction procedure involved 
binding of DNA onto a silica-gel-membrane and several washing steps to 
wash away protein and other contaminants. The DNA was eluted with an 
elution buffer. All DNA samples were quantified and kept at -20°C until use. 
2.2.3.2 Polymerase Chain Reaction (PCR). 
2.2.3.2.1 Buffers and Reagents. 
"25µI final reaction volume using 2x PCR Master-mix (ABgene) contains: 
"1.25 units Taq DNA polymerase, 75mM Tris-HCI (pH: 8.8), 20mM 
Ammonium Sulphate, 1.5mM Magnesium Chloride, 0.01% (v/v) Tween 20, 
0.2mM each of dATP, dCTP, dGTP and dTTP. 
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2.2.3.2.2 Experimental procedure. 
Genomic DNA and cDNA amplification was obtained using the Polymerase 
Chain Reaction (PCR) technique. PCR enables the amplification of a specific 
region of DNA through the use of thermo stable DNA polymerases. Typically, 
PCR often results in a million fold amplification of the target DNA. This 
technique is often used in such applications as gene cloning, sequencing and 
site-directed mutagenesis. 
All reactions were prepared according to manufacturers instructions at room 
temperature using sterile equipment. In all cases 100ng of DNA and 10 pmol 
of both forward and reverse primers were used unless stated. PCRs contain 
several components, apart from the template DNA and pairs of synthetic 
oligonucleotides which prime DNA synthesis, including a thermo stable DNA 
polymerase, deoxyribonucleoside triphosphates and divalent cations. The 
DNA Taq polymerase used is generally the most frequently used polymerase 
for routine PCRs. The optimal temperature for this, and most, polymerase 
enzymes is between 72 and 74°C. The synthetic oligonucleotides used were 
carefully designed in order to obtain the product of interest in high yield. 
Careful primer design also suppresses the amplification of unwanted 
sequences and facilitates subsequent manipulation of the amplified product. 
The oligonucleotides used, were on average 20 nucleotides in length and, 
where possible, had aG or aC residue as the last one or two bases on the 
3'end. Both of these factors enabled stronger hybridisation of the 
oligonucleotides to the target DNA and also ensured recognition by the 
polymerase. 
The mechanism by which PCR works involves denaturation of the target DNA 
by heat; annealing of primers which are complementary to the opposing 
strands; followed by extension of the annealed primers by DNA polymerases. 
The length and the G/C content of the dsDNA template determines both the 
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temperature and the length of time used for the denaturation step of typical 
PCRs. Denaturation is generally carried out at 94-95°C as this is the highest 
temperature that most polymerases can endure without being damaged. All 
PCRs used in the present study were carried out in a DNA thermocycler 
supplied by MWG. The initial denaturation step was carried out at 94°C for 5 
minutes in order to increase the chance of fully separating the DNA strands 
(Table 2.5). The temperatures used for annealing of synthetic 
oligonucleotides are described in the Appendix. Generally, annealing was 
carried out 2°C lower than the calculated melting temperature at which the 
oligonucleotide primer dissociates from the template. The extension of 
oligonucleotide primers was carried out at 72°C in all cases. 
All PCR products were then purified using either a QlAquick® PCR 
purification Kit or a QlAquick® Gel Extraction Kit. DNA samples purified 
using the QlAquick® Gel Extraction Kit were initially separated on 1% 
agarose gels and the correctly sized DNA fragment was carefully excised 
using a sharp blade. Both the PCR purification and gel extraction systems 
make use of a silica gel membrane which binds DNA in the presence of a 
high salt concentration and a pH of 57.5. Once bound, the DNA is washed 
off impurities (such as unincorporated primers and partially amplified 
products) by repeatedly washing the columns with an ethanol containing 
buffer. All DNA was finally eluted in 30pl of sterile water. 
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STEP CYCLES TEMPERATUR TIME 
Denaturation of template DNA 1 94°C 5 mins 
Denaturation of template DNA 
40 
94°C 30 secs 
Annealing of oligonucleotides 50-60°C 45 secs 
Primer extension 72°C 1 min/kb 
Final extension step 1 72°C 5 mins 
Table 2.5 Table showing typical PCR cycling steps and temperatures used for DNA 
amplification. 
2.2.3.3 Reverse-Transcriptase Polymerase Chain Reaction (RT- 
PCR). 
2.2.3.3.1 Buffers and Reagents. 
" 25µI final reaction volume using 2x RT-PCR Master-mix (ABgene) 
contains: 
Thermoprime plus DNA polymerase (Final concentration: 0.625U/25µ1, 
1.5mM Magnesium Chloride, 0.2mM each of dATP, dCTP, dGTP and dTTP. 
0.5µI of Reverse-iTTM Blend (50U/µl) was also added to each reaction. 
" RQ1 RNase-free DNase Kit (Promega). 
2.2.3.3.2 Experimental Procedure. 
RT-PCR is a technique frequently used to amplify cDNA copies of mRNA. It 
allows the detection of gene expression even when the RNA of interest is 
expressed at low levels and/or when there is only limiting amounts of RNA 
available. Principally, RT-PCR consists of two reactions, namely the reverse 
transcriptase reaction which is followed by polymerase chain reaction to 
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amplify cDNA copies. A reverse gene specific primer is initially hybridised to 
the mRNA transcript. The primer is extended by an RNA-dependent DNA 
polymerase called reverse transcriptase, which subsequently converts RNA 
into a single-stranded cDNA template. Once the first cDNA strand has been 
synthesised, the mRNA-cDNA hybrid is denatured to allow for second cDNA 
strand synthesis. The synthesis of the second strand is initiated by the 
forward primer and is completed with a thermo stable DNA polymerase. The 
cDNA product is then amplified by a standard PCR which generates multiple 
copies of desired cDNA. In our studies, this technique was used to screen for 
mutations in transcribed sequences containing mononucleotide runs. 
RT-PCRs contain several components, apart from the template RNA and the 
reverse transcriptase enzyme, including thermo stable DNA polymerases; 
pairs of synthetic oligonucleotides (which prime cDNA synthesis); 
deoxyribonucleoside triphosphates and divalent cations. A variety of primers 
can be used, apart from gene specific primers, including the use of Oligo (dT) 
primers (which bind specifically to endogenous poly (A) + tails of mammalian 
mRNAs) or random hexanucleotides (which prime cDNA synthesis at random 
points along RNA templates). Total RNA was extracted from mammalian cell 
lines using standard procedures (RNeasy(D protect mini kit, Qiagen) and 
subjected to DNase treatment (Promega) in order to eliminate genomic DNA 
contamination. The deoxyribonuclease' I present degrades both single and 
double stranded DNA molecules in order to produce 3'-hydroxyl 
oligonucleotides whilst maintaining the integrity of RNA. Briefly, 8pl of 
extracted RNA was mixed with 1 pI of 1 OX reaction buffer and 1 pI of RNase- 
Free DNase. The mixture was incubated at 37°C for 30 minutes, after which 
1 pi of DNase stop solution was added and the reaction incubated for a further 
10 minutes at 65°C to inactivate the DNase and terminate the reaction. 
RT-PCRs were conducted using the Reverse-iTTM 
ONE-STEP RT-PCR Kit 
(ABgene) following manufacturer instructions. Between 10pg - 1µg of total 
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extracted RNA was used along with 1Opmol of each forward and reverse 
primer in a 25pl total reaction volume. Typical reaction conditions are shown 
in Table 2.6 and were conducted in a DNA thermocycler (MWG). 
Temperatures used for annealing of synthetic oligonucleotides and respective 
sequences are described in the Appendix. All cDNA products were purified 
using either a QlAquick® PCR purification Kit or a QlAquick® Gel Extraction 
Kit as previously described. 5µI of cDNA product was loaded on a 2% 
agarose gel and compared to the DNA size marker to ensure that the correct 
sized product was obtained. 
STEP CYCLES TEMPERATURE TIME 
First Stand Synthesis 1 47°C 30 mins 
RTase Blend inactivation and initial 
denaturation 
1 94°C 2 mins 
Denaturation 
40 
94°C 30 secs 
Annealing 50-60°C 30 secs 
Extension 72°C 1 min/kb 
Final Extension 1 72°C 5 mins 
Table 2.6 Table showing typical RT-PCR cycling steps and temperatures used for 
cDNA amplification. 
2.2.3.4 DNA Sequencing. 
DNA sequencing enables the precise sequence of nucleotides in a sample of 
DNA to be determined. Both the Maxam and Gilbert (chemical, 1977) and the 
Sanger (enzyme, 1977) methods of sequencing involve the synthesis of a set 
of molecules which have a common end and can be separated by size 
fractionation using polyacrylamide gel electrophoresis. The enzymatic 
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method of sequencing, initially developed by Sanger (1977), makes use of 
four specific dideoxynucleotides (ddNTPs) which terminate the synthesis of 
template DNA. This method is also known as the chain termination method 
as the ddNTPs used, lack an OH group on the deoxyribose, thus resulting in 
the termination of chain elongation once incorporated. A primer labelled with 
a fluorescent tag is annealed to a single-stranded DNA template molecule 
and a DNA polymerase extends the primer by using ddNTPs. The extension 
reaction is split into four and each quarter is terminated separately with one of 
the four specific ddNTPs, thus creating a competition between extension of 
the chain and base-specific termination. The four samples can be separated 
by PAGE and the locations of each band can be detected through the 
emission of fluorescence. 
2.2.3.4.1 Experimental Procedure. 
cDNA expression studies and sequencing was accomplished using a 
SequiTerm EXCELTM II DNA Sequencing Kit (Epicentre Technologies) as 
described originally by Steffens et aL, (1995) which uses the chain 
termination principle. All sequencing reactions were prepared using sterile 
equipment, according to manufacturers' instructions. Reagents were thawed 
on ice and gently vortexed before use. All reactions were completed using a 
DNA thermocycler (MWG); typical cycling conditions are shown in Table 2.7. 
Temperatures used for annealing of synthetic oligonucleotides are described 
in the Appendix. The template DNA was purified extensively using either a 
QlAquick® PCR purification Kit or a QlAquick® Gel Extraction Kit prior to 
sequencing, as contamination by salt, RNA, protein and DNases could all 
obstruct the quality of sequence and read length obtained. The sequencing 
primer which annealed in a 5' to 3' direction to the template was labelled with 
a pentamethine carbocyanine dye (IRD700) and had an absorption maximum 
of 685nm. The complementary sequencing primer was labelled with a 
heptamethine cyanine dye (IRD800) and had an absorption maximum of 
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795nm. As both dyes become absorbed and fluoresce near to the infrared 
region of the spectrum, they enable DNA fragments to be sequenced in both 
directions. 
Upon completion of the sequencing reaction, 3µI of Stop/Loading Buffer 
(provided) was added to each reaction and samples stored at -20°C until 
ready for sequencing. All reactions were denatured at 96°C for 3 minutes 
prior to being subjected to electrophoresis, which was performed using a Li- 
Cor IR2 420-S DNA Analysis system (Li-Cor Inc. ). Between 0.5-1µI of each 
reaction was then loaded on to a 6% Long rang gel by Dr. Ian Brock (Institute 
for Cancer Studies) and run at 1500V for between 7-9 hours. Sequences of 
gene fragments were detected using the AlignIRTM and BaselmagIRTM soft 
wares (Li-Cor Inc. ). Detailed analysis was also conducted using the 
Sequencher software 4.1 (Gene code corporation) and Adobe Photoshop 
(7.0). 
STEP CYCLES TEMPERATURE TIME 
Denaturation of template DNA 1 94°C 5 mins 
Denaturation of template DNA 
40 
94°C 30 secs 
Annealing of oligonucleotides 50-60°C 45 secs 
Primer extension 72°C 1 min/Kb 
Final extension step 1 72°C 5 mins 
Table 2.7 Table showing typical sequencing reaction steps and temperatures used 
for DNA amplification. 
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2.2.4 Agarose Gel Electrophoresis 
2.2.4.1 Buffers and Reagents. 
" Low melting agarose (BioWittaker) was dissolved in 1x TAE at a 
concentration of either 1 or 2% by heating in a microwave oven 
(Panasonic). 
" 1X TAE: 30mM Tris base, 20mM glacial acetic acid and 2 ml 0.5M EDTA 
mix in 1 litre of water (pH: 8.0). 
" Loading dye: 0.25% Bromophenol blue, 0.25% xylene cyanol and 30% 
glycerol in water. 
" Ethidium Bromide (Sigma). One tablet (100mg) was dissolved in 40m! of 
ddH2O. 
" 100bp Molecular Weight Marker (Life Technologies Ltd). 
2.2.4.2 Experimental Procedure. 
Agarose gel electrophoresis separates DNA fragments according to their 
size. When agarose is dissolved in boiling water and then cooled it 
polymerizes thus resulting in a semi-solid matrix containing pores. The pore 
size can be controlled by the concentration of agarose used, thus different 
concentrations of gel allows the optimal resolution of fragments in different 
size ranges. The melted agarose was allowed to cool to approximately 55°C 
after which 0.5pg/ml Ethidium Bromide was added. Ethidium bromide 
intercalates into DNA molecules thus staining it and allowing visualization of 
fragments by UV. The solution was then allowed to solidify in an 
electrophoresis tray (Bio-Rad) containing an appropriately sized comb. Once 
the gel had set, the combs were removed and the tray transferred to an 
electrophoresis tank (Bio-Rad) containing 1x TAE running buffer. DNA 
samples were mixed with loading buffer and loaded into the wells. 
Electrophoresis was performed at 70-100 volts at room temperature until the 
tracking dye reached the bottom of the gel. DNA bands were visualized on a 
UV- Transilluminator (UVP Inc. ). The sizes of DNA fragments were estimated 
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by comparison to 5µI of DNA Hyperladder marker (Gibco BRL) which was run 
on the same gel. 
2.2.5 Pulse-Field Gel Electrophoresis. 
2.2.5.1 Buffers and Reagents 
" Pulse-field low melting agarose (BioWittaker) was dissolved in 0.5 x TBE 
at a concentration of either 0.8 or 1% by heating in a microwave oven 
(Panasonic). 
" 10 X TBE buffer: 108g Tris-base, 55g Boric acid, 40ml 0.5M EDTA and 
ddH2O. The pH was adjusted to 8.0 such that the final volume was 1 litre. 
" 10 X TE buffer: 10mM Tris-CI (pH 7.4) and 1mM EDTA (pH8.0) and the 
final pH was adjusted to 7.4. 
"0.5M EDTA: dissolve 186.1g of dissodium ethylene diamine tetra-acetate 
into 1 litre of ddH2O. The pH was adjusted to 8.0 with NaOH 
" Ethidium Bromide (Sigma). One tablet (100mg) was dissolved in 40ml of 
ddH2O. 
2.2.5.2 Experimental Procedure 
5x 106 cells were plated onto 10cm tissue culture plates 24 hours prior to 
treatment. Cells were treated with either 10mM thymidine or 100nM CPT. 
Following treatment, cells were trypsinised from the plates and 1x 106 cells 
were melted into 0.8% agarose inserts. For IR treatment, 1x 106 cells were 
melted into 0.8% agarose inserts, after which samples were placed in tubes 
containing 2mls of D-MEM medium. Such tubes were then placed on ice and 
exposed to 1OGy IR. All agarose inserts were then incubated at 50°C in 0.5M 
EDTA, 1% N-laurylsarcosyl and 1 mg/ml proteinase K for 48 hours. Inserts 
were then washed four times for 2 hours in 1x TE buffer. Samples were then 
loaded onto 1% agarose gels (made with pulse-field agarose and 0.5 x TBE). 
Electrophoresis was carried out at 120° angle, 60-240 seconds switch time at 
4V/cm for 24 hours (BioRad). Gels were subsequently stained in a solution 
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of 0.5 x TBE and 1mg/ml ethidium bromide for 2 hours before being 
visualized on a UV illuminator. 
2.2.6 Tissue Culture. 
2.2.6.1 Buffers and Reagents. 
" Phosphate Buffered Saline (PBS) was prepared by dissolving one tablet 
(Oxoid Ltd. ) in 100ml distilled water and was autoclaved before use. 
" Dimethyl Sulphoxide (DMSO) (BDH Merck) was prepared at 10% (v/v) in 
tissue culture media and used for freezing cells. 
. Tissue culture media: Dulbecco's modified eagle's medium (DMEM) 
supplemented with 4.5g/L Glucose and L-Glutamine was purchased from 
BioWhittaker Ltd. and stored at 4°C until use. All tissue culture media was 
supplemented with 10% foetal calf serum and checked for sterility before use. 
" Foetal Calf Serum (FCS) (Helena BioSciences) was aliquoted in 50ml tubes 
and stored at -20°C until use. 
" Non-essential Amino Acids was purchased from BioWhittaker Ltd. and 
stored at 4°C until use. 
" Presept was supplied by Johnson and Johnson Medical. One tablet of 
Presept containing 50% Sodium Dichloroisocyanurate was dissolved in 1 litre 
of sterilized water and kept in room temperature. 
" Trypsin (Gibco BRL) was purchased as a 2.5% solution and diluted at 1: 20 
with sterile PBS and stored at - 20°C until use. 
" Versene/EDTA (ethyelenediamine tetra-acetic acid) was supplied by BDH 
Merck. 0.2g EDTA was dissolved in 1litre of PBS, aliquoted in 10ml bottles, 
autoclaved at 1 Olb/inch2 for 10 minutes and stored at -20°C until use. 
" Geneticin (G418 sulphate) (Invitrogen) was made as a stock concentration 
of100mg/ml and dissolved in ddH2O. 
"Thymidine (Sigma) was made as a stock concentration of 10mM and 
dissolved in media. 
" CPT and MMC (Sigma) were both made at appropriate concentrations and 
dissolved in DMSO and media respectively. 
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2.2.6.2 Experimental Procedures. 
Maintenance and characteristics of cell lines used 
Cell culture was performed in Class II biological safety cabinet (Forma 
Scientific Inc. ) using sterile equipment. All cell lines used (Table 2.8a and 
2.8b) were cultured adherently in Dulbecco's Modified Eagle Medium 
supplemented with 10% foetal calf serum in a humidified 5% carbon-dioxide 
incubator, at 37°C. All cell lines were routinely passaged on 100mm culture 
dishes at a ratio of 1: 20 approximately every 4 days using a 1: 1 dilution of 
0.25% trypsin and 0.02% EDTA. 
Thawing and Freezing of cell lines. 
Cryovials of frozen cells were immediately transferred to a 37°C water bath, 
to allow rapid thawing and thus limiting the toxicity of the DMSO. Once 
thawed, cells were centrifuged at 400 xg to remove any traces of DMSO, 
re-suspended in culture medium and transferred to a 100mm culture dish. 
For freezing cells, 1x 107 cells were re-suspended in 10ml of culture media 
and centrifuged at 400 x g. The culture media was then removed and cells 
re-suspended in medium supplemented with DMSO (10% DMSO, 20% 
FCS, and 70% DMEM). The cell suspension was then transferred into 2 ml 
cryovial tubes and stored at -80°C. 
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MMR PROFICIENT TUMOUR CELL LINES 
OTHER 
CELL LINE TISSUE SOURCE IDENTIFIED 
CHANGES 
SW480 Colorectal adenocarcinoma p53""; 
APC truncation 
SW620 Colorectal adenocarcinoma p53-' 
MRC-5 Lung foetal fibroblast SV-40 
transformed 
LM217E Immortalised human 
fibroblast 
HELAS3 Cervical carcinoma 
Table 2.8a Table showing all MMR -proficient tumour cell lines used in the present 
study. Respective tissue sources and any additional changes are also indicated. All cell 
lines were obtained from ATCC unless stated otherwise 
Cytotoxicity Assays. 
The cytotoxic response to DNA damaging agents was measured in 
Dulbecco's Modified Eagle Medium supplemented with 10% foetal calf 
serum. The cytotoxic response to thymidine was measured in medium 
supplemented with 10% dialyzed serum (in which exogenous sources of 
deoxynucleosides have been removed). Briefly, 500 to 1000 cells were 
plated into 100mm culture dishes and continuously treated with varying 
concentrations of thymidine, camptothecin and mitomycin C. Cells were 
allowed to grow for 10 to 14 days in a humidified 5% carbon-dioxide 
incubator, at 37°C before staining with 0.4% methylene blue/ 50% methanol 
(Fisher Scientific). Colonies of >50 cells were scored. The surviving fraction 
was determined by dividing the average number of colonies for each 
treatment by the average number of colonies in the control plates. All 
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experiments were plated in triplicate and were repeated independently two to 
five times. 
The cytotoxic response to irradiation was measured in Dulbecco's Modified 
Eagle Medium supplemented with 10% foetal calf serum. 5x 105 cells were 
counted and incubated on ice for 10 minutes, after which they were irradiated 
at varying doses. The cells were then placed on ice for a further 10 minutes 
and re-plated at a cell density of 500cells/plate. Cells were incubated for 10 
to 14 days in a humidified 5% carbon-dioxide incubator, at 37°C before 
staining with 0.4% methylene blue/ 50% methanol (Fisher Scientific). 
Colonies of >50 cells were scored. The surviving fraction was determined by 
dividing the average number of colonies for each treatment by the average 
number of colonies in the control plate. All experiments were plated in 
triplicate and were repeated independently two to five times. 
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MMR -DEFICIENT TUMOUR CELL LINES 




2774 Ovarian hMSH2 " p53"" 
DLD-1 Colorectal adenocarcinom hMSH6-" Pols+-; p53 " 
SKUT-1 Leiyomyosarcoma hMSH2" p53 "" 
HCT116 Colorectal carcinoma hMLH1""; reduced 
expression of hPMS2 
Activated Ras; 
TGF-ß RII +/' 
HEC1A Adenocarcinoma hPMS2""; reduced 
expression of hMLH1 
RKO Colon MutL a TGF-ß RII 
RKO-E6 Colon MutL a p53 null 
LS411 N Colorectal carcinoma MutL a 
SW48 Colorectal adenocarcinom hMSH6-/-, hMLH1- 
methylation silenced 
expression 
Table 2.8b Table showing all MMR -deficient tumour cell lines used in the present 
study. Respective tissue sources, MMR defects and any additional changes are also 
indicated. All cell lines were obtained from ATCC unless stated otherwise 
Transfections. 
Transfection is a technique in which a gene of interest is introduced into a 
mammalian cell line by biochemical or physical methods. Applications for this 
process include studying gene function, as well as observing the genes 
regulation and interaction with other host mammalian genes. Various 
chemical and physical methods have been developed to enable the 
transfection of DNA into mammalian cells, including calcium phosphate co 
precipitation, electroporation, and complex formation with DEAE-dextran or 
cationic lipid reagents. 
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The ScNeo construct was stably integrated into the host genome by 
transfecting the various MMR -proficient and -deficient cells using 
electroporation. This method delivers DNA molecules by exposing cells to a 
brief electrical pulse of high field strength. The exposure to a cell suspension 
induces a potential difference across the membrane of the cell which 
subsequently is thought to instigate temporary hydrophobic and hydrophilic 
pores in the membrane and enables DNA molecules to enter. Briefly, 15 x 106 
cells were counted and re-suspended in a total volume of 750µI PBS. The 
cells were then mixed with 15µg of uncut ScNeo substrate (diluted with ddH2O 
to a final volume of 50µI) into pre-chilled 0.4cm electroporation cuvettes (Bio- 
Rad) and placed on ice for 10 minutes. Cells were then electroplated at 
0.4kV/ 50µF using an Easy Jet Plus Electroporator (Gene Flow), placed on 
ice for a further 10 minutes, after which they were plated on culture dishes 
containing non-selective medium. Hygromycin (final concentration 0.1mM) 
was added to the medium after 48 hours and subsequent colonies were 
isolated and expanded from each cell line. 
All other constructs used were transfected into the respective cell lines using 
LipofectamineTM 2000 (Invitrogen). This reagent contains positively charged 
liposomes which are attracted electro statically to the phosphate backbone of 
DNA as well as to the negatively charged surface of the cell membrane. 
Briefly, 1x 106 exponentially growing cells were plated into 6 well plates and 
allowed to attach overnight. The following day, 2µg of purified plasmid DNA 
was mixed with Lipofectamine (final concentration 10µg/ml) and 400mls of 
serum-free media. Serum-free medium was used as some serum proteins 
can interfere with the liposome-DNA complex formation. This mixture was 
allowed to amalgamate at room temperature for a minimum of 30 minutes. 
Cells were then washed twice with serum-free medium, after which the DNA 
containing mixture was added along with 1.6ml of serum-free medium. Cells 
were incubated at 37°C for either 5 hours or overnight and thereafter re- 
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plated in selective medium. Six to eight colonies were isolated and expanded 
from each cell line and plasmid expression analyzed. 
Recombination Assays. 
Verification for the integrity of the homologous recombination repair pathway, 
in both MMR -proficient and -deficient cells, was conducted using an assay 
developed by Jasin and co-workers. The ScNeo reporter substrate (Figure 
3.1, Page 104) enables the measurement for homology based recombination 
of two defective neomycin phosphotransferase genes following the 
introduction of either a DSB by a transiently expressed restriction 
endonuclease or a substrate which stimulates homologous recombination 
events. 
1-Scel induced. 
Approximately 5x 106 cells were plated onto 100mm culture dishes and 
allowed to attach overnight at 37°C. The DSB was then induced into the cells 
by transiently transfecting the pCMV3nls-I-Scel expression vector (10ng) for 
5 hours using Liopfectamine, after which the medium was changed to normal 
medium containing serum. The following day all cells were re-plated onto 
100mm culture dishes at varying cell densities, ranging from 2x 104 to 2x 
105 cells/plate, and again allowed to attach overnight. The recombination 
frequencies of Neo+ recombinants were determined by selection in media 
containing 1mg/ml G418 (Invitrogen). In addition, two dishes were plated with 
500 cells each for cloning efficiency. Cells were allowed to grow for 10-14 
days before staining with 0.4% methylene blue/50% methanol (Sigma). Only 
colonies of >_ 50 cells were subsequently scored. The frequencies of neo+ 
recombinants presented are the number of neo+ colonies formed/(cells plated 
x the cloning efficiency of the plated cultures). All experiments were plated in 
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duplicate and repeated independently four to six times. Recombination 
frequencies were determined using Microsoft Excell. 
Drug induced. 
Spontaneous recombination events induced by various agents were 
diminished by initially plating 1000 cells in 6-well plates. Twelve confluent 
wells for each dose used were then re-plated onto 100mm culture dishes and 
allowed to attach. Approximately 1x 106 cells per replica were treated with 
increasing doses of respective agent for 24 hours after which the cells were 
allowed to recover for 48 hours post treatment. Cells treated with varying 
doses of thymidine was performed using medium supplemented with 10% 
dialyzed serum. Each replica was then re-plated onto 100mm culture dishes 
(at a cell density of 2x 105 cells/plate) and allowed to attach overnight. The 
frequency of neomycin resistant colonies was determined by selection in 
media containing 1mg/ml G418 (Invitrogen). In addition, two dishes were 
plated with 500 cells each for cloning efficiency for each replica. Cells were 
allowed to grow for 10-14 days before staining with 0.4% methylene 
blue/50% methanol (Sigma). Only colonies of ? 50 cells were subsequently 
scored. The frequencies of neo+ recombinants presented are the number of 
neo+ colonies formed/(cells plated x the cloning efficiency of the plated 
cultures). Each replica was considered as an independent experiment and 
each dose of drug treatment was repeated at least twice. 
Apoptosis Measurements 
In order to determine whether MMR -deficient tumour strains possessed an 
acute sensitivity to cell death following expression of the I-Scel 
endonuclease, cells were co-transfected with a GFP-plasmid and the 
pCMV3nls-I-Scel expression vector (10ng). Transfection of DNA was 
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achieved using Liopfectamine as described above. 24 hours post- 
transfection, 0.01 mg/ml Hoechst 33342 stain was added to the medium in 
order to assess the number of condensed apoptotic nuclei. After 30 minutes, 
apoptosing cells were observed by fluorescence microscopy and a minimum 
of 500 nuclei expressing GFP were counted. Cells were counted as 
apoptotic if their nuclei were obviously bright blue and condensed. 
2.2.7 DNA Cloning 
2.2.7.1 Buffers and Reagents. 
"The pcDNA3.1N5-His© TOPOO TA Expression kit (Invitrogen) was used 
for cloning XRCC2 cDNA. 
*The plRESpuro3 expression vector (Clontech) was used to examine the 
effects of expressing 342delT on recombination frequencies. 
" Luria- Bertani (LB) medium was made by dissolving 25g of LB broth 
(Merck) in 1 litre of water. pH was adjusted to 7 with 5N NaOH. The 
medium was autoclaved at 15lb/inch2 for 20 minutes and kept at room 
temperature. 
" LB agar was made by dissolving 25g of LB broth in 1 litre of water. 15g 
agar was added and dissolved before autoclaving. 
2.2.7.2 Experimental Procedures. 
Bacterial Culture. 
The E-coli strain DH5a was used for maintenance and propagation of all 
plasmid DNA used. Bacterial cells were grown in L-Broth (supplemented with 
100pg/ml Ampicillin), at 37°C in a shaking incubator (225 rpm) in all cases. 
Transformed bacteria were plated onto agar plates which were made with 
1.5% (w/v) agar (in L-Broth) supplemented with 100pg/ml Ampicillin. 
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Plasmid Vector constructs. 
Plasmid vectors are circular, self-replicating DNA molecules that are capable 
of existing in cells as extra-chromosomal genetic elements. Plasmids are 
frequently used when investigating genetic functions as they are easy to 
isolate and manipulate. All plasmids are relatively small in size (2 - 200Kb), 
contain an origin of replication and have an antibiotic resistance gene. 
Genes of interest can be cloned into restriction sites contained within the 
multiple-cloning site of the plasmid. 
The pcDNA3.1N5-His-TOPO® expression vector contains a single 3' 
thymidine (T) overhang. Gene specific primers were used in an RT-PCR also 
containing Taq. polymerase which has a template independent terminal 
transferase activity that adds a single deoxyadenosine (A) residue to the 3' 
ends of the PCR product. Successful cloning reactions can be achieved by 
ligating the complementary ends together. The pcDNAXRCC2 vector was 
constructed by cloning the XRCC2 gene from the SKUT-1 cell line into the 
PCR site of the pcDNA3.1N5-His© TOPO® TA expression vector. Briefly, 2µI 
of the RT-PCR product was mixed with 1 µl of salt solution and 1 µl of TOPO 
vector DNA. Sterile water was added to a final volume of 5µI. The reaction 
was incubated for 5 minutes at room temperature before the plasmid was 
chemically transformed. 
Sub-cloning 
Effects of the mutant XRCC2 allele on HRR events were investigated by sub- 
cloning the gene into the pIRES-puro3 expression vector (Clontech). The 
pIRES-puro3 vector contains an internal ribosome entry site (IRES) of the 
encephalomyocarditis virus (ECMV), which permits the translation of two 
open reading frames from one messenger RNA. Therefore after selection 
with puromycin, nearly all surviving colonies will stably express the gene of 
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interest. The pIRES-XRCC2 vector was constructed by initially excising the 
XRCC2 gene from the pcDNAXRCC2 vector using the BamHl and Notl 
restriction endonucleases. The insert was separated by agarose gel 
electrphoresis and purified using a QlAquick0 Gel Extraction Kit. of the 
pIRES-puro vector was also digested using the same restriction 
endonucleases and purified using a QlAquick® PCR purification Kit. The 
vector was then treated with shrimp alkaline phosphatase at 65°C for 10 
minutes, thus preventing re-ligation of the linear vector. Alkaline 
phosphatase treatment removes phosphate groups from 5'ends of the DNA 
molecules. Concentration of both the vector and insert DNA was then 
estimated using agarose gel electrophoresis along with molecular weight 
standards of a known concentration. Recombinant DNA was produced by 
using ligases which catalyse the formation of phosphodiester bonds between 
the directly adjacent 3'hydroxyl and 5'-phosphoryl termini of nucleic acid 
molecules. The insert was ligated to the vector in a 3: 1 molar ratio of 
insert: vector. Briefly, 1 Weiss unit of T4 DNA ligase (New England Biolabs) 
was used in a 10µI reaction containing vector DNA, insert DNA, 10 x Ligase 
buffer and distilled water. The ligation reaction of the protruding ends was 
conducted overnight at 4°C. 
Transformation 
Transformation reactions were conducted using sterile equipment and in front 
of a flame. Briefly, a 50µI vial containing DH5a competent E-coli cells were 
gently thawed on ice. 2µI of the cloning reaction was incubated with the 
competent cells on ice for 30 minutes. The reaction was then heat shocked 
at 42°C for 30seconds and immediately transferred to ice for a further 2 
minutes. 250µI of room temperature SOC medium was added to the cells 
and the reaction was incubated in an orbital incubator (225rpm horizontally) 
at 37°C for approximately 1 hour. Varying cell concentrations were then 
plated onto LB-agar culture plates (supplemented with 50µg/ml Ampicillin) 
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and incubated overnight at 37°C. The following day, six to eight well isolated 
colonies were picked off the plates using sterile pipette tips and were 
inoculated in 10mIs of L-Broth (supplemented with 100µg/ml Ampicillin), at 
37°C in an orbital incubator (225 rpm). 
Plasmid Extraction and Purification 
Bacteria were recovered form overnight cultures by centrifugation at 4000 xg 
for 10 minutes at 4°C. The supernatant was discarded and plasmid 
extraction was performed using a QlAprep spin Miniprep kit (QIAGEN). 
Briefly, this method is based on alkaline lysis of bacterial cells followed by the 
binding of DNA to silica gel membranes in the presence of a high salt 
concentration and a pH of : 57.5. Once bound, the DNA is washed off 
impurities by repeatedly washing the columns with an ethanol containing 
buffer. All DNA was finally eluted in 30µI of sterile water. Conformation of 
both orientation and integrity of the inserted DNA was achieved by direct 
sequencing and/or restriction digestion and subsequent electrophoresis. 
2.2.8 Statistical Analysis 
Statistical analysis to measure standard deviation and standard error was 
conducted using Microsoft Excell. Wilcoxon signed rank test was 
conducted by Dr. Angie Cox using Stata (version 6) software. 
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3.1 INTRODUCTION 
Several studies have shown that MMR -deficient tumour cells are sensitive 
to some DNA damaging agents (e. g. MMC and camptothecin) and S-phase 
cell cycle inhibitors (e. g. thymidine) (Mohindra et al., 2002; Jacobs et al., 
2001 and Fiumicino et al., 2000). In the case of the MMR -deficient tumour 
cell line, HCT116, the hypersensitive phenotype to thymidine was shown 
not to be due to the consequence of the MMR deficiency itself. HCT116+3 
cells, that were corrected for the hMLH1 deficiency (by chromosomal 
transfer), still exhibited marked sensitivity to this agent (Mohindra et al., 
2002). These results therefore suggested that mechanisms other than the 
loss of MMR could lead to thymidine sensitivity. 
Studies conducted by Lundin and co-workers (2002a) showed that the HRR 
deficient cell line, irs1SF, was also sensitive to thymidine when compared to 
both the wild-type and XRCC3 corrected cell lines. The addition of 
thymidine induces an imbalance in dCTP and dTTP pools that subsequently 
results in the slowing of DNA replication forks (Bjursell and Reichard, 1973). 
It is proposed that this retardation of replication fork progression may result 
in the accumulation of DNA lesions that specifically requires a proficient 
HRR pathway for cell survival (Lundin et al., 2002a and Henry-Mowatt et al., 
2003). 
Increasing evidence suggests that components of the MMR system interact 
with various recombination repair intermediates. For example, the yeast 
MMR proteins are thought to assist in the removal of non-homologous 3' 
ends during both GC and SSA events and the removal of mismatched 
bases occurring in heteroduplex DNA (Evans et al., 2000; Sugawara et al., 
1997; Studamire et al., 1999 and Marsischky et aL, 1999). Taken together 
these studies suggest that proteins involved in both the MMR and HRR 
processes interact and that both pathways are required in order to maintain 
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the progression of DNA replication forks. Thus given such interactions, 
studies conducted in the present chapter investigated the integrity of the 
HRR pathway in MMR -deficient tumour cell lines. 
To determine the integrity of the HRR pathway in MMR -deficient tumour 
cell lines, a recombination reporter substrate, ScNeo, was used (Figure 
3.1). This substrate has effectively been used to demonstrate HRR 
deficiencies in XRCC2, XRCC3, BRCAI and BRCA2 -deficient cell lines 
(Johnson et al., 1999; Pierce et al., 1999, Moynahan et al., 2001a and 
2001b). Integration of the ScNeo substrate into cell lines enables HRR 
events to be assayed by measuring recombination events between two 
defective neomycin phospho-transferase genes. The first 0.7kb neo repeat, 
termed 3' neo, contains a 5' truncation of the neo gene and is upstream with 
respect to the promoter region. The second defective neomycin phospho- 
transferase gene, termed S2neo, however, is mutated by a small internal 
deletion that destroys an internal Ncol site and is replaced with an 18 base- 
pair I-Scel endonuclease site. The two neo repeats are in direct orientation 
to each other and are separated by a functional 2.1 kb hygromycin 
resistance gene. As this substrate is composed of two defective neo 
heteroalleles that are placed as direct repeats, it specifically detects DSB- 
induced recombination events which occur on the same chromatid (intra- 
chromatid) or on sister chromatids. 
Once integrated into cell lines, DSBs can be induced by transiently 
transfecting a plasmid that expresses the I-Scel endonuclease. I-Scel is a 
rare cutting endonuclease that can be used to generate a site-specific 
chromosomal break (reviewed in Dujon, 1989). Homologous recombination 
between the two neo repeats subsequently results in a functional neomycin 
phospho-transferase resistance gene. NHEJ recombinants, however, do 
not contain a functional copy of the neomycin resistance gene and therefore 
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the frequency of HRR events can be specifically scored by counting 
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Figure 3.1 Structure of the recombination reporter substrate, ScNeo. Two defective 
neomycin phospho-transferase genes, namely 3'neo and S2neo, are separated by a 
functional 2.1 kb hygromycin resistance gene. A functional neomycin phospho-transferase 
gene can be restored following the induction of a DSB. Two types of recombination events 
are possible. LTGC/SCE events repair the DSB by using the sister chromatid as the repair 
template and results in expansion of the substrate from 2 and 3 neo containing repeats. 
STGC events, however, repair DSBs through intra-chromatid pairing and do not alter the 
overall architecture of the ScNeo substrate. 
Two distinct neomycin resistant recombinants are formed depending on the 
type of repair substrate used. Analysis of both the short tract gene 
conversion (STGC) and long tract gene conversion (LTGC)/sister chromatid 
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exchange (SCE) event products revealed that non-crossover gene 
conversion events occurred as expected when using a direct repeat assay 
(Moynahan and Jasin, 1997; Richardson et al., 1998 and Johnson and 
Jasin, 2000). LTGC or SCE events result in the expansion of the substrate 
from two to three neo containing repeats. The broken end in S2neo 
invades the homologous 3' neo template for repair and after synthesis is 
completed, the newly synthesised strand can re-anneal with the non- 
invading strand. The subsequent repair product contains additional 
functional neomycin and hygromycin resistance genes. The STGC event 
occurs when the region immediately surrounding the DSB is repaired using 
the same chromatid or sister chromatid (following replication), thus not 
changing the overall length of the 4kb substrate. 
In addition to using the I-Scel endonuclease to induce HRR events, the 
integrity of other HRR mechanisms involved in repairing lesions induced by 
thymidine, was also investigated in the present chapter. Accumulating 
evidence from bacteria and yeast suggest that proteins involved in HRR are 
required to repair collapsed or stalled replication forks (Cox, 2001; Kraus et 
al., 2001 and Michel et al., 2001). In addition, Lundin and co-workers 
(2002a) have suggested that HRR is specifically required for mammalian 
cell survival following thymidine treatment. This suggests that thymidine 
induces DNA lesions that are repaired by HRR events. 
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3.2 RESULTS 
3.2.1 Integration of the ScNeo recombination substrate. 
The proficiency of the HRR pathway was initially investigated in both MMR 
-proficient and -deficient tumour cell lines. To test the integrity of this 
pathway, the ScNeo recombination reporter substrate was used to measure 
homology based recombination of two defective neomycin phospho- 
transferase genes following the introduction of a DNA DSB (Johnson et al., 
1999). The vector containing ScNeo was electroporated into three MMR - 
proficient (SW480, SW620 and MRC5VA) and four MMR -deficient tumour 
cell lines (DLD-1, Hec-1-A, HCT116 and SKUT-1). The integrity of the 
integrated substrate was confirmed by screening hygromycin resistant 
colonies. Southern blot analysis, using S2neo as the labelled probe, 
revealed that all strains used in the present study contained intact copies of 
ScNeo (Figure 3.2b). 
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Figure 3.2 Strains derived from both MMR -proficient and -deficient cells 
contain intact copies of ScNeo. (A) S2neo was used as a labelled probe to detect 
the recombination substrate in genomic DNA extracted from the various cell types. (B) 
Southern blot showing that all strains contained intact copies of ScNeo. SW480/SN. 3,4 
and 5 and SW620SN. 2 and 3 are strains derived from the MMR -proficient cell lines, 
SW480 and SW620, respectively. The MRC5VA/SN. 13 strain was derived from the MMR 
-proficient fibroblast MRC5VA cell line. The DLD-1/SN. 2 and 6 strains were isolated from 
the hMSH6-deficient cell line DLD-1. The Hec-1-A/SN. 2 and 3 strains were isolated from 
the hPMS2-deficient cell line Hec-1-A. The HCT116/SN. 2 and 3 strains were derived from 
the hMLH1-deficient cell line HCT116 and the SKUT-1/SN. 3 and 5 strains were isolated 
from the hMSH2-deficient SKUT-1 cell line. 
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To investigate whether expression of the ScNeo recombination substrate 
altered the phenotype of MMR -proficient and -deficient cells, with respect 
to the cytotoxic effects of thymidine, the sensitivity of ScNeo-containing 
strains to this agent was examined (Figure 3.3). Exponentially growing cells 
were treated with increasing doses of thymidine and cell survival was 
determined after 10-14 days. Studies revealed that at 10% survival, the four 
MMR -deficient tumour cell lines investigated were between 3.2 to 4.6-fold 
more sensitive to cytotoxic effects of thymidine when compared to the 
SW480/SN. 3 strain. Furthermore, the extent of sensitivity to thymidine was 
determined to be dose dependent. Taken together these results show that 
MMR -proficient and -deficient strains, expressing ScNeo, exhibit similar 
patterns of sensitivity to thymidine as those reported for parental cells 
(Mohindra et aL, 2002). 
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Figure 3.3 MMR -deficient strains, transfected with ScNeo, are 
hypersensitive to the cytotoxic effects of thymidine. MMR -deficient/ScNeo 
transfected clones have mutations in hMLH1 (HCT116, Q), hMSH2 (SKUT-1, A), hPMS2 
(Hec-1-A, o) and hMSH6 (DLD-1, X). The MMR -proficient/ScNeo transfected clone, 
SW480/SN. 3 (+), is derived from the colorectal carcinoma SW480 cell line. The mean 
(symbols) and standard deviation (error bars) of three independent experiments performed 
in triplicate are presented. 
3.2.2 Analysis of the HRR pathway in MMR -proficient cells. 
The integrity of the HRR pathway was examined in MMR -proficient strains 
transfected with the ScNeo construct. A DSB was induced in all strains by 
transiently transfecting cells with a plasmid expressing the I-Scel 
endonuclease. Following the selection of cells in medium supplemented 
with G418, the MMR -proficient (SW480 and SW620) colon cancer cell lines 
produced neo+ recombinants at a frequency of 0.8 - 3.5 x 10"3 (Figure 3.4). 
This was between 370 to 1000-fold higher than frequencies obtained when 
the same strains that were not transfected with the expression vector 
(p=0.0077, Wilcoxon signed rank test). The frequency of neo+ 
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recombinants in a MMR -proficient fibroblast, MRC5VA, was also 
investigated. A strain stably expressing the ScNeo substrate produced 
neo+ recombinants at a frequency of 4.38 x 10"3. This was 110-fold higher 
when compared to the results obtained from mock transfected cultures. 
Taken together, these results suggest that MMR -proficient cells also 
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Figure 3.4 Induction of a DSB results in an increase in the frequency of neo+ 
recombinants in MMR -proficient cells. Induction of a DNA DSB (solid bars) in 
multiple strains derived from three parental MMR -proficient cell lines (namely SW480, 
SW620 and MRC5VA) resulted in an increase the frequency of neo+ recombinants by 110 
to 1000-fold when compared to mock transfected cultures (empty bars). The results shown 
are an average of three independent experiments and standard deviation is indicated by 
error bars. 
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3.2.3 Analysis of the HRR pathway in MMR -deficient cells. 
Having determined the integrity of the HRR pathway in three MMR 
-proficient cell lines, the proficiency of this pathway was also investigated in 
MMR -deficient tumour cell lines. The frequency of neo+ recombinants in 
four MMR deficient cell lines containing the ScNeo substrate, namely, 
DLD-1 (hMSH6"l"), Hec-1-A (hPMS2"l"), SKUT-1 (hMSH2"l-) and HCT116 
(hMLH1"'") was measured. As shown in Figure 3.5, induction of a DSB did 
not increase the frequency of neo+ recombinants in any strain investigated 
when compared to strains that were not transfected with the endonuclease 
(p=0.58, Wilcoxon signed rank test). Typically, both DSB -induced and 
spontaneous values ranged from between 0.21 to 2.72 x 10-6 (Figure 3.5). 
This range is between 200 to 15000-fold lower than the frequencies 
obtained in the MMR -proficient strains. These results suggest that MMR - 
deficient cells are defective in the production of neo+ recombinants in a 
homology based recombination assay. 
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Figure 3.5 MMR -deficient tumour cells are defective in the production of 
neo+ recombinants in a homology based assay. Induction of a DNA DSB (solid 
bars) in strains derived from four parental MMR -deficient cell lines showed no increase in 
the frequency of neo+ recombinants when compared to mock transfected cultures (empty 
bars). Results obtained from the same experiments using a MMR -proficient, SW480/SN. 3 
strain, is included for reference. The results shown are an average of three independent 
experiments and standard deviation is indicated by error bars. 
3.2.4 Transfection controls. 
The observation that MMR -deficient strains are defective in the production 
of neo+ recombinants in a homology based recombination assay could 
however be the result of an inability of these strains to take up and express 
the plasmid expressing the I-Scel endonuclease. To test this hypothesis, 
the percentage of cells taking up a construct expressing a green fluorescent 
tagged protein (GFP) from the same cytomegalovirus promoter in the 
expression vector pcDNA3 was determined. The number of cells emitting a 
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green fluorescence was determined by FACS analysis in three ScNeo 
transfected strains (one MMR -proficient and two MMR -deficient). Such 
repeated experiments (n=3) showed no differences between the three 
strains, with respect to the percentage of cells expressing GFP, 24 hours 
post transfection (Figure 3.6). On average, 12.8% of MMR -proficient 
SW480/SN. 3 cells expressed the green fluorescent protein as opposed to 
11.2% of DLD-1/SN. 2 and 8.2% of Hec-1-A/SN. 3 MMR -deficient cells. 
These results therefore suggested that there is no significant difference in 
the uptake and expression of a transgene from a CMV promoter between 
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Figure 3.6 Both MMR -proficient and -deficient tumour cells express similar 
amounts of GFP. No significant difference in the percentage of GFP+ cells was 
observed when the GFP construct was transfected into a MMR -proficient (SW480/SN. 3, 
shaded box) strain and two MMR -deficient (DLD-1/SN. 2 and Hec-1-A/SN. 3, empty boxes) 
strains. GFP expression was determined by FACs analysis 24 hours post transfection. 
The results are an average of three independent experiments and standard deviation is 
indicated by error bars. 
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3.2.5 The decrease in frequency of neo+ recombinants is not a 
consequence of apoptosis. 
The possibility that the ScNeo transfected, MMR -deficient strains 
possessed an acute sensitivity to cell death, following expression of the I- 
Scel endonuclease, was also determined. As explained in the Materials 
and Methods, during the transfection process cells are able to take up 
multiple copies of plasmid DNA. Therefore cells expressing GFP were also 
likely to express the I-Scel endonuclease. Based on this concept, both the 
GFP and I-Scel constructs were co-transfected into MMR -proficient and - 
deficient strains, as GFP+ cells are also likely to express the I-Scel 
endonuclease. The fraction of GFP+ cells undergoing apoptosis was then 
determined 24 hours post transfection by Hoechst staining. Such staining 
specifically detects condensed apoptotic nuclei (refer to Page 97). As 
shown in Figure 3.7, in all strains tested, between 27 and 33% of cells 
expressing GFP underwent apoptosis; with no significant difference being 
observed between the MMR -proficient and -deficient strains, post I-Scel 
expression. Therefore the low levels of neo+ recombinants produced by the 
MMR -deficient strains does not seem to be due to the result of an induction 
of cell death following expression of the I-Scel endonuclease. 
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Figure 3.7 A similar percentage of MMR -proficient and -deficient, GFP+ cells 
undergo apoptosis. No significant difference was observed when the number of 
apoptosing cells were counted after a GFP construct was co-transfected with the I-Scel 
expression vector into a MMR -proficient (SW480/SN. 3, shaded bar) strain and two MMR 
-deficient (DLD-1/SN. 2 and HEC-1-A/SN. 3, empty bars) strains. Apoptosis events were 
defined as condensed nuclei following Hoechst staining 24 hours post transfection. The 
results are an average of three independent experiments and standard deviation is 
indicated by error bars. 
3.2.6 Effects on Recombination frequency in cells corrected for 
MMR defect. 
To determine whether a lack of MMR protein expression is responsible for 
recombination defects observed in Section 3.2.3, Hec-1-A/SN. 3 cells were 
corrected for the hPMS2 deficiency. To complement the MMR deficiency in 
Hec-1-A cells, human PMS2 cDNA (cloned into the plRESpuro3 expression 
vector) was stably introduced into a Hec-1-A strain containing the ScNeo 
construct, Hec-1-A/SN. 3. As this strain was initially cloned from a single 
cell, we were able to reduce potential genotypic heterogeneity within the 
MMR -deficient cell population. 
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3.2.6.1 Confirmation of hPMS2 expression 
As determined by Western Blot analysis of whole cell lysates, the hPMS2 
protein was weakly detected in 2 out of 7 transfectants examined (Figure 
3.8a). The hPMS2 protein was also detected in the SW480, MMR - 
proficient, cell line. Furthermore, no hPMS2 protein was detected in Hec-1- 
A/SN. 3 (hPMS2-'-) extracts. 
The hPMS2 protein is well documented to interact with and be required to 
stabilize another MMR protein, hMLH1. Furthermore, cells deficient in 
hPMS2 also have reduced levels of hMLH1 protein, presumably as a result 
of turnover of the un-complexed hMLH1 protein (Li et al., 1995). Thus the 
level of the hMLH1 protein was also investigated in the same transfectants 
in order to confirm that the MMR defect was corrected. As shown in Figure 
3.8b, the two transfectants in which hPMS2 was detected also expressed 
relatively higher levels of the hMLH1 protein when compared to parental 
Hec-1-A/SN. 3 extracts. 
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Figure 3.8 Stable transfection of hPMS2 cDNA into Hec-1-A/SN. 3 cells results 
in increased levels of both hPMS2 and hMLHI. Two transfectants, namely HPM. 4 
and HPM. 6, both expressed increased levels of (A) hPMS2 and (B) hMLH1 protein 
following stable transfection of hPMS2 cDNA. Protein expression was detected by 
Western Blot analysis of whole cell lysates. p-Actin was used as a loading control for all 
samples. 
In order to further establish the expression of wild type hPMS2 cDNA in 
Hec-1-A/SN. 3 cells, the effects of 6-thioguanine (6-TG) was tested. MMR - 
deficient cells have been reported to be resistant to the cytotoxic effects of 
6-TG when compared to cells expressing a functional MMR system (Hawn 
et al., 1995). 6-TG is a purine analogue that is incorporated into DNA and 
becomes either phosphorylated (by HPRT) or methylated (by S'- 
adenosylmehionine) (Waters and Swann, 1997 and Elion 1989). Following 
DNA replication, 6-meTG residues on the parental strand are matched with 
thymine or cytosine residues to form DNA mismatches. The MMR system 
recognises these mismatches and attempts are made for repair. Since both 
the parental and newly replicated strands contain the incorrect residue, the 
MMR system undergoes a futile cycle that is thought to eventually result in 
the formation of single stranded breaks. Such breaks subsequently result in 
117 
CHAPTER THREE: HRR DEFECTS IN MMR -DEFICIENT TUMOUR CELLS 
activation of the G2/M checkpoint and apoptosis (Yan et al., 2003). The 
loss of a functional MMR system results in cells being resistant to 6-TG due 
to an impaired ability to generate an appropriate signal that can inhibit cell 
growth. 
Cells were treated with increasing doses of 6-TG and allowed to grow for 
10-14 days in order to form viable colonies. The 6-TG cytotoxicity curves 
for the two transfectants that displayed highest levels of hPMS2 protein are 
shown in Figure 3.9. At 10% survival, both the HPM. 4 and HPM. 6, hPMS2- 
corrected, strains were between 2.6 to 2.8-fold more sensitive to 6-TG 
when compared to parental cells. These results therefore show that 











Figure 3.9 Cells expressing increased levels of hPMS2 protein are sensitive 
to 6-TG. Two Hec-1-A/SN. 3 transfectants, expressing the hPMS2 protein, are sensitive to 
6-TG when compared to parental Hec-1-A/SN. 3 cells. The mean (symbols) and standard 
deviation (error bars) of three independent experiments performed in duplicate are 
presented: Hec-1-A/SN. 3 (0), HPM. 4 (. ) and HPM. 6 (A). 
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Previous studies have shown that HCT116+3 cells, corrected for the MMR 
-deficiency, remain sensitive to the cytotoxic effects of thymidine (Mohindra 
et al., 2002). Therefore the effect of thymidine treatment on strains 
expressing increased levels of hPMS2 protein was also investigated in 
order to confirm that protein expression did not alter the sensitivity. Cells 
were treated with increasing doses of thymidine and allowed to form 
colonies for 10-14 days. The parental Hec-1-A/SN. 3 strain remained 
sensitive to thymidine following continuous exposure when compared to the 
MMR -proficient, SW480 cell line. In addition, both the hPMS2 corrected 
transfectants, namely HPM. 4 and HPM. 6, exhibited the same degree of 
sensitivity to thymidine as parental Hec-1-A/SN. 3 strains (Figure 3.10). At 
10% survival, the two transfectants showed only a 1.4-fold difference in 
sensitivity to thymidine when compared to parental Hec-1-A/SN. 3 cells. 
Thus correction of the hPMS2 defect, in Hec-1-A/SN. 3 strains, results in 
increased 6-TG sensitivity but does not alter the thymidine sensitivity. 
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Figure 3.10 Cells expressing increased levels of hPMS2 protein remain 
sensitive to thymidine. Two Hec-1-A/SN. 3 transfectants, expressing increased levels 
of the hPMS2 protein, remain sensitive to thymidine when compared to untransfected 
parental cells. Results showing sensitivity to thymidine of MMR -proficient, SW480 cells 
(+) is included for reference. The mean (symbols) and standard deviation (error bars) of 
three independent experiments performed in duplicate are presented: Hec-1-A/SN. 3 (. ), 
HPM. 4 (o) and HPM. 6 (0). 
3.2.6.2 DSB induced Recombination Assay 
The frequency of neo+ recombinants formed following the induction of a 
DSB was next determined using the two transfectants that displayed 
increased levels of hPMS2 protein. As shown in Figure 3.11, transient 
transfection of an I-Scel endonuclease resulted in no significant increase in 
the frequency of neo+ recombinants formed in either of the two transfectants 
tested. Interestingly, induced recombination frequencies were in fact lower 
(although not statistically significant) in the HPM. 4 strain that displayed the 
highest level of hPMS2 protein. Frequencies of neo+ recombinants 
obtained following induction of a DSB were however similar in the HPM. 6 
strain to that observed in the parental Hec-1-A/SN. 3 strain. Spontaneous 
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recombination frequencies were also similar in all strains tested. Taken 
together these results suggested that the hPMS2 deficiency in Hec-1-A 








HPM. 4 HPM. 6 HEC-1-A/SN. 3 SW480/SN. 3 
Figure 3.11 Both HPM. 4 and HPM. 6 strains show no increase in frequency of 
neo+ recombinants following expression of a DSB. Induction of a DNA DSB 
(solid bars), in two strains expressing increased levels of hPMS2 protein, showed no 
increase in the frequency of neo+ recombinants when compared to mock transfected 
cultures (empty bars). Results obtained from the same experiments using a MMR - 
proficient, SW480/SN. 3 strain, are included for reference. The results shown are an 
average of three independent experiments and standard deviation is indicated by error 
bars. 
3.2.7 MMR -deficient cells are hypersensitive to mitomycin C 
(MMC). 
Sensitivity of various MMR -deficient cells to the DNA cross-linking agent, 
MMC, was also determined. The HRR deficient hamster cell lines irsl and 
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irslSF (deficient for XRCC2 and XRCC3 respectively) were initially 
characterized on the basis of their sensitivity to MMC and IR (Jones et al., 
1987; and Fuller and Painter, 1988). MMC is a DNA cross-linking agent 
which reacts with DNA to form mono-adducts that are mainly thought to 
occur at the N2 position of guanine residues (for review see Lawley and 
Phillips, 1996). This subsequently causes the residue to rearrange and 
develop both inter-strand and intra-strand cross-links. Recent evidence 
suggests that proteins involved in excision repair pathways, such as the 
XPF/ERCC1 heterodimer, are initially required for repair by incising the 
DNA strands 5' with respect to such adducts (de Silva et al., 2000). These 
incisions are usually single-stranded breaks that maybe subsequently 
converted into DSBs following a round of DNA replication. Using both 
Saccharomyces cerevisiae and mammalian cells, it has been shown that 
proteins involved in HRR are required for the repair of DSB substrates 
induced by cross-linking agents (Mchugh, et al., 2000 and Liu et al., 1998). 
The effects of MMC on MMR -proficient and -deficient tumour cell lines 
was investigated by treating cells with increasing doses of this agent and 
allowing viable cells to form colonies (Figure 3.12). Results showed that all 
five MMR -deficient cell lines tested were significantly more sensitive to the 
cytotoxic effects of MMC when compared to the two MMR -proficient cell 
lines used. At 10% survival, both the hMLH1 deficient HCT116 and SW48 
cell lines were greater than 4.7-fold more sensitive than the MMR 
-proficient, SW480, cell 
line. The SKUT-1, Hec-1-A and LS411N, MMR 
-deficient cell lines, 
however, were up to 2.6-fold more sensitive to MMC 
when compared to SW480 cells. Thus taken together, this data suggests 
that MMR -deficient cells, like HRR -deficient cells, are sensitive to the 
DNA cross-linking agent, MMC. 
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Figure 3.12 MMR -deficient cells are sensitive to the cytotoxic effects of 
MMC. The MMR -deficient cell lines tested have mutations in hMLHI (HCT116, Q; 
SW48, *; LS411N, 0), hMSH2 (SKUT-1, x) and hPMS2 (Hec-1-A, +) respectively. The 
MMR -proficient cell lines used were the colorectal carcinoma cell line SW480 (+) and the 
fibroblast, MRC5VA (A). The mean (symbols) and standard deviation (error bars) of three 
independent experiments performed in triplicate are presented. 
3.2.8 MMR -deficient tumour cells are defective in homology 
based recombination induced by S-phase cell cycle inhibitors. 
The above experiments suggest that DLD-1 (hMSH6'l"), Hec-1-A (hPMS2""), 
SKUT-1 (hMSH2"") and HCT116 (hMLH1''') cells are defective in the 
production of neo+ recombinants when a DSB is initiated by an 
endonuclease. The integrity of the HRR pathways involved in repairing 
recombinogenic lesions induced by thymidine was next investigated in order 
to ascertain whether such processes are also defective in a MMR -deficient 
background. 
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The DNA lesion induced by thymidine is proposed to be recombinogenic as 
HRR processes are required for mammalian cell survival (Lundin et a/., 
2002a). The effect of exposing cells to increasing doses of thymidine on 
recombination frequency was therefore determined in both MMR -proficient 
and -deficient cells. MMR -proficient, SW480/SN. 3 strains, exposed to 
10mM of thymidine, exhibited an induction in the frequency of neo+ 
recombinants by up to 6-fold (Figure 3.13a). Furthermore, the effects 
observed were found to be dose-dependent with highest levels of 
recombinants occurring at 1 0mM thymidine. 
The recombinogenic effect of thymidine in a MMR, hMSH6 -deficient, DLD- 
1-ScNeo transfected strain was also tested (Figure 3.13b). However, 
following thymidine treatment, no neo+ recombinants were recovered, even 
when up to 36 million cells were plated in total. As DLD-1/SN. 2 cells are 
sensitive to the cytotoxic effects of thymidine, it was not possible to treat 
these cells with high thymidine doses. However, even when 12 million cells 
were treated with 2mM thymidine, no recombinants were recovered. A 
similar observation was also noted when DLD-1/SN. 2 cells were treated 
with hydroxyurea and camptothecin (data not shown). Taken together 
these results suggest that hMSH6 -deficient, DLD-1SN. 2, cells are unable 
to repair either thymidine-induced lesions or DSBs. 
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CELL LINE Thymidine Recombination 
[mM] frequency 
DLD-1/SN. 2 0 < 7.22 x 10' 
1 <2.59x10-7 
2 <2.41x10'7 
Figure 3.13 Thymidine induces the frequency of neo+ recombinants in the 
MMR -proficient, SW480/SN. 3 strain, but not in the DLD-1/SN. 2, hMSH6 - 
deficient strain. All cells were exposed to various concentrations of thymidine for 24 
hours, before being plated in G418 selective media. Thymidine induced the frequency of 
neo+ recombinants in the SW480/SN. 3 strain. However, no recombinants were retrieved 
from the DLD-1/SN. 2 strain (indicated by less than values). 
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3.3 DISCUSSION 
MMR -deficient cells acquire an additional series of mutations that provide 
a selective growth advantage and contribute to the mutator phenotype seen 
in such cells. Both MMR -deficient and HRR -deficient cell lines have been 
reported to be sensitive to the cytotoxic effects of thymidine (Mohindra et 
al., 2002 and Lundin et al., 2002a). Treatment with thymidine depletes cells 
of dCTP and subsequently results in the retardation of replication fork 
progression. Furthermore there is an increasing amount of evidence from 
bacteria and yeast for the involvement of HRR proteins in rescuing 
stalled/collapsed replication forks (Cox, 2001; Kraus et aL, 2001 and Michel 
et al., 2001). In the present study, the integrity of the HRR pathway was 
therefore determined in a MMR -deficient background. 
The recombination reporter substrate, ScNeo, was used to measure 
homology based recombination events between two defective neomycin 
phospho-transferase genes. Recombination events were induced using a 
variety of recombination inducing agents. The results showed that all four 
MMR -deficient cell lines tested, namely DLD-1 (hMSH6"'"), Hec-1-A 
(hPMS2"l"), SKUT-1 (hMSH2"'") and HCT116 (hMLH1-1-), were defective in 
the production of neo+ recombinants by homology based recombination 
following the expression of a site-specific DSB. This contrasted to the three 
MMR -proficient cell lines SW480, SW620 and MRC5VA tested which 
produced neo+ recombinants at a frequency of 0.8 - 4.38 x 10"3. These 
results are consistent with a study published by Slebos and Taylor (2001) 
which described the use of a host cell reactivation assay to measure HRR 
events based on the reactivation of a green-fluorescent protein in various 
MMR -proficient and -deficient cell lines. This study also provided 
evidence that the MMR -deficient, HCT1 16 cell line, showed no increase in 
recombination events. 
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The HRR defects observed in MMR -deficient cells was not due to a lack of 
ability of cells to express the I-Scel endonuclease, nor was it due to an 
increase in an I-Scel induced apoptosis event. Furthermore, correction of 
the MMR -deficiency in the Hec-1-A/SN. 3 strain did not alter the frequency 
of neo+ recombinants formed following the induction of a site-specific break. 
Such results therefore suggest the hPMS2 deficiency in Hec-1-A cells is not 
directly responsible for the HRR defects. 
In addition, all five MMR -deficient tumour cell lines tested were variably 
sensitive to the cross-linking agent MMC. These results are in agreement 
with a study conducted by Fiumicino and co-workers (2000) where a 
sensitivity of various MMR -deficient cells to MMC was also noted. Cells 
deficient in HRR (including XRCC2, XRCC3 and BRCA1) are also known to 
be acutely sensitive to MMC (Jones et al., 1987; Fuller and Painter, 1988 
and Moynahan et aL, 2001). However, the sensitivity to MMC observed in 
such cells is much greater than that observed in the tumour cell lines. 
Taken together these results suggest that HRR defects occur in MMR - 
deficient tumour cells. 
To address the question of whether DLD-1 cells were specifically defective 
in the processing of substrates induced by I-Scel or were also defective in 
the HR mediated repair of structures associated with collapsed or stalled 
replication forks, thymidine was used to induce recombination events. The 
results showed that potentially lethal substrates formed following exposure 
to thymidine could not be repaired in the DLD-1/SN. 2, hMSH6 -deficient, 
strain. Such treatment presumably led to cell death and therefore no 
detectable neo+ recombinants were observed. 
As described previously, the thymidine sensitivity observed in MMR 
-deficient cells was not 
directly due to the loss of MMR, as HCT116+3 cells 
(corrected for the hMLHI deficiency) remained sensitive to thymidine 
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(Mohindra et aL, 2002). In addition, Elliot and co-workers (2001) reported, 
using mouse MSH2 knockout ES cells, that deficiency in MMR does not 
directly result in defects in HRR. Consistent with the above studies, 
correction of the hPMS2 -deficiency in the Hec-1-A/SN. 3 strain did not alter 
thymidine sensitivity or the frequency of neo+ recombinants formed 
following the induction of a site-specific break. Taken together these 
studies suggest that both the loss of HRR and thymidine sensitivity appear 
to be the result of events that occur downstream from the initial loss of 
MMR. 
The addition of thymidine induces an imbalance in dCTP and dTTP pools 
that subsequently results in the slowing of DNA replication forks (Bjursell 
and Reichard, 1973). Increasing evidence from both prokaryotic and 
eukaryotic cells suggest that the loss of HRR could account for the 
thymidine sensitivity observed in various cell types (Cox, 2001; Kraus et al., 
2001 and Michel et aL, 2001). In addition, it is proposed that this 
retardation of DNA replication fork progression may result in the 
accumulation of DNA lesions that specifically require a proficient HRR 
pathway for mammalian cell survival (Lundin et al., 2002). Therefore the 
findings in the present study, which show HRR defects in MMR -deficient 
cells, are consistent with an involvement of HRR processes in conferring 
thymidine sensitivity. The absence of both MMR and HRR processes may 
therefore result in the loss of ability to form colonies instead of S-phase 
arrest. 
There are a number of possible advantages gained by HRR deficiency in 
terms of tumour progression in this subset of MMR -deficient tumours. 
Components of the MMR system interact with various HRR processes 
including: regulating homeologous recombination events, removing non- 
homologous DNA during both GC and SSA processes and regulating 
heteroduplex-DNA extension (Evans et al., 2000; Sugawara et al., 1997; 
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Studamire et al., 1999 and Marsischky et al., 1999). Therefore the loss of 
MMR and the subsequent loss of HRR pathways may provide a selective 
growth advantage as cells maybe unable to regulate homeologous 
recombination events between diverged sequences. The occurrence of 
chromosome translocations, deletions and/or insertions events would 
therefore be encouraged. In addition, as HRR processes seem to be 
involved in maintaining the integrity of replication forks, the loss of such a 
pathway would impair the S-phase cell cycle checkpoint (Henry-Mowatt et 
al., 2003). In further support of this argument, Morrison and co-workers 
(2000) used chicken DT40 cells to show that the DNA damage 'sensing' 
ATM protein and HRR act on the same pathway; although this study only 
used irradiation induced chromosomal aberrations to measure defects in 
HRR in various knock out cell lines. 
Phenotypic characterization of MMR -deficient cells revealed that such cells 
are resistant to DNA alkylating agents such as 6-thioguanine and cisplatin. 
Resistance to such classes of chemotherapeutic agents has subsequently 
hindered the treatment of tumours displaying microsatellite instability. The 
loss of HRR and the hypersensitivity of MMR -deficient cells to thymidine 
raise the possibility of using agents that induce dNTP pool imbalances in 
conjunction with current methods to improve the treatment of this subset of 
tumours. 
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4.1 INTRODUCTION 
The results obtained in the previous chapter suggest that MMR -deficient 
tumour cell lines contain defective HRR pathways. In order to determine 
whether this deficiency was the result of mutations in genes involved in 
HRR (and/or the signalling of DNA damage), cDNA sequences encoding a 
selection of these genes were screened for mutations. 
Eukaryotic genomic DNA consists of simple repetitive DNA regions which 
are each composed of a small number of repeated bases and are 
considered to be hotspots for mutations in a MMR -deficient background 
(Tautz and Schlotterer, 1994 and Strauss, 1999). These repeated bases 
range from between 1-13 base pairs (microsatellites) to greater than 15 
base pairs (minisatellites) in length. Approximately 100,000 microsatellite 
repeats are scattered throughout the human genome (Weber and May, 
1989). Experimental data indicates that in a MMR -deficient background, 
the rate of microsatellite instability at these repetitive sequences is 
dramatically elevated (reviewed by Kolodner, 1996 and Modrich and Lahue, 
1996). Such instability is thought to predominantly arise due to DNA 
polymerase slippage errors which occur during replication, rather than base 
mis-incorporations or recombination processes (reviewed by Kunkel, 1992 
and Sia et al., 1997). Streisinger and co-workers (1985) used T4 
bacteriophage to propose a model in which it was suggested that 
misalignment of re-associated primer and template strands occurred, 
possibly due to polymerase slippage (Figure 4.1). Such misalignment 
subsequently forms a loop containing one or more unpaired repeated unit 
which, if left un-repaired, results in alterations of the number of repeats 
following replication. 
132 
CHAPTER FOUR: SCREENING FOR MUTATIONS IN HRR GENES 
7A RUN (+1) 
AA 
AAAA AAAAAA-- 
T= -f mm 
5dra F, elical base 6A RUN (0) 
ai pinB shad 
Bta-heical base 
on terrplate strand 
5A RUN (-1) 
MM AAAM 
TTTTT -º TTTTT 
TT 
6ARUN(0) 
Figure 4.1 Generation of frameshift mutations due to DNA polymerase 
slippage on mononucleotide repeats. Such events involve a transient dissociation 
of the template and primer strands followed by misaligned annealing within the repeat tract. 
This subsequently results in the formation of a frameshift intermediate that is composed of 
an extra-helical loop. If this mismatch remains uncorrected, the repetitive tract will contain 
(A) more repeats or (B) fewer repeats, following replication. Adapted from Gragg et al., 
2002 
The addition or subtraction of bases in non-multiples of three within such 
repeats contained in coding sequences frequently generates frameshift 
mutations. Frameshift-type mutations predominate in MMR -deficient cells 
and almost always result in the alteration of the protein product and 
therefore protein function. Therefore the microsatellite instability (MSI) 
phenotype, in which alterations in mono- and di-nucleotide repeats of 
microsatellites occur, most likely reflects the accumulation of frameshift 
mutations. 
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MSI is well documented to be suppressed by the 3' to 5' exonucleolytic 
proofreading of DNA polymerases as well as by the post-replicative MMR 
system (Kroutil et al., 1996; Sagher et al., 1999; Strand et aL, 1993 and 
Tran et al., 1997). Mutation analysis studies show that MMR defective cells 
frequently display an increased rate of mutations both spontaneously and at 
specific loci (Gragg et al., 2002; Parsons et al., 1995; Shibata et aL, 1994; 
Bhattacharyya at al., 1994; Kat et al., 1993; Eshleman et al., 1995 and 
Phear et a/., 1996). Furthermore, the rates of frameshift mutations 
occurring in MMR -deficient cells have been shown to be increased by 
between 200 to 1000-fold when compared to MMR -proficient cells 
(Bhattacharyya et al., 1994 and Malkhosyan et al., 1996). Correction of the 
MMR deficiency was found to reduce the mutator phenotype by more than 
90% (Umar et al., 1997; Koi et al., 1994 and Glaab et al., 1997). Such 
results therefore confirm a direct involvement of MMR with MSI. 
The types of mutations accumulating in MMR -deficient cells, however, 
appear to be a function of the component of the MMR pathway that is 
altered (Bhattacharyya et al., 1994 and Malkhosyan et aL, 1996). For 
example HCT116 (hMLH1 deficient) and DLD-1 (hMSH6 deficient) cells 
both display high rates of spontaneous mutations at the hprt locus. 
Mutation spectra analysis, however, showed that in HCT116 cells frameshift 
mutations constituted a large proportion of such mutations at the hprt locus. 
The results of mutation spectra analysis studies in HCT116 cells are the 
opposite of that observed in DLD-1 cells, where point mutations were 
prominent. This is consistent with the role of hMLH1 in repairing all types of 
replication errors, whereas hMSH6 is specifically involved in the repair of 
single base-base mispairs. 
The inability of MMR -deficient cells to form neo+ recombinants, reported in 
the present study could be due to mutations in genes that are members of 
the RAD52 epistasis group. Alternatively mutations in genes that are 
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involved in the signalling of DNA damage could also be responsible for the 
HRR defects. As described above, in a MMR -deficient background, cells 
have a higher probability for incurring frameshift mutations specifically at 
mononucleotide runs. The sequence of genes involved in HRR and DSB 
signalling were therefore initially screened for the frequency of 
mononucleotide runs occurring within the coding sequence. Genes 
containing a high frequency of such runs were subsequently sequenced in 
the search for mutations. 
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4.2 RESULTS 
4.2.1 Analysis of genes involved in DNA damage signalling and 
HRR in MSI+ tumour cell lines. 
Mononucleotide runs were initially screened for in several genes that belong 
to the RAD52 epistasis group. As shown in Table 4.1, screening of coding 
sequences revealed that the RAD51 gene and the RAD51 paralogs, 
XRCC3, RAD51 B, RAD51C and RAD51 D, did not contain a significant 
number of mononucleotide runs that are greater than 6 base pairs in length. 
Analysis of the coding sequence within the XRCC2 gene, however, 
revealed three mononucleotide runs that were eight base pairs in length. 
The other significant genes of interest, namely RAD52 and RAD54B, had 
coding sequences that coded for a9 base pair and two seven base pair 
mononucleotide runs, respectively. 
In addition to the above genes, further sequence analysis was conducted 
on genes involved in the signalling of DSBs. As shown in Table 4.1 the 
coding sequences for the checkpoint signalling gene, CHK1, and the DNA 
helicases, WRN and BLM, all contained a high frequency of 
mononucleotide runs. These genes were therefore also considered to be 
potential candidates for incurring frameshift mutations. 
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Genes Number of mono-nucleotide runs 
Sequenced 
P 5-bp S bP 7 bp j'__8bJ 9 bp 
XRCC2 3 
XRCC3 4 2 (ý - - 
RAD51 ! I Iý ý ý 
RAD52 
RAD54 
1 J I I 
RAD54B ý ý 2 ý 
RAD516 
RAD51C I I ý Iý 
RAD51D 1 
I Number of mono-nucleotide runs 
FANCD2 
MUS81 2 




CHK2 15 2 
Table 4.1 Table showing the number of mononucleotide runs in some of the 
genes involved in HRR and/or signaling of DNA damage. Details of primers 
sequences and annealing temperatures used for the respective gene are stated in 
Appendix I-III (pages 236-238). 
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4.2.2 The MMR -deficient, SKUT-1, cell line has a frameshift 
mutation in the XRCC2 gene. 
Sequence analysis of all genes shown in Table 4.1 was limited to 
mononucleotide runs that were 6 base pairs in length as these regions have 
a higher probability for incurring frameshift mutations. Specific regions 
encoding such mononucleotide runs were subsequently amplified, 
sequenced and analyzed for mutations in SW480, HelaS3, LM217E (MMR 
-proficient) and HCT116, SKUT-1,2774, Hec-1-A, DLD-1 (MMR -deficient) 
cell lines. 
Sequencing of amplified cDNA products revealed a frameshift mutation in 
the XRCC2 gene of the SKUT-1, MMR -deficient cell line. As shown in 
Figure 4.2a, this mutation was a single nucleotide deletion in a run of eight 
thymine residues between nucleotides 342 and 350 of the XRCC2 coding 
sequence. The mutation appeared to be heterozygous as both wild-type 
and 342delT mutant allele sequences could be detected in the sequencing 
image (Figure 4.2b). Further confirmation for the presence of the mutant 
allele was achieved when the amplified fragment covering this region was 
sub-cloned into the pcDNA3.1 expression vector and sequenced (Figure 
4.2b). 
Analysis of cDNA amplified sequences derived from the XRCC3, RAD51, 
RAD52, RAD54, RAD54B, RAD51 B, RAD51 C or RAD51D genes, however, 
revealed no additional mutations in any of the MMR -proficient or -deficient 
cell lines used. In addition, sequence analysis of the CHK1, CHK2, WRN or 
BLM genes, did not reveal any further frameshift mutations in any of the 
MMR -proficient or -deficient tumour cell lines used. 
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(A) (B) 
snff im S 
ncc r 
ACGT 
Figure 4.2 A MMR -deficient tumour cell line, SKUT-1, encodes for a 
frameshift mutation within the XRCC2 gene. (A) XRCC2 sequence analysis of 
amplified cDNAs from both MMR -proficient and -deficient tumour cell lines revealed a 
frameshift mutation within the SKUT-1 cell line. (B) Further confirmation for the presence 
of a heterozygous -1 frameshift in the run of eight thymine residues (indicated by arrow) 
was achieved through cloning the gene into a pcDNA3.1 expression vector. 
As frameshift mutations are well documented to completely alter translated 
protein sequence, amino acid sequences of both wild-type XRCC2 and 
342de1T were therefore aligned. This alignment showed that the frameshift 
mutation of XRCC2 in SKUT-1 was a nonsense mutation as it introduced a 
premature stop codon 48 nucleotides downstream from the frameshift 
(Figure 4.3). This subsequently resulted in a loss of the wild type amino 
acid sequence after amino acid 116 out of the 280 encoded by the gene. In 
addition, the mutation found in the XRCC2 gene is predicted to encode a 
peptide that retains the Walker Box A but loses Walker Box B. 
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WALKER BOX A 
XRCC2 1 MCSAFHRAESGTELLARLEGRSSLKEIEPNLFADEDSPVHGDILEFHGPEGTGKTEMLYH 
342de1T 1 MCSAFHRAESGTELLARLEGRSSLKEIEPNLFADEDSPVHGDILEFHGPEGTGKTEMLYH 
XRCC2 61 LTARCILPKSEGGLEVEVLFIDTDYHFDMLRLVTILEHRLSQSSEEIIKYCLGRFFLVYC 
342delT 61 LTARCILPKSEGGLEVEVLFI DTDYHFDMLRLVTI LEHRLSQSSEEI IKYCLGRFFWCTA 
WALKER BOX B 
XRCC2 121 SSSTHLLLTLYSLESMFCSHPSLCLLILDSLSAFYWIDRVNGGESVNLQESTLRKCSQCL 
342de1T 121 WAPTYFLHFTH' 
XRCC2 181 EKLVNDYRLVLFATTQTIMQKASSSSEEPSHASRRLCDVDIDYRPYLCKAWQQLVKHR 
342de1T 181 
XRCC2 241 MFFSKQDDSQSSNQFSLVSRCLKSNSLKKHFFIIGESGV 
342de1T 241 
Figure 4.3 The frameshift mutation in XRCC2 alters the wild type protein 
sequence after amino acid 116 and produces a premature stop at codon 133. 
Wild-type XRCC2 amino acid sequence (red) is aligned with mutant peptide amino acid 
sequence (blue) to show that Walker box B is deleted in the mutant XRCC2 allele. An 
arrow indicates the location of the deleted residue. 
4.2.3 All cells in the SKUT-1 population carry the heterozygous 
XRCC2 mutation. 
The possibility that the frameshift mutation found in the XRCC2 gene only 
occurred in a subset of the SKUT-1 cell population was next investigated. 
To test this, cDNA was amplified and sequenced from well isolated colonies 
derived from single cells (Figure 4.4). Such sequencing revealed that all of 
the twelve such colonies isolated (six of which are shown), were 
heterozygous for this mutation, as both wild type and mutant XRCC2 alleles 
could be detected. However, a majority of the isolates predominantly 
displayed the mutant XRCC2 allele. 
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SW480 SKUT-1/C1 SKUT-1/C2 SKUT-1/C3 SKUT-1/C4 SKUT-1/C5 SKUT-1/C6 SKUT-1 
ACGT 
Figure 4.4 All cells in the SKUT-1 population carry the heterozygous XRCC2 
mutation. Amplified sequences from colonies derived from single cell isolates of the 
MMR -deficient, SKUT-1 cell line, show the presence of a frameshift mutation of XRCC2 
(indicated by arrow). A heterozygous -1 frameshift in a run of eight thymine residues 
(indicated by arrow) is evident in all cell isolates of SKUT-1. 
4.2.4 XRCC2 mutations in gynaecological tumours 
The SKUT-1 cell line was derived from a uterine sarcoma (Risinger et al., 
1995). The presence of the mutation in this cell line was therefore 
investigated in several similar gynaecological tumours. Malignancies of the 
uterus (excluding the cervix) are common. The vast majority of uterine 
malignancies are endometrial carcinomas. Endometrial carcinomas are the 
most frequent malignancy of the female genital tract in the Western world 
and account for 7% of all invasive cancers in women (Kumar et aL, 2003 
and Fletcher, 2000). Conversely, uterine sarcomas are very rare and only 
account for between 1 to 5% of all malignancies of the uterus. The essential 
difference between carcinomas and sarcomas is their embryological tissue 
of origin and differentiation. Carcinomas arise from epithelial tissues 
whereas sarcomas derive from mesenchymal connective tissues. The three 
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main categories of uterine sarcomas include leiomyosarcomas, endometrial 
stromal sarcomas and mixed Mullerian tumours. 
Leiomyosarcomas constitute 25% of uterine sarcomas. These tumours 
arise from smooth muscle cells within the myometrium and exhibit 
histological features that phenotypically resemble this path of differentiation 
towards smooth muscle. These tumours usually start as a rapidly growing, 
painless swelling in the wall of the uterus; with the exact cause being 
unknown. These tumours are usually solitary and appear as a large, poorly 
circumscribed mass having a soft flesh consistency with necrosis. The risk 
of malignancy of these tumours is graded by the number of cells undergoing 
cell division. Tumours having >10 mitotic figures/10 microscopic high- 
power fields (hpf) are classed as being highly aggressive (an example of 
which is shown in Figure 4.5), whereas tumours that are of intermediate risk 
of malignancy have 5-9 mitotic figures/10hpf. Other histological factors 
used to assess malignancy include nuclear pleomorphism and the presence 
of necrosis. Treatment for these tumours mainly includes surgery and/or 
chemotherapy. However, the survival prognosis for 5 years is only between 
40 to 50%. 
Another 15% of uterine sarcomas arise from the supporting stromal cells 
that surround the glands within the lining of the uterus (i. e. the 
endometrium) and are called endometrial stromal sarcomas. The 
endometrial stroma gives rise to a variety of sarcomas which can vary from 
low to very high grade. Endometrial stromal sarcomas are also treated with 
surgery and/or chemotherapy. 
The remainder of uterine sarcomas comprises the mixed-Mullerian tumours. 
These are characterised by both a neoplastic epithelial and stromal 
component (Kempson and Hendrickson, 2000). As the presence of a 
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neoplastic epithelial component provides a second variable in the analysis 





Figure 4.5 Image showing samples of normal and Ieiomyosarcomas tissue. 
The presence of marked nuclear pleomorphism (blue diamond arrowhead) and three 
mitotic figures (arrowed) in the leiomyosarcoma are displayed in the image on the right. 
Image supplied by Dr. Jason Stone. 
Only 4 endometrial stromal sarcomas and 8 Ieiomyosarcomas of the uterus 
could be sourced from the Sheffield area from the last six years. Benign 
mesenchymal neoplasias of the uterus (and therefore, by definition, not 
sarcomas) e. g. leiomyomas (fibroids) were not included in the study. 
Although these figures are small, these numbers are in keeping with those 
observed at other cancer centers (Goff et al., 1993; Amant et al., 2003; 
Melilli et at, 1999; Gonzalez-Bosquet et a!., 1997 and Chauveinc et a!., 
1999). Genomic DNA was extracted and purified from all microdissected 
tumour samples along with appropriate control tissue from each patient. All 
exons of the XRCC2 gene were amplified using the primer sequences and 
annealing temperatures indicated in the Appendix (Page 241). Sequence 
analysis of amplified regions containing the mononucleotide run of eight 
thymine residues in exon III revealed the 342delT frameshift in one of the 
uterine leiomyosarcomas (Figure 4.6). This specific tumour was classified 
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as a high-grade uterine leiomyosarcoma and furthermore, sequencing gels 
showed equal expression of both wild type and mutant alleles. Analysis of 
the four endometrial stromal sarcomas, however, did not reveal any 







a 440 ,_ 





Figure 4.6 Sequence analysis of eight independent Ieiomyosarcoma samples 
revealed the same frameshift mutation of XRCC2 found within the SKUT-1 
cell line. A heterozygous -1 frameshift in a run of eight thymine residues (indicated by 
arrow) was evident in a high grade leiomyosarcomas tissue sample (Sample 2). No such 
mutations were found in any of the endometrial stromal sarcomas examined. 
4.2.5 SKUT-1 cells express decreased levels of wild-type XRCC2 
protein. 
The MRE11 protein has previously been shown to be expressed at low 
levels in HCT1 16 and SW48, MMR -deficient cells, which both encode for a 
frameshift mutation in an intronic run of eleven thymine residues (Giannini 
et al., 2002). Therefore, by analogy to MRE11, XRCC2 protein expression 
levels were investigated in the MMR -deficient SKUT-1 cell line. 
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Western blot analysis of whole cell lysates extracted from both MMR 
-proficient and -deficient tumour cell lines revealed that the level of XRCC2 
protein was depressed in SKUT-1 cells (Figure 4.7). In addition, a rapidly 
migrating protein was also detected in the SKUT-1 cell line that interacted 
with the XRCC2 antibody. This peptide had approximately the same 
molecular weight (17.2kDa) predicted to be encoded by the mutant XRCC2 





Amomb XRCC2 -10 
342de1T -0 
ß-ACTIN > +2» mss' 
Figure 4.7 The SKUT-1, MMR -deficient, cell line expresses reduced levels of 
wild type XRCC2 protein. Western blot analysis of whole cell lysates was used to 
measure XRCC2 protein expression levels (indicated by arrow) in the MMR -proficient 
SW480 cell line and the MMR -deficient SKUT-1, cell line. ß-Actin was used for loading 
control. 
4.2.6 Functional analysis of 342delT 
As SKUT-1 cells expressed reduced levels of wild-type XRCC2 protein as 
well as a mutant peptide, the possibility that this could account for the 
thymidine sensitivity found in such cells was investigated. 
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The mutant XRCC2 allele was cloned into a pcDNA3.1 expression vector 
(Appendix 3) and stably transfected into the MMR -proficient cell line, 
SW480. The presence of the mutant construct was confirmed through 
sequencing of amplified XRCC2 cDNA. As shown in Figure 4.8, three such 
transfectants appeared to display approximately equal levels of both mutant 
and wild-type XRCC2 alleles. However, the degree of mutant expression in 
the three transfectants was found not to be as high as that found in the 
SKUT-1, MMR -deficient cell line. 
SW480 SW1A SW3A SW6A SKUT-1 
. .. 
AC GT 
Figure 4.8 Expression of 342de1T (indicated by arrow) can be detected in 
several SW480 clones transfected with the pcDNAXRCC2 construct. The 
sequence patterns in three transfectants (SW1A, SW3A and SW6A) is compared with un- 
transfected SW480 (containing only wild type XRCC2) and SKUT-1 (which carries both the 
frameshift mutation of XRCC2 as well as wild type) cells. 
4.2.6.1 Cells expressing 342de1T become sensitive to thymidine. 
The results obtained in the previous chapter indicated that defective HRR 
mechanisms could be responsible for the thymidine sensitivity observed in 
MMR -deficient cell lines. Therefore, the possibility that expression of the 
mutant allele could confer sensitivity to thymidine in SW480, MMR - 
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proficient, cells was investigated. The viability of plated cells was measured 
in the presence of increasing doses of thymidine after 10-14 days. The 
MMR -deficient, SKUT-1 cell line was 3-fold more sensitive to thymidine 
when compared to SW480 cells at 10% cell survival (Figure 4.9a). At 10% 
survival, the two MMR -proficient strains expressing the mutant XRCC2 
allele were up to 2-fold more sensitive than SW480 cells. 
In addition, the effect of expressing an empty vector into SW480 cells was 
also investigated as a control. As shown in Figure 4.9b, no increase in 
sensitivity was observed when cells expressing the empty vector were 
treated with increasing doses of thymidine. Taken together, these results 
suggest that the thymidine sensitivity observed in MMR -deficient, SKUT-1 
cells, could be due to the depressed level of XRCC2 protein. 
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Figure 4.9 Expression of 342delT in SW480, MMR -proficient cells confers 
sensitivity to thymidine. (A) Transfectants of SW480 expressing the mutant XRCC2 
allele (SWIA, 0 and SW6A, 0) are sensitive to thymidine when compared to untransfected 
SW480 cells ( ). Sensitivity of SKUT-1 cells to thymidine is included for reference (0). (B) 
Control experiments using empty-vector expressing transfectants (SWPC. 2, f and 
SWPC. 5, X) showed no significant difference to thymidine sensitivity when compared to 
SW480 cells ( ). Sensitivity of SKUT-1 cells to thymidine is included for reference (0). 
The mean (symbols) and standard deviation (error bars) of three independent experiments 
performed in duplicate are presented. 
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4.2.6.2 Restoration of wild-type XRCC2 protein levels in SKUT-1 
cells results in thymidine resistance. 
The results obtained above suggest that strains expressing the mutant 
XRCC2 allele are more sensitive to the cytotoxic effects of thymidine when 
compared to parental cells. The effect of increasing the level of wild type 
XRCC2 protein in SKUT-1 cells was therefore investigated next. Increased 
levels of wild-type XRCC2 protein were obtained through stably transfecting 
the pEBS7-XRCC2 construct (kindly provided by Prof. John Thacker) 
containing wild type XRCC2 cDNA into the MMR -deficient cell line. Whole 
cell extracts obtained from the transfectants, were analysed by Western 
blotting in order to confirm increased XRCC2 protein expression. Two 
colonies that were isolated following transfection of this construct, both 
showed increased levels of the wild type XRCC2 protein (Figure 4.10a). 
Furthermore it was observed that exposure of such strains to thymidine 
restored resistance to this agent in the MMR -deficient, SKUT-1, cell line 
(Figure 4.10b). Thus increased level of wild-type XRCC2 protein restores 
resistance to thymidine. 
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Figure 4.10 Restoration of wild type XRCC2 protein levels in SKUT-1 cells 
results in thymidine resistance. (A) Western blot analysis of whole cell extracts 
obtained from SKUT-1 cells transfected with wild type XRCC2 cDNA (arrow). Two 
transfectants (SX2A and SX8A) both expressed increased levels of wild type XRCC2 
protein. The XRCC2 protein levels in cell extracts obtained from SW480 and SKUT-1 cells 
are included for reference. (B) Restoration of wild type XRCC2 protein levels in SKUT-1 
cells resulted in thymidine resistance in two transfectants (SX2A, * and SX8A, 0). The 
sensitivity to thymidine of SKUT-1 cells (") and SW480 cells ( ) are included for reference. 
The mean (symbols) and standard deviation (error bars) of three independent experiments 
performed in duplicate are presented. 
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4.2.6.3 342delT expression in SW480 cells confers MMC 
sensitivity. 
The HRR deficient irsl (XRCC2-deficient) and irs9SF (XRCC3-deficient) 
cell lines have been well documented to be acutely sensitive to the DNA 
cross linking agent MMC, but only mildly sensitive to irradiation damage 
(Jones et aL, 1987; Fuller and Painter, 1988; Caldecott and Jeggo, 1991 
and Tebbs et al., 1995). The effects of both of these agents on cells 
expressing the mutant XRCC2 allele were therefore investigated. 
The viability of plated cells was measured in the presence of increasing 
doses of MMC after 10-14 days. At 10% survival, two strains expressing 
the mutant XRCC2 allele, exhibited sensitivity to MMC when compared to 
parental SW480 cells (Figure 4.11a). The MMR -deficient, SKUT-1, cell 
line remained significantly more sensitive to the cytotoxic effects of MMC at 
all doses used when compared to either transfected cells or SW480, MMR 
-proficient cells. The empty pcDNA3.1 vector was also transfected into the 
MMR -proficient, SW480, cell line in order to observe whether the 
sensitivity of both transfectants to MMC was influenced by vector 
expression or due to clonal variation. As shown in Figure 4.11b, no 
increase in sensitivity was observed when cells expressing the empty vector 
were treated with increasing doses of MMC. These results suggest that a 
functional XRCC2 protein (and therefore HRR pathway) is involved in the 
repair DNA damage induced by MMC. 
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Figure 4.11 Expression of 342delT in SW480, MMR -proficient cells confers 
sensitivity to MMC. (A) Transfectants of SW480 expressing the mutant XRCC2 allele 
(SW1A, 0 and SW6A, A) are sensitive to MMC when compared to parental SW480 cells 
(u). Sensitivity of SKUT-1 cells to MMC is included for reference ("). (B) Control 
experiments using empty-vector expressing transfectants (SWPC. 2, t and SWPC. 5, X) 
showed no significant difference to MMC sensitivity when compared to SW480 cells ( ). 
Sensitivity of SKUT-1 cells to MMC is included for reference (s). The mean (symbols) and 
standard deviation (error bars) of three independent experiments performed in duplicate 
are presented. 
20 40 60 80 
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4.2.6.4 342de1T expression in SW480 cells does not confer 
sensitivity to irradiation. 
The sensitivity of the strains expressing the mutant XRCC2 allele to 
irradiation was also investigated as this agent has previously been 
observed to have a weak toxic effect on HRR deficient cells (Jones et al., 
1987; Fuller and Painter, 1988; Caldecott and Jeggo, 1991 and Tebbs et 
al., 1995). SW480, SKUT-1 and two strains expressing the mutant XRCC2 
allele were exposed to increasing doses of irradiation and allowed to form 
colonies for 10-14 days. As shown in Figure 4.12a, SKUT-1 cells were 4- 
fold more sensitive to irradiation (at 10% survival) when compared to the 
MMR -proficient, SW480, cell line. The two strains expressing the mutant 
XRCC2 allele were not, however, significantly more sensitive to irradiation 
when compared to parental SW480 cells. Furthermore, SW480 cells 
transfected with an empty vector control exhibited similar resistance to 
irradiation as un-transfected cells (Figure 4.12b). 
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Figure 4.12 Expression of 342de1T in SW480, MMR -proficient cells does not 
confer sensitivity to Irradiation. (A) Transfectants of SW480 expressing the mutant 
XRCC2 allele (SW1A, 0 and SW6A, A) are not sensitive to irradiation when compared to 
parental SW480 cells (. ). Sensitivity of SKUT-1 cells to irradiation is included for 
reference (0). (B) Control experiments using empty-vector expressing transfectants 
(SWPC. 2, t and SWPC. 51 x) showed no significant difference to irradiation sensitivity 
when compared to SW480 cells (u). Sensitivity of SKUT-1 cells to irradiation is included 
for reference (. ). The mean (symbols) and standard deviation (error bars) of three 
independent experiments performed in duplicate are presented. 
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4.3 DISCUSSION 
The aim of the present study was to determine whether the apparent HRR 
defects observed in MMR -deficient cells was due to mutations in genes 
known to be involved in the pathway. Screening of eight MMR -proficient 
and -deficient tumour cell lines revealed a frameshift mutation within 
XRCC2 in the SKUT-1, MMR -deficient tumour cell line. Although the 
mutation identified was heterozygous, transfection of the mutant allele into a 
MMR -proficient tumour cell line conferred thymidine sensitivity. 
Furthermore, increasing the level of the wild-type protein in SKUT-1 cells, 
restored resistance to thymidine. Therefore thymidine sensitivity observed 
in the SKUT-1, MMR -deficient, cell line can be attributed, at least in part, to 
the presence of the mutant allele. Transfectants expressing the mutant 
XRCC2 allele were, however, found to be more resistant to MMC and to 
irradiation when compared to SKUT-1 cells. This can possibly be attributed 
to other unknown alterations within the SKUT-1 cell population which can 
further contribute to the sensitivity. 
Genes that contain small repeated sequences within the coding sequence 
are particularly susceptible to mutations in cells that express a microsatellite 
mutator phenotype (reviewed by Kolodner, 1996 and Modrich and Lahue, 
1996). Furthermore, in a MMR -deficient background, frameshift mutations 
have been shown to predominantly occur. This is probably due to an 
inability to repair polymerase slippage errors (reviewed by Kunkel, 1992 and 
Sia et al., 1997). Such mutations subsequently contribute to the MSI 
phenotype observed in HNPCC derived tumours. For example in MMR 
-deficient tumour cells, the transforming growth receptor factor ß receptor 
II 
(TGF- ßR11) is frequently inactivated due to targeted frameshift mutations in 
the Aio repeat (Markowitz et al., 1995 and Parsons et al., 1995). In 
addition, Rampino and co-workers (1997) showed that approximately 50% 
of MSI+ colon adenocarcinomas were found to have frameshift mutations in 
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the G8 tract within the coding sequence of the apoptosis promoting BAX 
gene. Therefore the XRCC2 frameshift mutation found in the T8 tract of 
SKUT-1 cells may be coupled with selection, as other mononucleotide runs 
in XRCC2 are not mutated. Furthermore, assuming that the loss of MMR 
occurs as an early event, the XRCC2 frameshift mutation further supports 
the argument that loss of HRR in MMR -deficient cells occurs as a 
downstream event with respect to tumour progression. 
Although the XRCC2 mutation was found in only one of the MSI+ tumour 
cell lines, such a mutation does not appear to be common in MSI+ or 
microsatellite stable colon cancers. Other studies conducted in our lab on a 
collection of 16 MSI+ and 92 microsatellite stable colon cancers did not 
detect the mutant allele (J. Scorah and M. Meuth). However, the same 
study revealed that a further intronic frameshift mutation in the MRE11 gene 
occurred in a high proportion (85%) of these MSI+ colon cancers. As the 
MRE11 protein seems to be implicated in HRR, the tumour data implies that 
a defective HRR pathway may further contribute to tumour development in 
MSI+ colon cancers. 
As the SKUT-1 cell line was originally derived from a uterine sarcoma 
(Risinger et al., 1995) the possible significance of XRCC2 frameshift 
mutations in gynaecological tumours was also investigated. In this 
particular study 4 endometrial stromal sarcomas and 8 leiomyosarcomas of 
the uterus were examined. Sequencing analysis revealed that one of the 8 
leiomyosarcomas of the uterus also carried the same XRCC2 frameshift 
mutation as that found in the SKUT-1 cell line. Interestingly, another study 
detected a translocation breakpoint which affects the last exon of a uterine 
specific isoform in RAD51 B in the more common uterine leiomyomas 
(Schoenmakers et al., 1999). Taken together these results imply that there 
is a selective pressure of gynaecological tumours to acquire mutations in 
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genes encoding the RAD51 paralogs with respect to enhancing tumour 
progression. 
The advantage gained by acquiring such mutations in these tumours, with 
respect to tumour development, can be explained in context to the reported 
role of HRR in delaying of DNA replication fork progression following DNA 
damage (Henry-Mowatt et aL, 2003). Cells losing part of the HRR pathway, 
for example through mutations in XRCC2 (and possibly RAD51 B), may be 
unable to regulate DNA synthesis on damaged templates. This would 
subsequently result in higher levels of genetic instability and 
tumourigenesis. In support of this, Griffin and co-workers (2000) recently 
showed an increase in chromosome missegregation associated with 
fragmented centrosomes in XRCC2 deficient cells which, the authors 
suggested, could subsequently lead to genetic instability and cancer. 
The difference in acquired mutations observed between the MSI+ colon 
cancers and the gynaecological samples could be due to a number of 
reasons. For example, the two types of tumours might undertake different 
pathogenic routes during progression with selective advantages being 
gained either through the loss of MRE11 with respect to colon cancers (and 
possibly other checkpoint related genes) or the loss of the RAD51 paralogs 
with respect to uterine leiomyosarcoma. Alternatively, the different rates of 
exposure to, and types of carcinogens in the colon, as opposed to that 
exposed in the uterus, may account for such differences that occur. 
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5.1 INTRODUCTION 
The observation that MMR -deficient tumour cells are sensitive to 
thymidine, in addition to the results obtained in Chapter 3, which 
demonstrated HRR defects in such cells, is consistent with the hypothesis 
that HRR is involved in repairing lesions that are induced by thymidine. 
Furthermore, cDNA sequence analysis in Chapter 4 revealed a frameshift 
mutation within the RAD51 paralog gene, XRCC2, in MMR -deficient 
SKUT-1 cells. The resulting peptide encoded a 132 amino acid protein that 
retained the ATPase Walker Box A but lost the highly conserved Walker 
Box B. Expression of this mutant allele into a MMR -proficient, SW480 
tumour cell line conferred sensitivity to both thymidine and, to a lesser 
extent, MMC. Given these results, the effects of the mutant XRCC2 allele 
on both DSB and thymidine-induced recombination was examined in the 
present chapter. 
The HRR pathway is required for the accurate repair of DNA breaks 
induced by agents such as MMC, as well as being involved in the rescue of 
stalled/collapsed replication forks. This repair process frequently utilizes 
interactions between the sister chromatids, which act as templates for DNA 
synthesis (van Gent et al., 2001). Such observations suggest that this 
pathway is particularly effective in the S-phase of the cell cycle. In 
eukaryotic cells, it has been noted that the RAD51 protein (a functional 
homologue of the E-coli RecA recombinase) plays an influential role in 
homologous recombination mediated repair. This protein forms 
nucleoprotein filaments on ssDNA fragments, thus promoting homologous 
pairing and DNA strand exchange (Baumann et al., 1996; Gupta et al., 1997 
and Sung et al., 1994). In human cells, efficient HRR requires other related 
genes, in addition to RAD51, that belong to the RAD52 epistasis group. 
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These genes include RAD52, RAD54 and the RAD51 paralogs amongst 
others (reviewed in Thompson and Schild, 2001). 
Currently, five mammalian RAD51 paralogs (namely XRCC2, XRCC3, 
RAD51 B, RAD51C and RAD51D) have been isolated and shown to share 
between 20-30% sequence homology to the RAD51 protein (Thacker, J., 
1999a and 1999b). These RAD51 paralogs were initially identified either 
due to their ability to functionally complement X-ray sensitive hamster cells 
(in the case of XRCC2 and XRCC3), or through data base searching for 
sequence similarities with XRCC2 and XRCC3 (in the case of RAD51 B, 
RAD51 C and RAD51 D) (Albala et al., 1997; Cartwright et al., 1998; Dosanjh 
et al., 1998 and Pittman et al., 1998). The RAD51 D protein is most closely 
related, in terms of structure and homology, to the yeast RAD57 protein; 
whereas the XRCC2 protein shares highest homology with the yeast 
RAD55 protein (Thacker J., 1999a and 1999b). 
It is proposed that the RAD51 paralogs may act as accessory factors in 
assisting with the 'loading' of RAD51 onto DNA, similar to the RAD55 and 
RAD57 gene products in Saccharomyces cerevisiae (Sung, P. 1997; Takata 
et al., 2001; Braybrooke et aL, 2000; O'Regan et al., 2001 and Masson et 
a/., 2001). Further evidence for the 'pre-synaptic' role of these paralogs, 
comes from the observation that the XRCC3 protein interacts with RAD51 
and that its presence is required for the assembly of RAD51 complexes in 
vivo (Bishop et al., 1998). Although the five paralogs share less than 30% 
sequence homology with each other (Thacker, J. 1999), knockouts of any 
paralogs exhibit extremely similar phenotypes. Studies using chicken DT40 
cells, in which each paralog was individually knocked out, showed that such 
strains all displayed reduced growth rates, exhibited chromosomal instability 
and frequently accumulated spontaneous breaks (Takata et al., 2001). 
Cells defective in any of the paralogs also displayed marked sensitivity to 
DNA damaging agents including MMC and IR (Tambini et al., 1997; 
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Cartwight et al., 1998; Liu et al., 1998 and Takata et al., 2001). 
Furthermore, XRCC2, XRCC3, RAD51C and RAD51B deficiency has been 
shown to directly result in impaired HRR (Johnson et al., 1999; Pierce et al., 
1999; French et al., 2002 and Takata at al., 2000). 
Recent studies have reported that the five paralogs co-immunoprecipitate 
as two distinct complexes as well as individual heterodimers (Masson et al., 
2001; Kurumizaka et al., 2002; Wiese et al., 2002 and Liu N., et al., 2002). 
One such complex comprises of RAD51 B, RAD51 C, RAD51 D, and XRCC2 
(the BCDX2 complex), whereas the second complex consists of the 
RAD51C and XRCC3 proteins. The BCDX2 complex was shown to 
specifically bind to ssDNA as well as to single-stranded regions or nicks in 
duplexed DNA (Masson et aL, 2001). The RAD51 C/XRCC3 complex, 
however, was shown to bind ssDNA and thus promote DNA-DNA 
interactions and annealing (Kurumizaka et al., 2002 and Masson et al., 
2001). 
Given the proposed 'pre-synaptic' involvement of XRCC2 in both DSB- 
induced HRR and the requirement of HRR in maintaining the integrity of 
collapsed/stalled replication forks, the effects of expressing the mutant 
XRCC2 allele on both DSB and thymidine-induced recombination are 
investigated in the present chapter. 
161 
CHAPTER FIVE: EFFECTS OF 342DELT EXPRESSION ON RECOMBINATION 
5.2 RESULTS 
5.2.1 Expression of 342delT in SW4801SN. 3 and MRCSVAISN. 13 
strains 
Having determined the phenotypic effects of the mutant XRCC2 allele on 
both thymidine and MMC sensitivity in the SW480 cell line, the effects of 
342delT expression on DSB-induced HRR were investigated. To achieve 
this, the mutant XRCC2 allele was sub-cloned into the plRESpuro3 
expression vector (see Appendix 4, Page 240) in order to allow for its 
introduction into the MMR -proficient, SW480/SN. 3 and MRC5VA/SN. 13 
strains containing the ScNeo recombination reporter substrate. Details of 
all cell lines and transfectants used in the present chapter are described in 
Table 5.1. Expression of the mutant construct was confirmed through 
sequencing of amplified XRCC2 cDNA. 
Cell line Parent Description 
SW480/SN. 3 SW480 MMR+ cell line carrying ScNeo recombination reporter 
SXIR. 1-4 SW480/SN. 3 Derivatives of above expressing XRCC2 mutant allele 
MRC5VA/SN. 13 MRC5VA MMR''fibroblast carrying ScNeo recombination reporter 
MX. 1 AND. 2 MR5VA/SN. 13 Derivatives of above expressing XRCC2 mutant allele 
SKUT-1 MMR --deficient uterine sarcoma cell line 
SKUT-1/SN. 3 SKUT-1 Derivative of above carrying ScNeo 
Table 5.1 Table showing parental lines and transfectants used in the present 
chapter. 
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As shown in the sequencing images presented in Figure 5.1a, SW480/SN. 3 
transfectants appeared to display both wild type and mutant alleles of 
XRCC2 in approximately equal quantities. MRC5VA/SN. 13 transfectants, 
however, appeared to display predominantly the mutant allele (Figure 5.1 b). 
A similar effect was observed in the MMR -deficient, SKUT-1/SN. 3 strain, 
which also appeared to predominantly display the mutant XRCC2 allele 
(Figure 5.1 b). 
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Figure 5.1 Sequencing gel images showing expression of 342delT. (A) 
Expression of the mutant XRCC2 allele (indicated by arrow) in the SW480/SN. 3 strain 
transfected with mutant XRCC2 cDNA. The sequence pattern for four such transfectants 
(SXIR. 1, SXIR. 2, SXIR. 3 and SXIR. 4) is compared with un-transfected SW480/SN. 3 cells 
(containing only wild type XRCC2). (B) Expression of the mutant XRCC2 allele (indicated 
by arrow) in the MRC5VA/SN. 13 strain transfected with the mutant XRCC2 cDNA sub 
cloned into pIRES-puor3 expression vector. The sequence patterns in two MRC5VA 
transfectants (MX. 1 and MX. 2) is compared with parental MRC5VA cells (containing only 
wild type XRCC2) and SKUT-1 (which carries both the frame shift mutation of XRCC2 as 
well as wild type). 
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Western blot analysis of whole cell extracts, obtained from transfected 
strains, revealed a peptide having approximately the same molecular weight 
as that predicted to be encoded for by 342delT in all transfectants (Figure 
5.2). This 17.2kDa peptide was not observed in any other MMR -proficient 
or -deficient cell lines examined, other than in SKUT-1 cells and 
transfectants, indicating that it had been translated from the mutant XRCC2 
allele. Consistent with results from the sequencing gels, the ratio of the 
levels of peptide and full length XRCC2 protein varied between the two 
strains transfected. The SW480/SN. 3 transfectants retained equal levels of 
wild type XRCC2 protein to that found in parental cells, and showed clear 
expression of the peptide (Figure 5.2). MRC5VA/SN. 13 transfectants, 
however, showed reduced levels of wild type XRCC2 protein but high levels 
of mutant peptide. The effect seen in MRC5VA/SN. 13 transfectants is 
similar to that noted in the SKUT-1/SN. 3 strain. Thus, all strains express 
342delT although the level of wild type XRCC2 protein in the MRC5VA and 
SKUT-1/SN. 3 strains is greatly reduced. 
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Figure 5.2 Detection of 342delT protein expression in transfected cell lines 
by Western blotting. Both the wild type XRCC2 protein and the mutant peptide are 
indicated by arrows in both SW480/SN. 3 (SXIR. 1, SXIR. 2, SXIR. 3 and SXIR. 4) and 
MRC5VA/SN. 13 (MX. 1 and MX. 2) transfectants. SW480/SN. 3 transfectants appear to 
express equal levels of both wild-type and mutant XRCC2 protein. MRC5VA/SN. 13 
transfectants, like the SKUT-1/SN. 3 strain, appear to display increased levels of mutant 
XRCC2 protein when compared to wild type. ß-actin was used for loading control. 
5.2.2 ScNeo containing strains expressing 342de1T become 
sensitive to thymidine and MMC. 
Experiments conducted in Chapter 4 showed that expression of 342delT 
could confer thymidine sensitivity when expressed in SW480 cells. 
Therefore to investigate whether expression of the pIRESpuro3-342de1T 
construct altered the phenotype of SW480/SN. 3 and MRC5VA/SN. 13 cells, 
with respect to thymidine, the sensitivity of transfectants to this agent was 
examined (Figure 5.3). Exponentially growing cells were continuously 
treated with increasing doses of thymidine and cell survival was determined 
after 10-14 days. Consistent with previous data, strains expressing 342delT 
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became more sensitive to the cytotoxic effects of thymidine when compared 
to the respective parental cell line. At 10% survival, SW480/SN. 3 
transfectants were up to 2-fold more sensitive to the cytotoxic effects of 
thymidine than parental cells (Figure 5.3a). The MRC5VA/SN. 13 
transfectants (which predominantly expressed 342deIT) were observed to 
exhibit a greater degree of sensitivity than SW480/SN. 3 transfectants. At 
10% survival such strains were between 3.8 to 4.8-fold more sensitive to 
thymidine than parental MRC5VA/SN. 13 cells (Figure 5.3b). The MMR 
-deficient, SKUT-1/SN. 3 strain remained significantly more sensitive (2- 
fold) when compared to both SW480/SN. 3 and MRC5VA/SN. 13 
transfectants at all doses tested. These results therefore suggested that 
342delT conferred thymidine sensitivity when expressed in MMR -proficient 
cells. 
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Figure 5.3 Expression of 342delT confers thymidine sensitivity. (A) 
Transfectants of SW480/SN. 3 expressing the mutant XRCC2 allele (SXIR. 3,0 and SXIR. 4, 
X) are sensitive to thymidine when compared to untransfected SW480/SN. 3 cells (. ). The 
sensitivity of the SKUT-1/SN. 3 strain (") to thymidine is included for reference. (B) 
Transfectants of MRC5VA/SN. 13 expressing the mutant XRCC2 allele (MX. 1,0 and MX. 2, 
o) are sensitive to thymidine when compared to untransfected MRC5VA/SN. 13 cells (A). 
The sensitivity of the SKUT-1/SN. 3 strain (") to thymidine is included for reference. The 
mean (symbols) and standard deviation (error bars) of three independent experiments 
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Findings from previous published studies suggest that the proteins involved 
in HRR proteins are involved in the repair of DNA damage induced by MMC 
(Jones et al., 1987; Fuller and Painter, 1988; Caldecott and Jeggo, 1991 
and Tebbs et al., 1995). The sensitivity to this agent was therefore 
investigated using exponentially growing cells transfected with the 
pIRESpuro3-342delT construct (Figure 5.4). Results showed that the 
SKUT-1/SN. 3 cells, SW480/SN. 3 and MRC5VA/SN. 13 transfectants 
expressing the mutant XRCC2 allele, all displayed increased sensitivity to 
MMC relative to SW480/SN. 3 and MRC5VA/SN. 13 parental strains. At 
10% survival, all SW480/SN. 3 (Figure 5.4a) and MRC5VA/SN. 13 (Figure 
5.4b) transfectants were found to be up to 2-fold more sensitive to MMC 
when compared to parental SW480/SN. 3 and MRC5VA/SN. 13 cells. At 
10% survival, the SKUT-1/SN. 3 strain was also 2-fold more sensitive to 
MMC when compared with either SW480/SN. 3 or MRC5VA/SN. 13 cells. 
Therefore, consistent with results presented in the previous chapter, 
expression of 342de1T conferred sensitivity to MMC when expressed in 
MMR -proficient cell lines. 
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Figure 5.4 Expression of 342deIT confers sensitivity to MMC. (A) Transfectants 
of SW480/SN. 3 expressing the mutant XRCC2 allele (SXIR. 3,0 and SXIR. 4, X) are 
sensitive to MMC when compared to untransfected SW480/SN. 3 cells (. ). The sensitivity 
of the SKUT-1/SN. 3 strain (s) to MMC is included for reference (B) Transfectants of 
MRC5VA/SN. 13 expressing the mutant XRCC2 allele (MX. 1,0 and MX. 2, Q) are sensitive 
to MMC when compared to parental MRC5VA/SN. 13 cells (A). The sensitivity of the 
SKUT-1/SN. 3 strain (") to MMC is included for reference. The mean (symbols) and 
standard deviation (error bars) of three independent experiments performed in duplicate 
are presented. 
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5.2.5 342delT exerts a cell line specific effect on I-Scel induced 
recombination. 
In agreement with the involvement of XRCC2 in HRR, Johnson and co- 
workers (1999) showed that XRCC2 deficient hamster cells exhibit a 
marked decrease in the production of neo+ recombinants in a homology 
based recombination assay. As described on Page 103, this assay 
measures homology based recombination events that occur between two 
defective neomycin phospho-transferase genes following the induction of a 
site specific DSB. 
In order to determine the effect of the mutant XRCC2 allele on DSB-induced 
recombination, SW480/SN. 3 and MRC5VA/SN. 13 cells stably transfected 
with the ScNeo recombination substrate were used. As shown in Figure 
5.5, induction of a DSB in a MMR -proficient, SW480/SN. 3, strain resulted 
in an 850-fold increase in the frequency of neo+ recombinants when 
compared to mock transfected cultures. Following transfection of the I-Scel 
endonuclease in SW480/SN. 3 transfectants expressing 342de1T, a 600- 
1500-fold increase in neo+ recombinants was also observed when 
compared to mock transfected cultures. This frequency is similar to that 
observed in the SW480/SN. 3 strain. 
In contrast to this observation, induction of a DSB in MRC5VA/SN. 13 
transfectants (expressing predominantly 342deIT) resulted in only a 1.7 to 
2.4-fold increase in the frequency of neo+ recombinants (Figure 5.5). This 
was a much weaker inductive effect when compared to the MRC5VA/SN. 13 
strain not expressing 342de1T, which showed a 110-fold increase in the 
frequency of neo+ recombinants. The results obtained in the 
MRC5VA/SN. 13 transfectants are similar to that observed in the SKUT- 
1/SN. 3 clone, which also showed no increase in the frequency of neo+ 
recombinants following the induction of a site-specific DSB. 
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Figure 5.5 Cell -specific effects of 342delT on homology directed repair of a 
site-specific DSB. SW480/SN3 cells expressing 342delT (namely SXIR. 1 and SXIR. 2) 
show a robust induction of neo+ recombinants, following transient transfection of the I-Scel 
expression construct (solid bars), when compared to mock transfected cultures (empty 
bars). In contrast the induction of neo+ recombinants is suppressed to levels similar to 
those found in SKUT-1 cells in MRC5/SN13 transfectants expressing the mutant XRCC2 
allele (namely MX. 1 and MX. 2). The results shown are an average of three independent 
experiments and standard deviation is indicated by error bars. 
Taken together, these results suggest that SW480/SN. 3 transfectants 
expressing 342delT and wild-type XRCC2 protein remain proficient in the 
repair of DSBs. The combination of depressed wild-type XRCC2 levels and 
the presence of the mutant XRCC2 allele in MRC5VA/SN. 13 strains, 
however, causes a much weaker inductive effect in the frequency of neo+ 
recombinants. Thus the effect of recombination events induced in the 
ScNeo recombination reporter by a site-specific DSB is dependent on the 
level of wild-type XRCC2 protein expression. 
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5.2.6 Both SW480/SN. 3 and MRC5VA/SN. 13 strains expressing 
342deIT are defective in thymidine induced recombination. 
Studies reported by Lundin and co-workers (2002) suggested that exposure 
of cells to thymidine subsequently results in the production of lesions at 
replication forks that are specifically repaired by proteins involved in HRR. 
The effect on recombination events induced by thymidine treatment was 
therefore investigated in clones expressing the mutant XRCC2 allele 
(Figure 5.6). Replica cultures were treated for 24 hours with increasing 
doses of thymidine and the frequency of neo+ recombinants determined. 
Such replica cultures were initially inoculated from 1000 cells in order to 
eliminate pre-existing neo+ cells and to obtain a more precise measurement 
of the inductive effects of thymidine. This approach is deemed to be more 
sensitive than the assay used to measure thymidine-induced recombination 
events in Chapter 3 where mass cultures were inoculated and exposed to 
thymidine. Treatment of the MMR proficient, SW480/SN. 3 and 
MRC5VA/SN. 13, parental strains resulted in a 6-fold increase in the 
frequency of neo+ recombinants (Figure 5.6a and 5.6b, respectively). 
Furthermore, the effects observed were found to be dose-dependent with 
maximal levels of recombinants occurring at 10mM thymidine treatment. 
SW480/SN. 3 transfectants, expressing 342delT, were treated with 2mM or 
10mM thymidine as they showed an intermediate sensitivity to thymidine. 
Using such doses, no increase in the frequency of neo+ recombinants was 
observed. This is in marked contrast to the results obtained when using the 
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Figure 5.6 Cells expressing 342delT are defective in HRR induced by 
thymidine. (A) 24 hour thymidine treatment induced recombination events in 
SW480/SN. 3 cells ( ) but not in the transfectants (SXIR. 1, o and SXIR. 2,0). (B) 24 hour 
thymidine treatment also induces recombination events in MRC5VA/SN. 13 cells (A -data 
supplied by Emma Bolderson) but not in cells expressing the mutant XRCC2 allele (MX. 1, 
0 and MX. 2, o). The frequencies of neo+ recombinants induced by thymidine in SKUT- 
1/SN. 3 cells were: 0mM = 1.01 x 10"7; 2mM =<1.81 x 10'7 and 4mM =<2.27 x 10"7. Six 
independent replica cultures were treated for each experiment and the results are an 
average of six independent experiments. The standard deviation for each treatment is 
indicated by error bars 
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parental SW480/SN. 3 strain. Additionally no increase in the frequency of 
neo+ recombinants was observed in MRC5VA/SN. 13 transfectants when 
treated with 2mM or 4mM thymidine. The parental strain, however, 
displayed a3 to 4-fold increase in the frequency of neo+ recombinants at 
the same doses. The SKUT-1/SN. 3 strain was also investigated using this 
approach as it had previously been demonstrated that the DLD-1/SN. 2 
(MMR -deficient) strain was also defective in thymidine-induced HRR. 
Since SKUT-1/SN. 3 cells are sensitive to this agent, these cells could not 
be treated with 5 or 10mM thymidine. However, even when 12 million cells 
were treated with 2mM thymidine, no neo+ recombinants were retrieved 
(frequency <1.8 x 10'7). Treating SW480/SN. 3 cells with this same 
concentration of thymidine, however, resulted in a 3-fold increase in the 
frequency of neo+ recombinants (Figure 5.6a). 
5.2.7 Thymidine fails to induce any detectable DSBs in treated 
cells. 
Thymidine treatment is suggested to induce DNA lesions at stalled 
replication forks. To determine whether thymidine induced DSBs at such 
replication forks, all strains were treated with thymidine as well as 
camptothecin and irradiation (which are known to induce DSBs). Cells were 
treated with either 10mM thymidine or 100nM camptothecin for 24 hours, or 
exposed to 1OGy of irradiation. After the respective treatment, cells were 
harvested and analyzed for DSBs by pulse field gel electrophoresis. 
Consistent with previous reports, no DSBs were detected in any strain when 
treated with 10mM thymidine (Figure 5.7). This was in contrast to that 
observed when cells were exposed to either 100nM of CPT or 1OGy of 
irradiation, which both induced large amounts of DSBs compared to 
untreated cells. 
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SW480/SN. 3 SXIR. 1 MRC5VA/SN. 13 MX. 1 SKUT-1/SN. 3 
TdR (10 mM) -+-- 
CPT (100 nM) --+- 
IR (10 Gy) ---+ 









Figure 5.7 Thymidine fails to induce any detectable DSBs in treated cells. 
The indicated cells were treated with 10 mM thymidine, 20 nM camptothecin for 24 hours 
or exposed to10 Gy of irradiation before being harvested for analysis of DSBs by PFGE. 
DSBs are readily detectable in all cells treated by camptothecin or exposed to irradiation 
but not thymidine. 
5.2.8 Cells expressing 342delT are sensitive to camptothecin. 
The results presented above suggest that SW480/SN. 3 strains expressing 
342delT remain competent for repairing I-Scel induced DSBs but are 
unable to repair lesions induced by thymidine. One reason for such results 
could be that cells expressing 342delT are unable to repair DNA lesions 
specifically induced by thymidine. An alternative explanation for such 
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results is that the HRR pathway is saturated by thymidine treatment as this 
agent is capable of inducing HRR events at every replication fork. To 
investigate this, the DNA Topoisomerase I inhibitor, camptothecin (CPT) 
was used to initiate HRR events. CPT specifically induces DSBs in a global 
manner at replicating forks throughout the genome. This type of lesion is 
suggested to be repaired primarily by the HRR pathway (Ryan et al., 1994). 
The sensitivity of strains expressing the mutant allele to CPT was initially 
investigated. Exponentially growing cells were continuously treated with 
increasing doses of CPT and cell survival was determined after 10-14 days. 
SW480/SN. 3 transfectants expressing 342delT showed intermediate 
sensitivity and at 10% survival were at least 1.2-fold more sensitive to CPT 
when compared to the parental strain (Figure 5.8a). At 10% survival, 
MRC5VA/SN. 13 strains expressing 342delT were also found to be 1.4-fold 
more sensitive to CPT when compared to the parental strain (Figure 5.8b). 
The MMR -deficient, SKUT-1/SN. 3 strain was 1.4-fold more sensitive to the 
cytotoxic effects of this agent when compared to either of the MMR - 
proficient, SW480/SN. 3 and MRC5VA/SN. 13, strains tested. 
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Figure 5.8 Expression of 342delT confers sensitivity to camptothecin (CPT). 
(A) Transfectants of SW480/SN. 3 expressing the mutant XRCC2 allele (SXIR. 3,0 and 
SXIR. 4, X) are sensitive to CPT when compared to untransfected SW480/SN. 3 cells ( ). 
The sensitivity of the SKUT-1/SN. 3 strain (. ) to CPT is included for reference (B) 
Transfectants of MRC5VA/SN. 13 expressing the mutant XRCC2 allele (MX. 1,0 and MX. 2, 
o) are sensitive to CPT when compared to parental MRC5VA/SN. 13 cells (A). The 
sensitivity of the SKUT-1/SN. 3 strain (") to CPT is included for reference. The mean 
(symbols) and standard deviation (error bars) of three independent experiments performed 
in duplicate are presented. 
0.01 
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5.2.9 SW480/SN. 3 cells expressing 342delT are proficient in HRR 
induced by CPT. 
Previous published studies have shown that exposure of cells to CPT 
induces HRR events in mammalian cells (Ryan et al., 1994). Therefore the 
ability of CPT to induce HRR events in cells expressing the mutant XRCC2 
allele was investigated. Approximately 18 million cells were treated for 24 
hours with increasing doses of CPT in replica cultures and the frequency of 
neo+ recombinants determined. Such replica cultures were initially 
inoculated from 1000 cells in order to eliminate pre-existing Neo+ 
recombinants and to obtain a more precise measurement of the 
recombinogenic effects of CPT. As shown in Figure 5.9, CPT induced the 
frequency of neo+ recombinants up to"10-fold in a dose dependent manner 
in the SW480/SN. 3 parental strain. Furthermore, the two transfectants 
expressing 342delT also exhibited an increase in the frequency of neo+ 
recombinants to levels that were similar to the parental strain. These 
results therefore show that SW480/SN. 3 strains expressing 342delT are 
able to repair recombination events following CPT treatment but not 
following thymidine treatment. 
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Figure 5.9 Cells expressing 342delT are proficient in HRR induced by CPT. 
CPT treatment for 24 hours induced recombination events in SW480/SN. 3 cells as well as 
in the SXIR. 1 or SXIR. 2 transfectants (labeled). Six independent replica cultures were 
treated for each experiment and the results are an average of six independent 
experiments. The standard deviation for each treatment is indicated by error bars. 
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5.3 DISCUSSION 
The aim of the present study was to determine whether the mutation found 
within XRCC2 of SKUT-1 cells was responsible for the HRR defects 
observed in the cell line. Recombination events were induced using site- 
specific breaks, as well as camptothecin and thymidine (agents which have 
all previously been noted to be potent inducers of such events, Lundin et 
al., 2002 and Ryan et al., 1994). The results suggest that expression of 
342delT is responsible for the HRR defects observed in the SKUT-1 cell 
line. Furthermore this effect seemed to depend upon the level of wild-type 
XRCC2 protein expression as well as expression of the mutant XRCC2 
allele. 
Western blot analysis of protein extracts obtained from SW480/SN. 3 strains 
expressing 342delT appeared to display an equal level of both wild-type 
and mutant allele. MRC5VA/SN. 13 strains expressing 342delT, however, 
appeared to display reduced levels of the wild-type XRCC2 protein but 
higher levels of the mutant peptide. A similar observation was noted when 
the SKUT-1/SN. 3 strain was examined. The mechanism responsible for the 
depression in the level of the full length XRCC2 protein in MRC5VA/SN13 
cells and SKUT-1 is not clear. MRC5VA/SN. 13 transfectants and SKUT-1 
cells appear to produce an excess of the mutant transcript as judged by the 
level of the cDNAs amplified from these cells. However it is unlikely that 
enhanced expression of the mutant allele would suppress expression of the 
wild-type. Nonsense mediated decay (which alters the stability of 
messenger RNAs containing nonsense mutations) should specifically affect 
the mutant gene in these cells and not the wild-type (reviewed in Wilusz et 
al., 2001). One possible explanation is that the decreased level of wild-type 
XRCC2 protein is the result of increased turnover of the protein. It is known 
that XRCC2 forms a complex with other RAD51 paralogs (Masson et al., 
2001 and Liu N., et al., 2002). The mutant peptide may associate more 
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effectively with the complex than the full length protein and the un- 
complexed protein may be degraded. This would be similar to the situation 
with the MMR proteins hMLH1 and hPMS2 which are normally found in 
cells in the form of heterodimers (Li et al., 1995). Nonsense mutations that 
eliminate the full length wild-type hMLH1 also result in a decline in the level 
of the un-complexed partner protein hPMS2 (Drummond et al., 1996). 
The differences in the ratio of the levels of wild type: mutant protein 
expression in the two cell lines appears to be reflected in the ability to form 
recombinants following induction of DNA DSBs. SW480/SN. 3 
transfectants, expressing equal levels of both wild-type and mutant allele 
342delT, repaired both I-Scel and camptothecin induced DSBs as 
effectively as the parental strain. MRC5VA/SN. 13 strains however, 
expressing reduced levels of wild type XRCC2 protein, displayed a reduced 
ability to repair I-Scel induced DSBs via a homology based repair assay 
when compared with the parental strain. This latter effect is similar to that 
observed in the SKUT-1/SN. 3 strain, in which the level of wild type XRCC2 
protein is also depressed when compared to the level of mutant peptide. 
The results obtained using I-Scel and CPT contrast to those obtained when 
HRR events were induced using thymidine. Both SW480/SN. 3 and 
MRC5VA/SN. 13 strains expressing 342delT showed no increase in the 
frequency of neo+ recombinants following thymidine exposure. These 
results suggest that 342de1T specifically acts in a dominant negative 
manner to suppress HRR events induced by thymidine. This suppression is 
further highlighted when the cytotoxic effect of thymidine was measured in 
transfectants expressing 342delT. All strains expressing 342de1T were 
between 1.4 to 4.8-fold more sensitive to this agent when compared to 
parental strains. 
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Taken together these results suggest that the wild type XRCC2 protein is 
involved in the specific repair of DNA DSB lesions induced by agents 
including an I-Scel endonuclease and CPT. This is consistent with 
suggestions that a functional wild-type XRCC2 protein is required in the 
repair of DNA DSBs in hamster cells (Johnson et a/., 1999). Either 
expression of 342delT and/or the reduced level of wild-type XRCC2 protein 
may interfere with thymidine-induced recombination events in both 
SW480/SN. 3 and MRC5VA/SN. 13 cells. 
To date, the structure of the lesion induced by thymidine is unknown. 
Evidence from bacteria and yeast suggest that one such structure could 
involve a four-way DNA junction that forms due to the reversal of stalled 
replication forks (Postow et al., 2001). Such lesions are proposed to form 
substrates for HRR as they involve long tracts of gapped DNA. Given the 
involvement of the XRCC2 protein in HRR processes, expression of 
342delT can potentially impair the resolution of such structures at several 
steps. Firstly, the BCDX2 complex has recently was shown to specifically 
bind to gapped DNA structures (Masson et al., 2001). The function of this 
complex is proposed to be within the 'pre-synaptic' phase of HRR in 
assisting with the 'loading' of the RAD51 protein in order to initiate 
recombination events. By analogy, in bacterial cells the RecFOR complex 
loads the RecA recombinase protein onto gapped sequences (Morimatsu et 
a/., 2003). Furthermore Kurumizaka and co-workers (2003) found that the 
XRCC3 fragment containing amino acid residues 63-346 is essential for 
RAD51 C binding. This region contains the Walker-type ATPase motifs. 
Both of XRCC3 and XRCC2 have some sequence homology and display 
similar phenotypes with respect to DNA damaging agents. Therefore, it is 
possible that loss of the last 164 amino acids from XRCC2 may inhibit 
binding with RAD51 D, by analogy with XRCC3 and RAD51C. Such an 
inability to bind may therefore inhibit the function of the BCDX2 complex. 
Thus cells expressing the mutant peptide would be unable to 'load' RAD51 
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onto these gapped DNA structures (Figure 5.10). 342delT, however, may 
not interfere with the repair of DNA DSBs as effectively and the presence of 
relatively high levels of wild type protein may be sufficient to load RAD51 
onto DNA ends of DSBs and promote repair (as observed in SW480/SN. 3 
transfectants). 
GAPPED DNA 
5' TO 3' RESECTIONING 
ý- 342deIT 
i 
STRAND INVASION AND 
RESYNTHESIS 
Figure 5.10 Expression of 342de1T may inhibit the binding of the BCDX2 
complex to gapped DNA structures. Four-way DNA junctions (formed following the 
reversal of stalled replication forks) may include gapped DNA structures. The BCDX2 
complex specifically binds to gapped DNA structures (Masson et al., 2001) in order to 
assist in the loading of RAD51 (indicated as blue circles). Expression of 342delT may 
therefore inhibit the processing of lesions induced by thymidine by inhibiting the function of 
the BCDX2 complex. 
An alternative explanation to the effects of 342delT is made clear from a 
recent report that implicates the BCDX2 complex in being necessary for 
branch migration within Holliday junctions (Liu et al., 2004). Furthermore it 
183 
CHAPTER FIVE: EFFECTS OF 342DELT EXPRESSION ON RECOMBINATION 
was suggested that within the BCDX2 complex, the RAD51D/XRCC2 
heterodimer acted as an 'ATP-dependent motor' which drives the branch 
migration process. This heterodimer is proposed to be initially recruited by 
RAD51 B or the RAD51 B/RAD51 C heterodimer in a similar manner in which 
the bacterial RuvA protein targets the RuvB protein (Figure 5.11). Hence 
deletion of Walker Box B from XRCC2 may inhibit 'ATP-dependent motor' 
activity of the RAD51 D/XRCC2 heterodimer. Such a situation may result in 
the accumulation of unresolved Holliday junctions which are thought to 
occur during the repair of DSBs or when stalled replication forks reverse. 
Figure 5.11 Expression of 342delT may alter the kinetics of Holliday Junction 
resolution. The 'ATP-dependent motor activity of the RAD51 DIXRCC2 heterodimer, 
within the BCDX2 complex (indicated) may be inhibited by the presence of 342delT. Such 
events may subsequently lead to unresolved Holliday Junctions. 
In additional support to the present study, the RAD51 C/XRCC3 complex 
has also recently been shown to regulate eukaryotic replication fork 
progression following DNA damage induced by cisplatin (Henry-Mowatt et 
aL, 2003). These observations therefore suggest a strong involvement of 
the RAD51 paralogs in maintaining the integrity of stalled replication forks 
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(that are induced by agents such as thymidine and cisplatin). Furthermore, 
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6.1 Overview and discussion of results 
The aim of this research project was three fold: 
(i) To determine the integrity of the Homologous recombination repair 
pathway in MMR -deficient tumour cell lines. 
(ii) To determine the extent to which a deficiency in the Homologous 
recombination repair pathway was the result of mutations in genes. 
(iii) In the event of gene mutations contributing to Homologous 
recombination repair deficiency, to determine whether such 
mutations were responsible for the thymidine sensitivity observed in 
Mismatch repair tumour cells. 
The results described in the present study show that the HRR pathway is 
defective in MMR -deficient tumour cell lines. In support of this, four MMR 
-deficient tumour cell lines were defective in the production of neo+ 
recombinants by homology based recombination following the transient 
expression of a site specific break. Furthermore, DLD-1/SN. 2 cells were 
also defective in the production of neo+ recombinants when recombination 
events were induced using the replication inhibitor, thymidine. These 
results are consistent with a study published by Slebos and Taylor (2001) 
which described the use of a host cell reactivation assay to measure HRR 
events based on the reactivation of a green-fluorescent protein in various 
cell lines. This study also provided evidence that the MMR -deficient, 
HCT116 cell line, showed no increase in recombination events. In addition, 
all five MMR -deficient tumour cell lines tested were sensitive to the cross- 
linking agent MMC. These results are in agreement with a study conducted 
by Fiumicino and co-workers (2000) where a sensitivity of various MMR 
-deficient cells to MMC was also noted. Cells deficient in HRR (including 
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XRCC2, XRCC3 and BRCA1) are also known to be acutely sensitive to 
MMC (Jones et al., 1987; and Fuller and Painter, 1988 and Moynahan et 
al., 2001). Taken together these results suggest that HRR defects occur in 
MMR -deficient tumour cells. 
To further our understanding of suggested defects in HRR acquired in these 
specific tumour cell lines, genes involved in HRR and DSB signalling were 
sequenced. Screening of eight tumour cell lines revealed a frameshift 
mutation within the RAD51 paralog, XRCC2, of the MMR -deficient SKUT-1 
cell line. Such frameshift mutations occur predominantly in a MMR 
defective background. This provides further evidence to support the 
argument that the loss of HRR is a downstream event, following the initial 
loss of MMR in these specific cell lines. 
The experiments conducted in the present study further showed that the 
XRCC2 mutation could account for the thymidine sensitivity observed in 
SKUT-1 cells. Transfection of 342de1T into two different MMR -proficient 
cell lines, conferred both thymidine sensitivity and suppressed HRR events 
induced by thymidine. Increasing evidence from both prokaryotic and 
eukaryotic cells suggest that the loss of HRR may account for the thymidine 
sensitivity observed in various cell types (Cox, 2001; Kraus et a!., 2001 and 
Michel et aL, 2001). The addition of thymidine induces an imbalance in 
dCTP and dTTP pools which subsequently results in the slowing of DNA 
replication forks (Bjursell and Reichard, 1973). Exposure of cells to 
thymidine has previously been shown to specifically require a proficient 
HRR pathway for cell survival (Lundin et al., 2002a). In addition, other 
studies have used CHO cells deficient in HRR, to show that such cells 
exhibit delayed cell cycle progression (Fuller and Painter, 1988; Griffin et 
al., 2000 and Tebbs et aL, 1995), hypersensitivity to agents known to stall 
DNA replication forks (Lundin et a!., 2002a), increased mutation rates 
(Thacker et al., 1994 and Fuller and Painter, 1988) and chromosome 
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instability (Griffin et a/., 2000 and Cui et al., 1999). RAD51 foci have also 
been shown to form in post-replicative DNA and at stalled replication forks 
(Tashiro of al., 2000 and Sengupta et al., 2003). 
MMR -deficient cell lines have been previously shown to become 
hypersensitive to the cytotoxic effects of thymidine. This sensitivity was 
documented not to be due to the loss of MMR (Mohindra et aL, 2002). 
Therefore, it appears that the thymidine sensitivity, like the loss of HRR, is 
also a result of events downstream from the initial loss of MMR. 
To date, the precise structure of the lesion induced by thymidine is 
unknown, although it seems unlikely to involve the formation of DSBs (as 
determined by pulse field gel electrophoresis - Figure 5.7, Page 175). 
However, the present and a previous published study (Lundin et al., 2002) 
have shown that treatment of cells with thymidine and hydroxyurea (agents 
proposed to stall DNA replication forks) can potently induce HRR events. 
Therefore it appears that HR proteins repair additional substrates other than 
DSBs which may form at stalled replication forks. In support of this 
argument, expression of the mutant XRCC2 allele specifically suppressed 
recombination events induced by thymidine in a dominant negative manner. 
The BCDX2 complex has recently been reported to preferentially bind to 
gapped DNA structures (Masson et al., 2001). Therefore it seems possible 
that expression of the mutant XRCC2 allele may inhibit the BCDX2 complex 
from binding onto the long tracts of gapped DNA regions which may form 
following thymidine exposure. 
A replication fork falters when it encounters an un-repaired DNA lesion or 
when its progress is blocked by a DNA bound protein. Emerging evidence 
from both bacteria and yeast implies that stalled replication forks can be 
bypassed and/or restored via a so-called fork reversion reaction. A similar 
phenomenon is proposed to occur in mammalian cells, however, at present 
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no evidence exists to suggest that such an event occurs. Restoration of 
stalled replication forks is initially proposed to occur either due to direct 
nuclease action or alternatively due to positive torsional strain within DNA 
(Postow et al., 2001). Initially, the newly replicated daughter strand is 
thought to reverse in direction and subsequently produce a so-called 'half 
chicken foot' substrate (Figure 6.1). Such substrates are thought to be 
recognised and cleaved by the Mus8l/Emel endonuclease in human cells 
and subsequently initiate HRR events using a single end for repair (Ciccia 
et al., 2003 and Chen et aL, 2001). Continual reversal of replication forks, 
however, produce a four-way junction that includes a Holliday junction 
(termed a 'chicken foot'). Such structures are well documented to require 
HRR proteins for processing and are proposed to be either resolved directly 
in order to form a DSB or (if HRR is activated prior to Holliday junction 
resolution) restore replication. As Holliday junctions are predominantly 
resolved in non-crossover events in mitotic mammalian cells, the products 
formed following the resolution of a chicken foot are thought to be almost 
always the result of a gene conversion event (Figure 6.1). 
190 
CHAPTER SIX-DISCUSSION 
(a) staged repixabon fats 
5 
3 
(b) half dIdei foot 
3 

















y ,f resokbon 










(h) restored re kation 
ý E-- Fý 
5 









Figure 6.1 HR mediated repair of stalled replication forks. (A) Treating cell with 
thymidine may stall replication forks. (B) Such stalled replication forks may reverse either 
due to positive torsional strain in DNA or due to enzymatic action (Postow et al., 2001). 
(C) The intermediary structure formed when only one strand reverses (half chicken foot), 
may be cleaved by endonucleases therefore, resulting a collapsed replication fork with one 
free end. (D) Such structures will result in a sister chromatid exchange (SCE) when 
repaired by HRR. (E) Alternatively, a stalled replication fork may fully reverse to form a 
four-way DNA junction (chicken foot). (F) The subsequent Holliday junction may be 
cleaved resulting in a 1-end DSB that can be repaired by proteins involved in HRR in order 
to restore replication. (G) However, the 3' end may also directly be used to initiate 
recombination events and thus also restore replication. Such an event avoids the 
formation of a DSB. (I)The resolution of the two Holliday junctions with crossing over 
would result in a gene conversion event, as predicted in the Szostak model (Szostak et al., 
1983). Arrows indicate the direction of DNA synthesis, blue lines indicate template DNA 
and red lines indicate newly synthesised DNA. Adapted from Helleday, T. (2003). 
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6.2 Future Studies 
Future experiments are required in order to confirm the precise type of 
lesion induced by thymidine and the subsequent substrate generated which 
initiates HR mediated repair. In addition, the signalling steps required for 
HRR activation following thymidine exposure need to be investigated. 
Evidence from other studies conducted in the laboratory suggest a possible 
role for the ATM kinase in the initial steps of damage signalling induced by 
thymidine, although the mechanisms involved remain unknown. A 
truncation of the MRE1 1 gene (which is a substrate for ATM when part of 
the MRE11/RAD50/NBS1 complex) has also been reported to give rise to 
thymidine sensitivity and act in a dominant negative manner with respect to 
thymidine induced recombination (Scorah et al., unpublished data). 
Therefore the direct involvement of ATM, MRE11 and XRCC2 in the repair 
of thymidine induced lesions could be achieved using co-transfected 
combinations of the genes into the SW480, MMR proficient cell line and 
observing any effects on thymidine induced recombination events. 
Biochemical alterations which may occur as a result of expressing 342delT 
need to be investigated with respect to the processing of lesions induced by 
thymidine. Recent studies conducted by Masson and co-workers (2001) 
suggested that the RAD51 paralogs are present as two distinct complexes 
(termed the BCDX2 and RAD51 C/XRCC3 complexes). The 
RAD51 C/XRCC3 complex has been reported to regulate eukaryotic 
replication fork progression following cisplatin exposure (Henry-Mowatt et 
a/., 2003). However, the BCDX2 complex may be involved in regulating 
stalled replication forks induced by thymidine in mammalian cells. 
Furthermore, to improve our understanding for the requirement of the 
RAD51 paralogs in the maintenance of replication forks, a clearer insight 
into the factors responsible for determining which of these two complexes 
act on a particular lesion is needed. 
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Alterations in the XRCC2 amino acid sequence (as noted in the SKUT-1 cell 
line) may inhibit the formation of, or alter the alignment of proteins involved 
in the BCDX2 complex. Co-immunoprecipitation experiments, using 
mammalian extracts, could be conducted to ascertain any such alterations 
both pre- and -post thymidine treatment. The phenotypic effects of 
mutating the other RAD51 paralogs, with respect to thymidine induced 
recombination events, could also be investigated. A similar mutation to that 
present in XRCC2 in SKUT-1 cells can be introduced using techniques such 
as site-directed mutagenesis. These studies would provide a better 
understanding of the requirement of ATP-hydrolysis within the BCDX2 
complex's function, as deletion of Walker Box B seems to have detrimental 
effects on the function of XRCC2. 
6.3 Implications to Cancer 
To date, published studies provide evidence that strongly link MMR 
-deficiency to the MSI phenotype observed in HNPCC cases. However, 
alterations in other proteins which are required for the maintenance of the 
genome may also contribute to this phenotype. Genes encoding proteins 
which appear to be involved in HRR (as well as genes that encode for 
proteins that regulate the S-phase checkpoint) may be potential targets for 
such alterations. In agreement with this, other studies have shown that the 
MRE11 gene is mutated in 85% of MSI+ colon cancers (Scorah, J. et aL, 
unpublished). Although the XRCC2 frameshift mutation reported in the 
present study does not seem to contribute to the MSI phenotype, data 
obtained from functional studies do support a role for XRCC2 in maintaining 
the integrity of the mammalian genome. Future work, however, is required 
to establish whether the mutations which give rise to the various genetic 
instability disorders promote the disruption of a specific step within a 
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common pathway. Such studies should also determine whether these 
events are unrelated. 
It is possible that the XRCC2 mutation acquired in the SKUT-1 (hMSH2- 
deficient) cell line is a random event, with respect to the development of 
gynaecological uterine tumours. However, the frameshift mutation found in 
the T8 tract of SKUT-1 cells is likely be coupled with selection, as other 
mononucleotide runs in XRCC2 are not mutated. Furthermore, the RAD52 
and RAD54B genes (which encode for 9 base pair and two seven base pair 
mononucleotide runs, respectively) were not mutated, even though the 
probability for incurring mutations is expected to be higher in longer runs. 
The XRCC2 frameshift mutation found in SKUT-1 cells and 
leiomyosarcomas seems to confer a dominant negative phenotype when 
expressed in either SW480 or MRC5VA cells. A dominant negative 
phenotype is often observed when the product of the defective gene inhibits 
the function of the wild-type gene product within the same cell (Herskowitz, 
1987). Therefore, expression of the mutant XRCC2 peptide may confer 
thymidine and MMC sensitivity by destroying the activity of the BCDX2 
complex. 
Such a dominant negative effect exerted by the XRCC2 frameshift mutation 
may also stimulate genetic instability and therefore cancer. Dominant 
negative mutations are documented to promote various types of cancer. 
Bertrand and co-workers (2003) injected a dominant negative form of 
RAD51 in mice in order to measure the tumourigenic effect. The study 
concluded that such mice exhibited a higher frequency of tumours as well 
as a faster growth rate when compared with control mice. Furthermore, 
expression of a dominant negative form of TGFß -RII in transgenic mice 
increased the amount of tumour metastasis with respect to both prostate 
and mammary tumour formation (Tu et al., 2003 and Gorska et al., 2003). 
194 
CHAPTER SIX-DISCUSSION 
Finally, dominant negative p53 mutations have also been observed in 
serous adenocarcinomas (Sakuragi eta!., 2001). 
A greater number of leiomyosarcoma tumour samples would need to be 
examined in order to ascertain whether the XRCC2 mutation is indeed a 
random event. In the present study, the XRCC2 mutation occurred in one 
out of eight tumour samples. However, in addition to these results, 
Schoenmakers and co-workers (1999) published the finding of additional 
mutations in RAD51B in uterine leiomyomas. The advantage gained by 
such events can be explained in context with the reported role of HRR 
proteins in delaying DNA replication fork progression following cisplatin or 
UV treatment (Henry-Mowatt et al., 2003). Hence MMR -deficient cells that 
acquire further mutations in the HRR genes may be unable to regulate 
correct DNA synthesis on damaged templates which would lead to a higher 
level of genetic instability and promote tumourigenisis. 
Furthermore, phenotypic characterization of MMR -deficient cells revealed 
that these cells are resistant to DNA alkylating agents such as 6- 
thioguanine and cisplatin. Resistance to such classes of chemotherapeutic 
agents has subsequently hindered the treatment of tumours displaying 
microsatellite instability. The loss of HRR and the hypersensitivity of MMR 
-deficient cells to thymidine raise the possibility of using agents that induce 
dNTP pool imbalances in conjunction with current methods to improve the 
treatment of this subset of tumours. 
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